Zimmer Biomet (ZBH) 10-K 29 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 24, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	ZBH
Entity Registrant Name	ZIMMER BIOMET HOLDINGS, INC.
Entity Central Index Key	1,136,869
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		198,834,321
Entity Public Float			$ 18,873,280,711

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Net Sales	$ 5,997.8	$ 4,673.3	$ 4,623.4
Cost of products sold, excluding intangible asset amortization	1,800.6	1,242.8	1,266.7
Intangible asset amortization	337.4	92.5	78.5
Research and development	268.8	187.4	203
Selling, general and administrative	2,284.2	1,750.7	1,749.3
Certain claims (Note 20)	7.7	21.5	47
Special items (Note 3)	831.8	341.1	210.3
Operating expenses	5,530.5	3,636	3,554.8
Operating Profit	467.3	1,037.3	1,068.6
Other expense, net	(36.9)	(46.7)	(6)
Interest income	9.4	11.9	15.6
Interest expense	(286.6)	(63.1)	(70.1)
Earnings before income taxes	153.2	939.4	1,008.1
Provision for income taxes	7	220.2	229.5
Net earnings	146.2	719.2	778.6
Less: Net loss attributable to noncontrolling interest	(0.8)	(1.1)	(1.8)
Net Earnings of Zimmer Biomet Holdings, Inc.	$ 147	$ 720.3	$ 780.4
Earnings Per Common Share - Basic	$ 0.78	$ 4.26	$ 4.60
Earnings Per Common Share - Diluted	$ 0.77	$ 4.20	$ 4.54
Weighted Average Common Shares Outstanding
Basic	187.4	169	169.6
Diluted	189.8	171.7	171.8
Cash Dividends Declared Per Common Share	$ 0.88	$ 0.88	$ 0.80

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Net earnings	$ 146.2	$ 719.2	$ 778.6
Other Comprehensive Income (Loss):
Foreign currency cumulative translation adjustments	(305.2)	(223.1)	(35)
Unrealized cash flow hedge gains, net of tax	52.7	55.9	33.4
Reclassification adjustments on cash flow hedges, net of tax	(93)	(18.9)	(4.4)
Unrealized (losses)/gains on securities, net of tax	(0.2)	(0.5)	0.1
Reclassification adjustments on securities, net of tax		(0.4)	0
Adjustments to prior service cost and unrecognized actuarial assumptions, net of tax	(21.4)	(75.8)	38.5
Total Other Comprehensive (Loss) Income	(367.1)	(262.8)	32.6
Comprehensive (Loss) Income	(220.9)	456.4	811.2
Comprehensive Loss Attributable to Noncontrolling Interest	(0.3)	(1)	(2)
Comprehensive (Loss) Income Attributable to Zimmer Biomet Holdings, Inc.	$ (220.6)	$ 457.4	$ 813.2

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 1,459.3	$ 1,083.3
Short-term investments	164.6	612.5
Accounts receivable, less allowance for doubtful accounts	1,446.5	912.1
Inventories	2,254.1	1,193.3
Prepaid expenses and other current assets	538.4	317.2
Deferred income taxes		194.9
Total Current Assets	5,862.9	4,313.3
Property, plant and equipment, net	2,062.6	1,285.3
Goodwill	9,934.2	2,514.2
Intangible assets, net	8,746.3	603.5
Other assets	613.5	941.7
Total Assets	27,219.5	9,658
Current Liabilities:
Accounts payable	284.8	145.2
Income taxes	147.2	80.3
Other current liabilities	1,185.9	798.5
Total Current Liabilities	1,617.9	1,024
Deferred income taxes	3,150.2	45.9
Other long-term liabilities	1,005.7	610.9
Long-term debt	11,556.3	1,425.5
Total Liabilities	$ 17,330.1	$ 3,106.3
Commitments and Contingencies (Note 20)
Stockholders' Equity:
Common stock, $0.01 par value, one billion shares authorized, 302.7 million (268.4 million in 2014) issued	$ 3	$ 2.7
Paid-in capital	8,195.3	4,330.7
Retained earnings	8,347.7	8,362.1
Accumulated other comprehensive (loss) income	(329)	38.1
Treasury stock, 100.0 million shares (98.7 million shares in 2014)	(6,329.1)	(6,183.7)
Total Zimmer Biomet Holdings, Inc. stockholders' equity	9,887.9	6,549.9
Noncontrolling interest	1.5	1.8
Total Stockholders' Equity	9,889.4	6,551.7
Total Liabilities and Stockholders' Equity	$ 27,219.5	$ 9,658

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	302,700,000	268,400,000
Treasury stock, shares	100,000,000	98,700,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Shares [Member]	Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Treasury Shares [Member]	Noncontrolling Interest [Member]
Balance at Dec. 31, 2012	$ 5,848	$ 2.6	$ 3,500.6	$ 7,143.2	$ 268.3	$ (5,072.1)	$ 5.4
Balance, shares at Dec. 31, 2012		257.1				(85.5)
Net earnings	778.6			780.4			(1.8)
Other comprehensive income (loss)	32.4				32.6		(0.2)
Purchase of additional shares from noncontrolling interest	(1.7)		(1.1)				(0.6)
Cash dividends declared	(135.4)			(135.4)
Stock compensation plans, including tax benefits	507.7		501.1	1.2		$ 5.4
Stock compensation plans, including tax benefits, shares		7.2				0.1
Share repurchases	(719)					$ (719)
Share repurchases, shares						(9.1)
Balance at Dec. 31, 2013	6,310.6	$ 2.6	4,000.6	7,789.4	300.9	$ (5,785.7)	2.8
Balance, shares at Dec. 31, 2013		264.3				(94.5)
Net earnings	719.2			720.3			(1.1)
Other comprehensive income (loss)	(262.7)				(262.8)		0.1
Cash dividends declared	(148.6)			(148.6)
Stock compensation plans, including tax benefits	333.7	$ 0.1	330.1	1		$ 2.5
Stock compensation plans, including tax benefits, shares		4.1
Share repurchases	(400.5)					$ (400.5)
Share repurchases, shares						(4.2)
Balance at Dec. 31, 2014	6,551.7	$ 2.7	4,330.7	8,362.1	38.1	$ (6,183.7)	1.8
Balance, shares at Dec. 31, 2014		268.4				(98.7)
Net earnings	146.2			147			(0.8)
Other comprehensive income (loss)	(366.6)				(367.1)		0.5
Cash dividends declared	(164.4)			(164.4)
Stock compensation plans, including tax benefits	149.8		142.2	3		$ 4.6
Stock compensation plans, including tax benefits, shares		1.6				0.1
Share repurchases	$ (150)					$ (150)
Share repurchases, shares	(1.4)					(1.4)
Biomet merger consideration	$ 3,722.7	$ 0.3	3,722.4
Biomet merger consideration, shares		32.7
Balance at Dec. 31, 2015	$ 9,889.4	$ 3	$ 8,195.3	$ 8,347.7	$ (329)	$ (6,329.1)	$ 1.5
Balance, shares at Dec. 31, 2015		302.7				(100)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows provided by (used in) operating activities:
Net earnings	$ 146.2	$ 719.2	$ 778.6
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	712.4	375.8	358.5
Biomet merger consideration compensation expense	90.4	0	0
Share-based compensation	46.4	49.4	48.5
Income tax benefit from stock option exercises	81.4	37.2	38.4
Excess income tax benefit from stock option exercises	(11.8)	(11.1)	(8.6)
Inventory step-up	317.8	5.4	8
Gain on divestiture of assets	(19)
Deferred income tax provision	(164)	(90.5)	(126.2)
Changes in operating assets and liabilities, net of acquired assets and liabilities
Income taxes	163.3	(50.4)	104.4
Receivables	(56.1)	(40.4)	(74.3)
Inventories	(205.4)	(164.6)	(148.1)
Accounts payable and accrued liabilities	(263.1)	108.4	33.6
Other assets and liabilities	(21.8)	114.4	(49.7)
Net cash provided by operating activities	816.7	1,052.8	963.1
Cash flows provided by (used in) investing activities:
Additions to instruments	(266.4)	(197.4)	(192.9)
Additions to other property, plant and equipment	(167.7)	(144.9)	(100)
Purchases of investments	(214.8)	(1,350.9)	(732.7)
Sales of investments	802.9	1,282.2	830.8
Proceeds from divestiture of assets	69.9
Biomet acquistion, net of acquired cash	(7,760.1)
Business combination investments		(54.3)	(74.2)
Investments in other assets	(21.7)	(4.1)	(13.5)
Net cash used in investing activities	(7,557.9)	(469.4)	(282.5)
Cash flows provided by (used in) financing activities:
Proceeds from (payments on) senior notes	7,628.2	(250)
Proceeds from term loan	3,000
Redemption of senior notes	(2,740)
Payments on term loan	(500)
Net proceeds (payments) under revolving credit facilities	0.1	2.3	(97.5)
Dividends paid to stockholders	(157.1)	(145.5)	(132.4)
Proceeds from employee stock compensation plans	105.2	284.7	474.8
Excess income tax benefit from stock option exercises	11.8	11.1	8.6
Debt issuance costs	(58.4)	(64.1)
Repurchase of common stock	(150)	(400.9)	(720.8)
Net cash provided by (used in) financing activities	7,139.8	(562.4)	(467.3)
Effect of exchange rates on cash and cash equivalents	(22.6)	(18.3)	(17)
Increase in cash and cash equivalents	376	2.7	196.3
Cash and cash equivalents, beginning of year	1,083.3	1,080.6	884.3
Cash and cash equivalents, end of period	$ 1,459.3	$ 1,083.3	$ 1,080.6

Business

Business	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	1. Business We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. On June 24, 2015 (the “Closing Date”), pursuant to an agreement and plan of merger dated April 24, 2014, we acquired LVB Acquisition, Inc. (“LVB”), the parent company of Biomet, Inc. (“Biomet”), and LVB and Biomet became our wholly-owned subsidiaries (sometimes hereinafter referred to as the “Biomet merger” or the “merger”). For more information on the merger, see Note 4. In connection with the merger, we changed our name from Zimmer Holdings, Inc. to Zimmer Biomet Holdings, Inc. The words “Zimmer Biomet,” “we,” “us,” “our,” “the Company” and similar words refer to Zimmer Biomet Holdings, Inc. and its subsidiaries. “Zimmer Biomet Holdings” refers to the parent company only. “Zimmer” used alone refers to the business or information of us and our subsidiaries on a stand-alone basis without inclusion of the business or information of LVB or any of its subsidiaries.

Revision of Prior Period Financ

Revision of Prior Period Financial Statements	12 Months Ended
	Dec. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Revision of Prior Period Financial Statements	2. Revision of Prior Period Financial Statements In the three month period ended September 30, 2015, we discovered two errors related to our financial statements for prior periods. One error related to accounts payable accruals. For certain received goods and services, we did not completely relieve the related accrual in a timely manner. As a result, our accounts payable balance was overstated. This error had been accumulating since 2012. The second error related to the accounting for the divestiture of certain Biomet product lines and rights in the three month period ended June 30, 2015. We calculated a gain on the divestiture based upon the pre-merger net book value of the assets. However, the gain should have been calculated based upon the fair value of such assets post-merger. We evaluated the impact of these errors on our prior period quarterly and annual financial statements, assessing materiality both quantitatively and qualitatively, and concluded the errors were not material to any of our previously issued financial statements. However, we concluded the cumulative corrections of these errors would be material to our financial statements for the three month period ended September 30, 2015 and, therefore, it was not appropriate to recognize the cumulative corrections in that period. Consequently, we revised previous periods’ financial statements to correct these errors as well as other unrelated, immaterial out of period adjustments that had been previously recorded. Following is a summary of the financial statement line items impacted by these revisions for the periods presented in this Form 10-K (in millions, except per share amounts). Revisions to the Consolidated Statements of Earnings and Comprehensive Income (Loss) Year Ended December 31, 2014 Year Ended December 31, 2013 As Reported Adjustments As Revised As Reported Adjustments As Revised Cost of products sold, excluding intangible asset amortization $ 1,242.7 $ 0.1 $ 1,242.8 $ 1,280.1 $ (13.4 ) $ 1,266.7 Research and development 187.9 (0.5 ) 187.4 203.4 (0.4 ) 203.0 Selling, general and administrative 1,744.4 6.3 1,750.7 1,758.8 (9.5 ) 1,749.3 Special items 342.5 (1.4 ) 341.1 214.0 (3.7 ) 210.3 Operating expenses 3,631.5 4.5 3,636.0 3,581.8 (27.0 ) 3,554.8 Earnings before income taxes 943.9 (4.5 ) 939.4 981.1 27.0 1,008.1 Provision for income taxes 224.9 (4.7 ) 220.2 221.9 7.6 229.5 Net earnings 719.0 0.2 719.2 759.2 19.4 778.6 Net Earnings of Zimmer Holdings, Inc. $ 720.1 $ 0.2 $ 720.3 $ 761.0 $ 19.4 $ 780.4 Earnings Per Common Share - Basic $ 4.26 $ – $ 4.26 $ 4.49 $ 0.11 $ 4.60 Earnings Per Common Share - Diluted $ 4.19 $ 0.01 $ 4.20 $ 4.43 $ 0.11 $ 4.54 Foreign currency cumulative translation adjustments $ (241.5 ) $ 18.4 $ (223.1 ) $ (44.4 ) $ 9.4 $ (35.0 ) Total Other Comprehensive Income (Loss) (281.2 ) 18.4 (262.8 ) 23.2 9.4 32.6 Comprehensive Income 437.8 18.6 456.4 782.4 28.8 811.2 Comprehensive Income Attributable to Zimmer Holdings, Inc. 438.8 18.6 457.4 784.4 28.8 813.2 Revisions to the Consolidated Balance Sheet December 31, 2014 As Reported Adjustments As Revised Inventories $ 1,169.0 $ 24.3 $ 1,193.3 Total Current Assets 4,289.0 24.3 4,313.3 Property, plant and equipment, net 1,288.8 (3.5 ) 1,285.3 Other assets 939.2 2.5 941.7 Total Assets 9,634.7 23.3 9,658.0 Accounts payable 167.1 (21.9 ) 145.2 Income taxes payable 72.4 7.9 80.3 Other current liabilities 798.5 – 798.5 Total Current Liabilities 1,038.0 (14.0 ) 1,024.0 Long-term income tax payable 181.7 8.2 189.9 Total Liabilities 3,112.1 (5.8 ) 3,106.3 Retained earnings 8,285.2 76.9 8,362.1 Accumulated other comprehensive income 85.9 (47.8 ) 38.1 Total Zimmer Holdings, Inc. stockholders’ equity 6,520.8 29.1 6,549.9 Total Stockholders’ Equity 6,522.6 29.1 6,551.7 Total Liabilities and Stockholders’ Equity 9,634.7 23.3 9,658.0 Revisions to the Consolidated Statements of Cash Flows Year ended December 31, 2014 Year ended December 31, 2013 As Reported Adjustments As Revised As Reported Adjustments As Revised Net earnings $ 719.0 $ 0.2 $ 719.2 $ 759.2 $ 19.4 $ 778.6 Deferred income tax provision (84.2 ) (6.3 ) (90.5 ) (126.2 ) – (126.2 ) Changes in operating assets and liabilities, net of effect of acquisitions: Income taxes payable (51.9 ) 1.5 (50.4 ) 96.8 7.6 104.4 Inventories (154.1 ) (10.5 ) (164.6 ) (128.4 ) (19.7 ) (148.1 ) Accounts payable and accrued expenses 120.1 (11.7 ) 108.4 38.3 (4.7 ) 33.6 Other assets and liabilities 87.6 26.8 114.4 (47.1 ) (2.6 ) (49.7 ) We have not presented revisions to our consolidated statements of stockholders’ equity. The only revisions to these statements are related to retained earnings caused by revisions to net earnings and accumulated other comprehensive income caused by revisions to other comprehensive income (loss). These revisions have already been presented in the tables for the consolidated statements of earnings and comprehensive income and the consolidated balance sheets. In the fourth quarter of 2015 we discovered an error that was immaterial to previous quarters’ condensed consolidated statements of cash flows. As further discussed in Note 4, we recognized $90.4 million of compensation expense related to previously unvested LVB stock options and LVB stock-based awards that vested immediately prior to the merger under the terms of the merger agreement. $52.8 million of the $90.4 million represented cash payments to holders of these options and stock-based awards. In the six month period ended June 30, 2015 and nine month period ended September 30, 2015, we presented the $52.8 million as a cash outflow from investing activities. However, since the payment represented compensation expense, the $52.8 million should have been presented as an operating cash outflow. We have corrected this error in the consolidated statement of cash flows for the year ended December 31, 2015. We will also revise future interim filings to correct for this error.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Presentation Use of Estimates Foreign Currency Translation Revenue Recognition Sales to stocking distributors, healthcare dealers, dental practices and dental laboratories accounted for approximately 20 percent of our net sales in 2015. With these types of sales, revenue is recognized when title to product passes, either upon shipment of the product or in some cases upon implantation of the product. Product is generally sold at contractually fixed prices for specified periods. Payment terms vary by customer, but are typically less than 90 days. If sales incentives are earned by a customer for purchasing a specified amount of our product, we estimate whether such incentives will be achieved and, if so, recognize these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. Occasionally products are returned and, accordingly, we maintain an estimated sales return reserve that is recorded as a reduction in revenue. Product returns were not significant for the years ended December 31, 2015, 2014 and 2013. Taxes collected from customers and remitted to governmental authorities are presented on a net basis and excluded from revenues. Shipping and Handling Research and Development Litigation Special Items For the Years Ended December 31, 2015 2014 2013 Biomet-related Merger compensation expense $ 90.4 $ – $ – Retention plans 73.0 – – Employee termination benefits 101.0 – – Consulting and professional fees 167.4 61.5 – Dedicated project personnel 62.3 0.4 – Relocated facilities 5.6 – – Contract terminations 95.0 – – Information technology integration 5.2 – – Other 19.2 – – Other Employee termination benefits 1.9 0.9 14.2 Consulting and professional fees 114.8 115.2 99.1 Dedicated project personnel 31.8 50.4 34.0 Impairment/loss on disposal of assets 2.3 24.0 10.9 Certain R&D agreements – 4.5 0.8 Relocated facilities – 0.7 3.6 Distributor acquisitions – 0.6 0.4 Certain litigation matters 31.2 70.0 26.9 Contract terminations – 1.8 3.9 Information technology integration 1.8 – – Contingent consideration adjustments 2.4 0.6 9.0 Accelerated software amortization 1.5 6.0 6.0 Other 25.0 4.5 1.5 Special items $ 831.8 $ 341.1 $ 210.3 Pursuant to the Biomet merger agreement, all outstanding LVB stock options and LVB stock-based awards vested immediately prior to the effective time of the merger, and holders of these options and awards received a portion of the aggregate merger consideration. Some of these options and awards were already vested under the terms of LVB’s equity incentive plans. We accounted for the fair value of the consideration we paid in exchange for previously vested options and awards as consideration to complete the merger. As part of the merger agreement terms, all previously unvested options and awards vested immediately prior to the effective time of the merger. Under LVB’s equity incentive plans, unvested options and awards would have otherwise been forfeited. We have concluded that the discretionary accelerated vesting of these unvested options and awards was for the economic benefit of the combined company, and, therefore, we classified the fair value of the merger consideration we paid to holders of such unvested options and awards of $90.4 million as compensation expense. Pursuant to the LVB merger agreement, retention plans were established for certain Biomet employees and third-party sales agents. Retention payments were earned by employees and third-party sales agents who remained with Biomet through the Closing Date. We recognized $73.0 million of expense resulting from these retention plans. After the Closing Date, we started to implement our integration plans to drive operational synergies. Part of these integration plans included termination of employees and certain contracts. Expenses attributable to the initial phase of these integration plans that were recognized in 2015 as part of “Special items” related to employee termination benefits and contract termination expense associated with agreements with independent agents, distributors, suppliers and lessors. Our integration plans are expected to last through 2018 and we expect to incur a total of $170.0 million for employee termination benefits and $130.0 million for contract termination expense in that time period. The following table summarizes the liabilities related to these integration plans (in millions): Employee Contract Total Balance, Closing Date $ – $ – $ – Additions 101.0 95.0 196.0 Cash payments (54.1 ) (39.0 ) (93.1 ) Foreign currency exchange rate changes (0.1 ) – (0.1 ) Balance, December 31, 2015 $ 46.8 $ 56.0 $ 102.8 Consulting and professional fees relate to third-party consulting, professional fees and contract labor related to our quality and operational excellence initiatives, third-party consulting fees related to certain information system implementations, third-party integration consulting performed in a variety of areas such as tax, compliance, logistics and human resources for our business combinations and merger with Biomet, third-party fees related to severance and termination benefits matters and legal fees related to certain litigation matters. Our quality and operational excellence initiatives are company-wide and include improvements in quality, distribution, sourcing, manufacturing and information technology, among other areas. Dedicated project personnel expenses include the salary, benefits, travel expenses and other costs directly associated with employees who are 100 percent dedicated to our quality and operational excellence initiatives or integration of acquired businesses. Impairment/loss on disposal of assets relates to impairment of intangible assets that were acquired in business combinations or impairment of or a loss on the disposal of other assets. This caption also includes the effect of reducing the estimated useful life of certain intangible assets to zero, which resulted in the remaining net book values of those assets being amortized immediately. Certain R&D agreements relate to agreements with upfront payments to obtain intellectual property to be used in R&D projects that have no alternative future use in other projects. Relocated facilities expenses are the moving costs and the lease expenses incurred during the relocation period in connection with relocating certain facilities. Over the past few years we have acquired a number of U.S. and foreign-based distributors. We have incurred various costs related to the consummation and integration of those businesses. Certain litigation matters relate to net expenses recognized during the year for the estimated or actual settlement of certain pending litigation and similar claims, including matters where we recognized income from a settlement on more favorable terms than our previous estimate, or we reduced our estimate of a previously recorded contingent liability. These litigation matters have included royalty disputes, patent litigation matters and commercial litigation matters. Contract termination costs relate to terminated agreements in connection with the integration of acquired companies and changes to our distribution model as part of business restructuring and operational excellence initiatives. The terminated contracts primarily relate to sales agents and distribution agreements. Information technology integration costs are non-capitalizable costs incurred related to integrating information technology platforms of acquired companies or other significant software implementations as part of our quality and operational excellence initiatives. Contingent consideration adjustments represent the changes in the fair value of contingent consideration obligations to be paid to the prior owners of acquired businesses. Accelerated software amortization is the incremental amortization resulting from a reduction in the estimated life of certain software. Due to an approved plan to replace certain software, the estimated economic useful life of the existing software was decreased to represent the period of time expected to implement replacement software. As a result, the amortization from the shortened life of this software is substantially higher than the previous amortization being recognized. Cash and Cash Equivalents Investments Accounts Receivable Inventories Property, Plant and Equipment Software Costs Instruments Goodwill Intangible Assets In determining the useful lives of intangible assets, we consider the expected use of the assets and the effects of obsolescence, demand, competition, anticipated technological advances, changes in surgical techniques, market influences and other economic factors. For technology-based intangible assets, we consider the expected life cycles of products, absent unforeseen technological advances, which incorporate the corresponding technology. Trademarks and trade names that do not have a wasting characteristic (i.e., there are no legal, regulatory, contractual, competitive, economic or other factors which limit the useful life) are assigned an indefinite life. Trademarks and trade names that are related to products expected to be phased out are assigned lives consistent with the period in which the products bearing each brand are expected to be sold. For customer relationship intangible assets, we assign useful lives based upon historical levels of customer attrition. Intellectual property rights are assigned useful lives that approximate the contractual life of any related patent or the period for which we maintain exclusivity over the intellectual property. Income Taxes – We reduce our deferred tax assets by a valuation allowance if it is more likely than not that we will not realize some portion or all of the deferred tax assets. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. We operate on a global basis and are subject to numerous and complex tax laws and regulations. Our income tax filings are regularly under audit in multiple federal, state and foreign jurisdictions. Income tax audits may require an extended period of time to reach resolution and may result in significant income tax adjustments when interpretation of tax laws or allocation of company profits is disputed. Because income tax adjustments in certain jurisdictions can be significant, we record accruals representing management’s best estimate of the probable resolution of these matters. To the extent additional information becomes available, such accruals are adjusted to reflect the revised estimated probable outcome. Derivative Financial Instruments Other Comprehensive Income (Loss) Treasury Stock Noncontrolling Interest Accounting Pronouncements Revenue from Contracts with Customers (Topic 606) In April 2015, the FASB issued ASU 2015-03 – Simplifying the Presentation of Debt Issuance Costs In September 2015, the FASB issued ASU 2015-16 – Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments On November 20, 2015, the FASB issued ASU 2015-17 – Balance Sheet Classification of Deferred Taxes There are no other recently issued accounting pronouncements that we have not yet adopted that are expected to have a material effect on our financial position, results of operations or cash flows.

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Business Combinations	4. Business Combinations Biomet Merger On the Closing Date, we completed our merger with LVB, the parent company of Biomet. We paid $12,030.3 million in cash and stock and assumed Biomet’s senior notes. The fair value of the principal amount of the senior notes was $2,740.0 million, which we repaid in full prior to June 30, 2015. The merger enhances our position in the nearly $50.0 billion musculoskeletal industry. Our product portfolio now includes Biomet’s legacy product lines, including knee and hip reconstructive products; sports medicine, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental reconstructive products; and cement, biologics and other products. Our larger scale provides for increased competitiveness in our core and emerging franchises and a stronger presence in our geographic markets. The merger positions us to increase cross-selling opportunities between our legacy product portfolios and sales force specialization. The combination of our R&D functions will allow us to allocate a greater portion of the combined R&D spending towards innovations designed to address unmet clinical needs and create new-market adjacencies. We also expect to realize operational synergies to enhance value for stockholders. In order to consummate the merger under applicable antitrust laws and regulations in certain countries, we had to divest certain product line rights and assets. As a result, we recognized a net gain of $19.0 million in non-operating other expense, net in the year ended December 31, 2015. We funded the cash portion of the merger consideration with available cash on hand, as well as proceeds from a $3.0 billion senior unsecured term loan and $7.65 billion in senior unsecured notes issued in March 2015. See Note 12 for further information regarding these debt instruments. The aggregate merger consideration paid was $12,030.3 million, consisting of $8,307.6 million of cash and 32.7 million shares of our common stock valued at $3,722.7 million. The value of our common stock was based upon a stock price of $113.83 per share using the average of the high and low trading prices on the Closing Date. As discussed in Note 3, $90.4 million of the cash and common stock consideration was allocated to compensation expense due to the acceleration of the vesting of unvested LVB stock options and LVB stock-based awards in connection with the merger. Therefore, the amount of merger consideration utilized for the acquisition method of accounting was $11,939.9 million. The merger was accounted for under the acquisition method of accounting. Accordingly, LVB’s results of operations have been included in our consolidated results of operations starting on the Closing Date, and LVB’s assets and liabilities were recorded at their estimated fair values in our consolidated statement of financial position as of the Closing Date, with the excess of the purchase price over the estimated fair values being allocated to goodwill. During the year ended December 31, 2015, Biomet contributed net sales of $1,602.0 million. During the year ended December 31, 2015, Biomet contributed net operating losses of $295.8 million to our consolidated results, driven by $90.4 million of merger compensation expense for unvested LVB stock options and LVB stock-based awards, $73.0 million of retention plan expense, severance expense, inventory step-up expense and intangible asset amortization. The purchase price allocation as of December 31, 2015 is preliminary. The primary tasks to be completed related to our purchase price accounting are refinements to intangible assets for certain less significant products, finalizing tax accounts, including, but not limited to, the allocation of acquired intangible assets and goodwill on a jurisdictional basis, and finalizing the estimated fair values of contingent assets and liabilities. There may be differences between these preliminary estimates of fair value and the final acquisition accounting, which differences could be material. The final estimates of fair value are expected to be completed as soon as possible, but no later than one year from the Closing Date. The following table summarizes our estimate of the preliminary fair values of the assets acquired and liabilities assumed at the Closing Date, including measurement period adjustments recognized from our initial purchase price allocation through December 31, 2015 (in millions): Closing Date Adjustments Closing Date Cash $ 494.8 $ – $ 494.8 Accounts receivable, net 544.7 (15.7 ) 529.0 Inventory 1,161.7 84.0 1,245.7 Other current assets 123.4 (97.0 ) 26.4 Property, plant and equipment 699.4 92.0 791.4 Intangible assets not subject to amortization: Trademarks and trade names 515.0 (36.0 ) 479.0 In-process research and development (IPR&D) – 246.0 246.0 Intangible assets subject to amortization: Technology 3,075.3 (583.2 ) 2,492.1 Customer relationships 5,829.0 (873.0 ) 4,956.0 Trademarks and trade names – 389.0 389.0 Other assets 29.5 211.6 241.1 Goodwill 5,270.2 2,303.7 7,573.9 Total assets acquired 17,743.0 1,721.4 19,464.4 Current liabilities 588.9 39.2 628.1 Long-term debt 2,740.0 – 2,740.0 Deferred taxes 2,489.7 1,607.8 4,097.5 Other long-term liabilities 58.2 0.7 58.9 Total liabilities assumed 5,876.8 1,647.7 7,524.5 Net assets acquired $ 11,866.2 $ 73.7 $ 11,939.9 Adjustments to the initial preliminary fair values of the assets acquired and liabilities assumed related to a change in estimate to the fair value of merger compensation expense for unvested LVB stock options and LVB stock-based awards, refinement of the estimated fair values of inventory, property, plant and equipment and intangible assets, refinement of income and deferred tax balances and adjustments to contingent liabilities and contingent gains based upon additional evidence obtained, among other adjustments. There may be additional adjustments to these preliminary estimates of fair value which could be material. The weighted-average amortization period selected for trademarks and trade names, technology and customer relationship intangible assets was 15 years, 15 years and 18 years, respectively. IPR&D intangible assets represent acquired R&D projects which have not received regulatory approval. IPR&D intangible assets are capitalized and accounted for as indefinite lived intangible assets and will be subject to periodic impairment testing until the successful completion or abandonment of the associated R&D project. Upon successful completion of each R&D project, the associated indefinite lived intangible asset is then accounted for as a finite lived intangible asset and amortized on a straight-line basis over its estimated useful life. If an R&D project is abandoned, the associated indefinite lived asset is charged to expense. The IPR&D intangible assets recognized in the Biomet merger relates to a variety of R&D projects. The fair values of the IPR&D intangible assets were determined using the income approach. Most of these projects are expected to be completed within a year or two after the Closing Date. Remaining costs to complete these projects are expected to be an insignificant amount of our total annual R&D spending. The goodwill is generated from the operational synergies we expect to achieve from our combined operations. None of the goodwill is expected to be deductible for tax purposes. The following sets forth unaudited pro forma financial information derived from (i) the audited financial statements of Zimmer for the years ended December 31, 2015 and 2014; and (ii) the unaudited financial statements of LVB for the period January 1, 2015 to June 23, 2015 and for the year ended December 31, 2014. The pro forma financial information has been adjusted to give effect to the merger as if it had occurred on January 1, 2014. Pro Forma Financial Information (Unaudited) Year Ended December 31, 2015 2014 (in millions) Net Sales $ 7,517.7 $ 7,965.2 Net Earnings $ 327.4 $ 314.5 These unaudited pro forma results have been prepared for comparative purposes only and include adjustments such as inventory step-up, amortization of acquired intangible assets and interest expense on debt incurred to finance the merger. Material, nonrecurring pro forma adjustments directly attributable to the Biomet merger include: • The $90.4 million of merger compensation expense for unvested LVB stock options and LVB stock-based awards was removed from net earnings for the year ended December 31, 2015 and recognized as an expense in the year ended December 31, 2014. • The $73.0 million of retention plan expense was removed from net earnings for the year ended December 31, 2015 and recognized as an expense in the year ended December 31, 2014. • Transaction costs of $17.7 million was removed from net earnings for the year ended December 31, 2015 and recognized as an expense in the year ended December 31, 2014. Other Acquisitions We made a number of business acquisitions during the years 2014 and 2013. In October 2014, we acquired ETEX Holdings, Inc. (“Etex”). The Etex acquisition enhanced our biologics portfolio through the addition of Etex’s bone void filler products. In May 2013, we acquired the business assets of Knee Creations, LLC (“Knee Creations”). The Knee Creations acquisition enhanced our product portfolio of joint preservation solutions. In June 2013, we acquired NORMED Medizin-Technik GmbH (“Normed”). The Normed acquisition strengthened our Extremities and Trauma product portfolios and brought new product development capabilities in the foot and ankle and hand and wrist markets. The results of operations of these acquired companies have been included in our consolidated results of operations subsequent to the transaction dates, and the respective assets and liabilities of the acquired companies have been recorded at their estimated fair values in our consolidated statement of financial position as of the transaction dates, with any excess purchase price being recorded as goodwill. Pro forma financial information and other information required by GAAP have not been included for these acquisitions as they, individually and in the aggregate, did not have a material impact upon our financial position or results of operations.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	5. Share-Based Compensation Our share-based payments primarily consist of stock options and restricted stock units (“RSUs”). Share-based compensation expense was as follows (in millions): For the Years Ended December 31, 2015 2014 2013 Total expense, pre-tax $ 46.4 $ 49.4 $ 48.5 Tax benefit related to awards (14.5 ) (15.5 ) (15.6 ) Total expense, net of tax $ 31.9 $ 33.9 $ 32.9 Stock Options We had two equity compensation plans in effect at December 31, 2015: the 2009 Stock Incentive Plan (“2009 Plan”) and the Stock Plan for Non-Employee Directors. The 2009 Plan succeeded the 2006 Stock Incentive Plan (“2006 Plan”) and the TeamShare Stock Option Plan (“TeamShare Plan”). No further awards have been granted under the 2006 Plan or under the TeamShare Plan since May 2009, and shares remaining available for grant under those plans have been merged into the 2009 Plan. Vested stock options previously granted under the 2006 Plan, the TeamShare Plan and another prior plan, the 2001 Stock Incentive Plan, remained outstanding as of December 31, 2015. We have reserved the maximum number of shares of common stock available for award under the terms of each of these plans. We have registered 57.9 million shares of common stock under these plans. The 2009 Plan provides for the grant of nonqualified stock options and incentive stock options, long-term performance awards in the form of performance shares or units, restricted stock, RSUs and stock appreciation rights. The Compensation and Management Development Committee of the Board of Directors determines the grant date for annual grants under our equity compensation plans. The date for annual grants under the 2009 Plan to our executive officers is expected to occur in the first quarter of each year following the earnings announcements for the previous quarter and full year. In 2015, the Compensation and Management Development Committee set the Closing Date as the grant date for awards to our executive officers. The Stock Plan for Non-Employee Directors provides for awards of stock options, restricted stock and RSUs to non-employee directors. It has been our practice to issue shares of common stock upon exercise of stock options from previously unissued shares, except in limited circumstances where they are issued from treasury stock. The total number of awards which may be granted in a given year and/or over the life of the plan under each of our equity compensation plans is limited. At December 31, 2015, an aggregate of 5.6 million shares were available for future grants and awards under these plans. Stock options granted to date under our plans vest over four years and have a maximum contractual life of 10 years. As established under our equity compensation plans, vesting may accelerate upon retirement after the first anniversary date of the award if certain criteria are met. We recognize expense related to stock options on a straight-line basis over the requisite service period, less awards expected to be forfeited using estimated forfeiture rates. Due to the accelerated retirement provisions, the requisite service period of our stock options range from one to four years. Stock options are granted with an exercise price equal to the market price of our common stock on the date of grant, except in limited circumstances where local law may dictate otherwise. A summary of stock option activity for the year ended December 31, 2015 is as follows (options in thousands): Stock Options Weighted Weighted Intrinsic (in millions) Outstanding at January 1, 2015 7,846 $ 71.94 Options granted 1,717 107.10 Options exercised (1,404 ) 73.09 Options forfeited (185 ) 97.02 Options expired (43 ) 80.59 Outstanding at December 31, 2015 7,931 $ 78.73 5.7 $ 201.1 Vested or expected to vest as of December 31, 2015 7,497 $ 77.59 5.5 $ 197.4 Exercisable at December 31, 2015 4,969 $ 68.67 3.9 $ 168.6 We use a Black-Scholes option-pricing model to determine the fair value of our stock options. Expected volatility was derived from a combination of historical volatility and implied volatility because the traded options that were actively traded around the grant date of our stock options did not have maturities of over one year. The expected term of the stock options has been derived from historical employee exercise behavior. The risk-free interest rate was determined using the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options. The dividend yield was determined by using an estimated annual dividend and dividing it by the market price of our stock on the grant date. The following table presents information regarding the weighted average fair value for stock options granted, the assumptions used to determine fair value, and the intrinsic value of options exercised in the indicated year: For the Years Ended December 31, 2015 2014 2013 Dividend yield 0.8 % 0.9 % 1.1 % Volatility 22.2 % 25.2 % 24.5 % Risk-free interest rate 1.7 % 1.8 % 1.1 % Expected life (years) 5.3 5.5 6.1 Weighted average fair value of options granted $ 22.30 $ 22.59 $ 16.33 Intrinsic value of options exercised (in millions) $ 49.4 $ 99.6 $ 97.9 As of December 31, 2015, there was $40.3 million of unrecognized share-based payment expense related to nonvested stock options granted under our plans. That expense is expected to be recognized over a weighted average period of 3.0 years. RSUs We have awarded RSUs to certain of our employees. The terms of the awards have been two to four years. Some of the awards have only service conditions while some have performance and market conditions in addition to service conditions. The service condition-only awards vest ratably on the anniversary date of the award. The awards that have performance and market conditions vest all at once on the third anniversary date. Future service conditions may be waived if an employee retires after the first anniversary date of the award, but performance and market conditions continue to apply. Accordingly, the requisite service period used for share-based payment expense on our RSUs range from one to four years. A summary of nonvested RSU activity for the year ended December 31, 2015 is as follows (RSUs in thousands): RSUs Weighted Average Grant Date Fair Value Outstanding at January 1, 2015 1,475 $ 76.60 Granted 556 104.77 Vested (347 ) 67.50 Forfeited (384 ) 74.82 Outstanding at December 31, 2015 1,300 91.64 For the RSUs with service conditions only, the fair value of the awards was determined based upon the fair market value of our common stock on the date of grant. For the RSUs with market conditions, a Monte Carlo valuation technique was used to simulate the market conditions of the awards. The outcome of the simulation was used to determine the fair value of the awards. We are required to estimate the number of RSUs that will vest and recognize share-based payment expense on a straight-line basis over the requisite service period. As of December 31, 2015, we estimate that approximately 795,000 outstanding RSUs will vest. If our estimate were to change in the future, the cumulative effect of the change in estimate will be recorded in that period. Based upon the number of RSUs that we expect to vest, the unrecognized share-based payment expense as of December 31, 2015 was $39.6 million and is expected to be recognized over a weighted-average period of 2.4 years. The fair value of RSUs vesting during the years ended December 31, 2015, 2014 and 2013 based upon our stock price on the date of vesting was $40.6 million, $29.3 million and $32.5 million, respectively.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	6. Inventories Inventories consisted of the following (in millions): As of December 31, 2015 2014 Finished goods $ 1,827.9 $ 924.2 Work in progress 146.1 87.8 Raw materials 280.1 181.3 Inventories $ 2,254.1 $ 1,193.3 Finished goods inventory as of December 31, 2015 includes $284.4 million to step-up the acquired Biomet inventory to fair value. Amounts charged to the consolidated statement of earnings for excess and obsolete inventory in the years ended December 31, 2015, 2014 and 2013 were $118.4 million, $51.8 million and $112.0 million, respectively.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	7. Property, Plant and Equipment Property, plant and equipment consisted of the following (in millions): As of December 31, 2015 2014 Land $ 39.6 $ 20.4 Building and equipment 1,789.3 1,283.4 Capitalized software costs 330.1 294.7 Instruments 2,160.5 1,692.8 Construction in progress 108.4 115.8 4,427.9 3,407.1 Accumulated depreciation (2,365.3 ) (2,121.8 ) Property, plant and equipment, net $ 2,062.6 $ 1,285.3 Depreciation expense was $375.0 million, $268.6 million and $262.6 million for the years ended December 31, 2015, 2014 and 2013, respectively.

Investments

Investments	12 Months Ended
	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Investments	8. Investments We invest in short and long-term investments classified as available-for-sale securities. Information regarding our investments is as follows (in millions): Gross Unrealized Amortized Cost Gains Losses Fair As of December 31, 2015 Corporate debt securities $ 245.7 $ 0.1 $ (0.4 ) $ 245.4 U.S. government and agency debt securities 21.6 – (0.1 ) 21.5 Commercial paper 4.2 – – 4.2 Certificates of deposit 2.0 – – 2.0 Total short and long-term investments $ 273.5 $ 0.1 $ (0.5 ) $ 273.1 As of December 31, 2014 Corporate debt securities $ 516.9 $ 0.1 $ (0.5 ) $ 516.5 U.S. government and agency debt securities 194.3 – – 194.3 Commercial paper 57.8 – – 57.8 Certificates of deposit 100.3 – – 100.3 Total short and long-term investments $ 869.3 $ 0.1 $ (0.5 ) $ 868.9 The unrealized losses on our investments in corporate debt securities were caused by increases in interest yields in the global credit markets. We believe the unrealized losses associated with these securities as of December 31, 2015 are temporary because we do not intend to sell these investments, and we do not believe we will be required to sell them before recovery of their amortized cost basis. The amortized cost and fair value of our available-for-sale fixed-maturity securities by contractual maturity are as follows (in millions): As of December 31, 2015 Amortized Cost Fair Due in one year or less $ 164.7 $ 164.6 Due after one year through two years 108.8 108.5 Total $ 273.5 $ 273.1

Fair Value Measurements of Asse

Fair Value Measurements of Assets and Liabilities	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements of Assets and Liabilities	9. Fair Value Measurements of Assets and Liabilities The following financial assets and liabilities are recorded at fair value on a recurring basis (in millions): As of December 31, 2015 Fair Value Measurements at Reporting Date Using: Description Recorded Quoted Prices Significant Other (Level 2) Significant (Level 3) Assets Available-for-sale securities Corporate debt securities $ 245.4 $ – $ 245.4 $ – U.S. government and agency debt securities 21.5 – 21.5 – Commercial paper 4.2 – 4.2 – Certificates of deposit 2.0 – 2.0 – Total available-for-sale securities 273.1 – 273.1 – Derivatives, current and long-term Foreign currency forward contracts 96.9 – 96.9 – Interest rate swaps 26.8 – 26.8 – $ 396.8 $ – $ 396.8 $ – Liabilities Derivatives, current and long-term Foreign currency forward contracts 1.6 – 1.6 – $ 1.6 $ – $ 1.6 $ – As of December 31, 2014 Fair Value Measurements at Reporting Date Using: Description Recorded Quoted Prices Significant Other (Level 2) Significant (Level 3) Assets Available-for-sale securities Corporate debt securities $ 516.5 $ – $ 516.5 $ – U.S. government and agency debt securities 194.3 – 194.3 – Commercial paper 57.8 – 57.8 – Certificates of deposit 100.3 – 100.3 – Total available-for-sale securities 868.9 – 868.9 – Derivatives, current and long-term Foreign currency forward contracts 125.5 – 125.5 – Interest rate swaps 24.0 – 24.0 – $ 1,018.4 $ – $ 1,018.4 $ – Liabilities Derivatives, current and long-term Foreign currency forward contracts 1.7 – 1.7 – Forward starting interest rate swaps 59.3 – 59.3 – $ 61.0 $ – $ 61.0 $ – We value our available-for-sale securities using a market approach based on broker prices for identical assets in over-the-counter markets and we perform ongoing assessments of counterparty credit risk. We value our foreign currency forward contracts and foreign currency options using a market approach based on foreign currency exchange rates obtained from active markets and we perform ongoing assessments of counterparty credit risk. We value our interest rate swaps using a market approach based on publicly available market yield curves and the terms of our swaps and we perform ongoing assessments of counterparty credit risk.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	10. Goodwill and Other Intangible Assets The following table summarizes the changes in the carrying amount of goodwill (in millions): Americas EMEA Asia Product Category Total Balance at January 1, 2014 Goodwill $ 894.8 $ 1,271.9 $ 161.8 $ 655.7 $ 2,984.2 Accumulated impairment losses – – – (373.0 ) (373.0 ) 894.8 1,271.9 161.8 282.7 2,611.2 Acquisitions 40.6 – – – 40.6 Currency translation (4.3 ) (114.6 ) (13.6 ) (5.1 ) (137.6 ) Balance at December 31, 2014 Goodwill 931.1 1,157.3 148.2 650.6 2,887.2 Accumulated impairment losses – – – (373.0 ) (373.0 ) 931.1 1,157.3 148.2 277.6 2,514.2 Biomet Merger 6,445.2 225.6 408.1 495.0 7,573.9 Currency translation (48.3 ) (91.9 ) (7.4 ) (6.3 ) (153.9 ) Balance at December 31, 2015 Goodwill 7,328.0 1,291.0 548.9 1,139.3 10,307.2 Accumulated impairment losses – – – (373.0 ) (373.0 ) $ 7,328.0 $ 1,291.0 $ 548.9 $ 766.3 $ 9,934.2 The components of identifiable intangible assets were as follows (in millions): Technology Intellectual Trademarks Customer IPR&D Other Total As of December 31, 2015: Intangible assets subject to amortization: Gross carrying amount $ 3,161.6 $ 181.0 $ 583.3 $ 5,133.0 $ – $ 101.8 $ 9,160.7 Accumulated amortization (591.9 ) (164.8 ) (50.9 ) (269.6 ) – (64.8 ) (1,142.0 ) Intangible assets not subject to amortization: Gross carrying amount – – 479.0 – 248.6 – 727.6 Total identifiable intangible assets $ 2,569.7 $ 16.2 $ 1,011.4 $ 4,863.4 $ 248.6 $ 37.0 $ 8,746.3 As of December 31, 2014: Intangible assets subject to amortization: Gross carrying amount $ 727.2 $ 173.4 $ 74.2 $ 213.8 $ – $ 93.9 $ 1,282.5 Accumulated amortization (458.3 ) (157.7 ) (34.1 ) (99.6 ) – (58.3 ) (808.0 ) Intangible assets not subject to amortization: Gross carrying amount – – 129.0 – – – 129.0 Total identifiable intangible assets $ 268.9 $ 15.7 $ 169.1 $ 114.2 $ – $ 35.6 $ 603.5 During 2015, we reclassified $129.0 million of indefinite lived trademarks and trade names to finite lived trademarks and trade names as they were determined to have a finite useful life. Estimated annual amortization expense based upon intangible assets recognized as of December 31, 2015 for the years ending December 31, 2016 through 2020 is (in millions): For the Years Ending December 31, 2016 $ 559.9 2017 546.2 2018 529.3 2019 516.1 2020 514.4

Other Current and Long-term Lia

Other Current and Long-term Liabilities	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Other Current and Long-term Liabilities	11. Other Current and Long-term Liabilities Other current and long-term liabilities consisted of the following (in millions): As of December 31, 2015 2014 Other current liabilities: License and service agreements $ 144.1 $ 100.2 Certain claims accrual (Note 20) 50.0 50.0 Litigation settlement accrual (Note 20) – 70.0 Forward starting interest rate swaps – 59.3 Salaries, wages and benefits 265.9 167.7 Accrued liabilities 725.9 351.3 Total other current liabilities $ 1,185.9 $ 798.5 Other long-term liabilities: Long-term income tax payable $ 478.1 $ 189.9 Certain claims accrual (Note 20) 264.6 307.2 Other long-term liabilities 263.0 113.8 Total other long-term liabilities $ 1,005.7 $ 610.9

Debt

Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt	12. Debt Our debt consisted of the following (in millions): As of December 31, 2015 2014 Long-term debt 1.450% Senior Notes due 2017 $ 500.0 $ – 2.000% Senior Notes due 2018 1,150.0 – 4.625% Senior Notes due 2019 500.0 500.0 2.700% Senior Notes due 2020 1,500.0 – 3.375% Senior Notes due 2021 300.0 300.0 3.150% Senior Notes due 2022 750.0 – 3.550% Senior Notes due 2025 2,000.0 – 4.250% Senior Notes due 2035 500.0 – 5.750% Senior Notes due 2039 500.0 500.0 4.450% Senior Notes due 2045 1,250.0 – U.S. Term Loan 2,500.0 – Japan Term Loan 96.8 98.0 Other long-term debt 4.6 4.9 Debt discount (21.9 ) (1.4 ) Adjustment related to interest rate swaps 26.8 24.0 Total long-term debt $ 11,556.3 $ 1,425.5 At December 31, 2015, our total debt consisted of $8.95 billion aggregate principal amount of our senior notes, a $2.5 billion U.S. term loan (“U.S. Term Loan”), an 11.7 billion Japanese Yen term loan agreement (“Japan Term Loan”) that will mature on May 31, 2018, and other debt, debt discount and fair value adjustments totaling $9.5 million. The U.S. Term Loan is part of our $4.35 billion credit agreement (“Credit Agreement”) that contains: (i) a 5-year unsecured term loan facility in the principal amount of $3.0 billion (the “U.S. Term Loan Facility”), and (ii) a 5-year unsecured multicurrency revolving facility in the principal amount of $1.35 billion (the “Multicurrency Revolving Facility”). The Credit Agreement contains customary affirmative and negative covenants and events of default for an unsecured financing arrangement, including, among other things, limitations on consolidations, mergers and sales of assets. Financial covenants include a consolidated indebtedness to consolidated EBITDA ratio of no greater than 5.0 to 1.0 through June 24, 2016 and no greater than 4.5 to 1.0 thereafter. If our credit rating falls below investment grade, additional restrictions would result, including restrictions on investments and payment of dividends. We were in compliance with all covenants under the Credit Agreement as of December 31, 2015. On June 24, 2015, we borrowed $3.0 billion under the U.S. Term Loan Facility to fund a portion of the Biomet merger. Under the terms of the U.S. Term Loan Facility, starting September 30, 2015, principal payments are due as follows: $75.0 million on a quarterly basis during the first three years, $112.5 million on a quarterly basis during the fourth year, and $412.5 million on a quarterly basis during the fifth year. In 2015, we paid $500.0 million in principal under the U.S. Term Loan Facility, resulting in $2.5 billion in outstanding borrowings as of December 31, 2015. Due to the $500.0 million of advanced payments in 2015 on the U.S. Term Loan Facility, we have no quarterly principal obligations in 2016. Borrowings under the Multicurrency Revolving Facility may be used for general corporate purposes. There were no borrowings outstanding under the Multicurrency Revolving Facility as of December 31, 2015. Of the total $8.95 billion aggregate principal amount of senior notes outstanding at December 31, 2015, we issued $7.65 billion of this amount in March 2015 (the “Merger Notes”), the proceeds of which were used to finance a portion of the cash consideration payable in the Biomet merger, pay merger related fees and expenses and pay a portion of Biomet’s funded debt. The Merger Notes consist of the following seven tranches: the 1.450% Senior Notes due 2017, the 2.000% Senior Notes due 2018, the 2.700% Senior Notes due 2020, the 3.150% Senior Notes due 2022, the 3.550% Senior Notes due 2025, the 4.250% Senior Notes due 2035 and the 4.450% Senior Notes due 2045. We may, at our option, redeem our senior notes, in whole or in part, at any time upon payment of the principal, any applicable make-whole premium, and accrued and unpaid interest to the date of redemption. In addition, the Merger Notes and the 3.375% Senior Notes due 2021 may be redeemed at our option without any make-whole premium at specified dates ranging from one month to six months in advance of the scheduled maturity date. Between the Closing Date and June 30, 2015, we repaid the Biomet senior notes we assumed in the merger. The fair value of the principal amount plus interest was $2,798.6 million. These senior notes required us to pay a call premium in excess of the fair value of the notes when they were repaid. As a result, we recognized $22.0 million in non-operating other expense related to this call premium. The estimated fair value of our senior notes as of December 31, 2015, based on quoted prices for the specific securities from transactions in over-the-counter markets (Level 2), was $8,837.5 million. The estimated fair value of the Japan Term Loan as of December 31, 2015, based upon publicly available market yield curves and the terms of the debt (Level 2), was $96.4 million. The carrying value of the U.S. Term Loan approximates fair value as it bears interest at short-term variable market rates. We have entered into interest rate swap agreements which we designated as fair value hedges of underlying fixed-rate obligations on our senior notes due 2019 and 2021. See Note 14 for additional information regarding the interest rate swap agreements. We also have available uncommitted credit facilities totaling $35.8 million. At December 31, 2015 and 2014, the weighted average interest rate for our long-term borrowings was 2.9 percent and 3.5 percent, respectively. We paid $207.1 million, $67.5 million and $68.1 million in interest during 2015, 2014 and 2013, respectively.

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Accumulated Other Comprehensive (Loss) Income	13. Accumulated Other Comprehensive (Loss) Income OCI refers to certain gains and losses that under GAAP are included in comprehensive income but are excluded from net earnings as these amounts are initially recorded as an adjustment to stockholders’ equity. Amounts in OCI may be reclassified to net earnings upon the occurrence of certain events. Our OCI is comprised of foreign currency translation adjustments, unrealized gains and losses on cash flow hedges, unrealized gains and losses on available-for-sale securities, and amortization of prior service costs and unrecognized gains and losses in actuarial assumptions on our defined benefit plans. Foreign currency translation adjustments are reclassified to net earnings upon sale or upon a complete or substantially complete liquidation of an investment in a foreign entity. Unrealized gains and losses on cash flow hedges are reclassified to net earnings when the hedged item affects net earnings. Unrealized gains and losses on available-for-sale securities are reclassified to net earnings if we sell the security before maturity or if the unrealized loss is considered to be other-than-temporary. Amounts related to defined benefit plans that are in OCI are reclassified over the service periods of employees in the plan. The reclassification amounts are allocated to all employees in the plans and, therefore, the reclassified amounts may become part of inventory to the extent they are considered direct labor costs. See Note 15 for more information on our defined benefit plans. The following table shows the changes in the components of OCI, net of tax (in millions): Foreign Cash Unrealized Defined Balance December 31, 2014 $ 111.8 $ 70.1 $ (0.4 ) $ (143.4 ) OCI before reclassifications (305.2 ) 52.7 (0.2 ) (30.6 ) Reclassifications – (93.0 ) – 9.2 Balance December 31, 2015 $ (193.4 ) $ 29.8 $ (0.6 ) $ (164.8 ) The following table shows the reclassification adjustments from OCI (in millions): Amount of Gain / (Loss) Reclassified from OCI Location on Statement of Earnings For the Years Ended December 31, Component of OCI 2015 2014 2013 Cash flow hedges Foreign exchange forward contracts $ 122.3 $ 33.3 $ 8.0 Cost of products sold Foreign exchange options – – (0.2 ) Cost of products sold Forward starting interest rate swaps (1.3 ) – – Interest expense 121.0 33.3 7.8 Total before tax 28.0 14.4 3.4 Provision for income taxes $ 93.0 $ 18.9 $ 4.4 Net of tax Investments Realized gains on securities $ – $ 0.4 $ – Interest income – 0.4 – Total before tax – – – Provision for income taxes $ – $ 0.4 $ – Net of tax Defined benefit plans Prior service cost $ 5.6 $ 3.9 $ 3.9 * Unrecognized actuarial (loss) (20.1 ) (11.1 ) (16.6 ) * (14.5 ) (7.2 ) (12.7 ) Total before tax (5.3 ) (3.0 ) (4.8 ) Provision for income taxes $ (9.2 ) $ (4.2 ) $ (7.9 ) Net of tax Total reclassifications $ 83.8 $ 15.1 $ (3.5 ) Net of tax * These OCI components are included in the computation of net periodic pension expense (see Note 15). The following table shows the tax effects on each component of OCI recognized in our consolidated statements of comprehensive income (in millions): Before Tax Tax Net of Tax For the Years Ended December 31, 2015 2014 2013 2015 2014 2013 2015 2014 2013 Foreign currency cumulative translation adjustments $ (305.2 ) $ (223.1 ) $ (35.0 ) $ – $ – $ – $ (305.2 ) $ (223.1 ) $ (35.0 ) Unrealized cash flow hedge gains 59.1 60.5 63.6 6.4 4.6 30.2 52.7 55.9 33.4 Reclassification adjustments on foreign currency hedges (121.0 ) (33.3 ) (7.8 ) (28.0 ) (14.4 ) (3.4 ) (93.0 ) (18.9 ) (4.4 ) Reclassification adjustments on securities – (0.4 ) – – – – – (0.4 ) – Unrealized gains/(losses) on securities (0.2 ) (0.5 ) 0.1 – – – (0.2 ) (0.5 ) 0.1 Adjustments to prior service cost and unrecognized actuarial assumptions (25.0 ) (104.8 ) 50.3 (3.6 ) (29.0 ) 11.8 (21.4 ) (75.8 ) 38.5 Total Other Comprehensive (Loss) Income $ (392.3 ) $ (301.6 ) $ 71.2 $ (25.2 ) $ (38.8 ) $ 38.6 $ (367.1 ) $ (262.8 ) $ 32.6

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	14. Derivative Instruments and Hedging Activities We are exposed to certain market risks relating to our ongoing business operations, including foreign currency exchange rate risk, commodity price risk, interest rate risk and credit risk. We manage our exposure to these and other market risks through regular operating and financing activities. Currently, the only risks that we manage through the use of derivative instruments are interest rate risk and foreign currency exchange rate risk. Interest Rate Risk Derivatives Designated as Fair Value Hedges We use interest rate derivative instruments to manage our exposure to interest rate movements by converting fixed-rate debt into variable-rate debt. Under these agreements, we agree to exchange, at specified intervals, the difference between fixed and variable interest amounts calculated by reference to an agreed-upon notional principal amount. The objective of the instruments is to more closely align interest expense with interest income received on cash and cash equivalents. These derivative instruments are designated as fair value hedges under GAAP. Changes in the fair value of the derivative instrument are recorded in current earnings and are offset by gains or losses on the underlying debt instrument. We have multiple fixed-to-variable interest rate swap agreements that we have designated as fair value hedges of the fixed interest rate obligations on our 4.625% Senior Notes due 2019 and 3.375% Senior Notes due 2021. The total notional amounts are $250.0 million and $300.0 million for the 4.625% Senior Notes due 2019 and 3.375% Senior Notes due 2021, respectively. On the interest rate swap agreements for the 4.625% Senior Notes due 2019, we receive a fixed interest rate of 4.625 percent and pay variable interest equal to the three-month LIBOR plus an average of 133 basis points. On the interest rate swap agreements for the 3.375% Senior Notes due 2021, we receive a fixed interest rate of 3.375 percent and pay variable interest equal to the three-month LIBOR plus an average of 99 basis points. Derivatives Designated as Cash Flow Hedges In 2014, we entered into forward starting interest rate swaps that were designated as cash flow hedges of the thirty year tranche of senior notes we expected to issue in 2015. The forward starting interest rate swaps mitigated the risk of changes in interest rates prior to the completion of the Merger Notes offering. The total notional amounts of the forward starting interest rate swaps were $1 billion and settled in March 2015 at a loss of $97.6 million. The loss will be recognized using the effective interest rate method over the maturity period of the 4.450% Senior Notes due 2045. Foreign Currency Exchange Rate Risk We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts and options with major financial institutions. We are primarily exposed to foreign currency exchange rate risk with respect to transactions and net assets denominated in Euros, Swiss Francs, Japanese Yen, British Pounds, Canadian Dollars, Australian Dollars, Korean Won, Swedish Krona, Czech Koruna, Thai Baht, Taiwan Dollars, South African Rand, Russian Rubles and Indian Rupees. We do not use derivative financial instruments for trading or speculative purposes. Derivatives Designated as Cash Flow Hedges Our revenues are generated in various currencies throughout the world. However, a significant amount of our inventory is produced in U.S. Dollars. Therefore, movements in foreign currency exchange rates may have different proportional effects on our revenues compared to our cost of products sold. To minimize the effects of foreign currency exchange rate movements on cash flows, we hedge intercompany sales of inventory expected to occur within the next 30 months with foreign currency exchange forward contracts and options. We designate these derivative instruments as cash flow hedges. We perform quarterly assessments of hedge effectiveness by verifying and documenting the critical terms of the hedge instrument and that forecasted transactions have not changed significantly. We also assess on a quarterly basis whether there have been adverse developments regarding the risk of a counterparty default. For derivatives which qualify as hedges of future cash flows, the effective portion of changes in fair value is temporarily recorded in other comprehensive income and then recognized in cost of products sold when the hedged item affects net earnings. The ineffective portion of a derivative’s change in fair value, if any, is immediately reported in cost of products sold. On our consolidated statement of cash flows, the settlements of these cash flow hedges are recognized in operating cash flows. For foreign currency exchange forward contracts and options outstanding at December 31, 2015, we had obligations to purchase U.S. Dollars and sell Euros, Japanese Yen, British Pounds, Canadian Dollars, Australian Dollars, Korean Won, Swedish Krona, Czech Koruna, Thai Baht, Taiwan Dollars, South African Rand, Russian Rubles and Indian Rupees and obligations to purchase Swiss Francs and sell U.S. Dollars. These derivatives mature at dates ranging from January 2016 through June 2018. As of December 31, 2015, the notional amounts of outstanding forward contracts and options entered into with third parties to purchase U.S. Dollars were $1,427.5 million. As of December 31, 2015, the notional amounts of outstanding forward contracts and options entered into with third parties to purchase Swiss Francs were $307.2 million. Derivatives Not Designated as Hedging Instruments We enter into foreign currency forward exchange contracts with terms of one month to manage currency exposures for monetary assets and liabilities denominated in a currency other than an entity’s functional currency. As a result, any foreign currency re-measurement gains/losses recognized in earnings are generally offset with gains/losses on the foreign currency forward exchange contracts in the same reporting period. Starting in 2015, the net amount of these offsetting gains/losses is recorded in other expense. In prior periods, the net amount was recorded in cost of products sold and was not material. Prior periods have been reclassified to conform to the 2015 presentation. These contracts are settled on the last day of each reporting period. Therefore, there is no outstanding balance related to these contracts recorded on the balance sheet as of the end of the reporting period. The notional amounts of these contracts are typically in a range of $1.5 billion to $2.0 billion per quarter. Income Statement Presentation Derivatives Designated as Fair Value Hedges Derivative instruments designated as fair value hedges had the following effects on our consolidated statements of earnings (in millions): Gain /(Loss) on Instrument Gain /(Loss) on Hedged Item Derivative Instrument Location on Statement of Earnings Year Ended December 31, Year Ended December 31, 2015 2014 2013 2015 2014 2013 Interest rate swaps Interest expense $ 2.8 $ 14.7 $ (24.6 ) $ (2.8 ) $ (14.7 ) $ 24.6 We had no ineffective fair value hedging instruments nor any amounts excluded from the assessment of hedge effectiveness during the years ended December 31, 2015, 2014 and 2013. Derivatives Designated as Cash Flow Hedges Derivative instruments designated as cash flow hedges had the following effects, before taxes, on OCI and net earnings on our consolidated statements of earnings, consolidated statements of comprehensive income and consolidated balance sheets (in millions): Amount of Gain / (Loss) Amount of Gain / (Loss) Year Ended December 31, Year Ended December 31, Derivative Instrument 2015 2014 2013 Location on Statement of Earnings 2015 2014 2013 Foreign exchange forward contracts $ 97.4 $ 119.8 $ 63.9 Cost of products sold $ 122.3 $ 33.3 $ 8.0 Foreign exchange options – – (0.3 ) Cost of products sold – – (0.2 ) Forward starting interest rate swaps (38.3 ) (59.3 ) – Interest expense (1.3 ) – – $ 59.1 $ 60.5 $ 63.6 $ 121.0 $ 33.3 $ 7.8 The net amount recognized in earnings during the years ended December 31, 2015, 2014 and 2013 due to ineffectiveness and amounts excluded from the assessment of hedge effectiveness were not significant. The fair value of outstanding derivative instruments designated as cash flow hedges and recorded on the balance sheet at December 31, 2015, together with settled derivatives where the hedged item has not yet affected earnings, was a net unrealized gain of $26.1 million, or $29.8 million after taxes, which is deferred in accumulated other comprehensive income. Of the net unrealized gain, $101.4 million, or $76.7 million after taxes, is expected to be reclassified to earnings in cost of products sold and a loss of $1.7 million, or $1.1 million after taxes, is expected to be reclassified to earnings in interest expense over the next twelve months. Derivatives Not Designated as Hedging Instruments The following gains from these derivative instruments were recognized on our consolidated statements of earnings (in millions): Derivative Instrument Location on Year Ended December 31, Statement of Earnings 2015 2014 2013 Foreign exchange forward contracts Other expense, net $ 28.8 $ 15.3 $ – This impact does not include any offsetting gains/losses recognized in earnings as a result of foreign currency remeasurement of monetary assets and liabilities denominated in a currency other than an entity’s functional currency. Balance Sheet Presentation As of December 31, 2015 and December 31, 2014, all derivative instruments designated as fair value hedges and cash flow hedges are recorded at fair value on the balance sheet. On our consolidated balance sheets, we recognize individual forward contracts and options with the same counterparty on a net asset/liability basis if we have a master netting agreement with the counterparty. Under these master netting agreements, we are able to settle derivative instrument assets and liabilities with the same counterparty in a single transaction, instead of settling each derivative instrument separately. We have master netting agreements with all of our counterparties. The fair value of derivative instruments on a gross basis is as follows (in millions): As of December 31, 2015 As of December 31, 2014 Balance Sheet Location Fair Value Balance Sheet Location Fair Value Asset Derivatives Foreign exchange forward contracts Other current assets $ 100.5 Other current assets $ 98.7 Foreign exchange forward contracts Other assets 19.8 Other assets 53.1 Interest rate swaps Other assets 26.8 Other assets 24.0 Total asset derivatives $ 147.1 $ 175.8 Liability Derivatives Foreign exchange forward contracts Other current liabilities $ 16.7 Other current liabilities $ 16.4 Forward starting interest rate swaps Other current liabilities – Other current liabilities 59.3 Foreign exchange forward contracts Other long-term liabilities 8.3 Other long-term liabilities 11.6 Total liability derivatives $ 25.0 $ 87.3 The table below presents the effects of our master netting agreements on our consolidated balance sheets (in millions): As of December 31, 2015 As of December 31, 2014 Description Location Gross Offset Net Amount Gross Offset Net Amount Asset Derivatives Cash flow hedges Other current assets $ 100.5 $ 16.3 $ 84.2 $ 98.7 $ 15.9 $ 82.8 Cash flow hedges Other assets 19.8 7.1 12.7 53.1 10.4 42.7 Liability Derivatives Cash flow hedges Other current liabilities 16.7 16.3 0.4 16.4 15.9 0.5 Cash flow hedges Other long-term liabilities 8.3 7.1 1.2 11.6 10.4 1.2

Retirement Benefit Plans

Retirement Benefit Plans	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Retirement Benefit Plans	15. Retirement Benefit Plans We have defined benefit pension plans covering certain U.S. and Puerto Rico employees. The employees who are not participating in the defined benefit plans receive additional benefits under our defined contribution plans. Plan benefits are primarily based on years of credited service and the participant’s average eligible compensation. In addition to the U.S. and Puerto Rico defined benefit pension plans, we sponsor various foreign pension arrangements, including retirement and termination benefit plans required by local law or coordinated with government sponsored plans. We use a December 31 measurement date for our benefit plans. Defined Benefit Plans The components of net pension expense for our defined benefit retirement plans were as follows (in millions): U.S. and Puerto Rico Foreign For the Years Ended December 31, 2015 2014 2013 2015 2014 2013 Service cost $ 11.8 $ 10.9 $ 11.9 $ 18.9 $ 14.7 $ 16.1 Interest cost 15.8 15.5 13.2 8.8 9.2 5.6 Expected return on plan assets (31.8 ) (30.8 ) (28.7 ) (13.9 ) (11.0 ) (6.7 ) Amortization of prior service cost (3.7 ) (2.6 ) (2.6 ) (1.9 ) (1.3 ) (1.3 ) Amortization of unrecognized actuarial loss 17.4 10.6 14.8 2.7 0.5 1.8 Net periodic benefit cost $ 9.5 $ 3.6 $ 8.6 $ 14.6 $ 12.1 $ 15.5 The weighted average actuarial assumptions used to determine net pension expense for our defined benefit retirement plans were as follows: U.S. and Puerto Rico Foreign For the Years Ended December 31, 2015 2014 2013 2015 2014 2013 Discount rate 4.56% 4.98% 4.32% 1.94% 2.46% 2.13% Rate of compensation increase 3.29% 3.29% 3.29% 2.00% 1.48% 2.29% Expected long-term rate of return on plan assets 7.75% 7.75% 7.75% 3.05% 2.88% 2.74% The expected long-term rate of return on plan assets is based on the historical and estimated future rates of return on the different asset classes held in the plans. The expected long-term rate of return is the weighted average of the target asset allocation of each individual asset class. We believe that historical asset results approximate expected market returns applicable to the funding of a long-term benefit obligation. Discount rates were determined for each of our defined benefit retirement plans at their measurement date to reflect the yield of a portfolio of high quality bonds matched against the timing and amounts of projected future benefit payments. Beginning in 2016, we will change the method used to estimate the service and interest costs for pension and postretirement benefits. The new method utilizes a full yield curve approach to estimate service and interest costs by applying specific spot rates along the yield curve used to determine the benefit obligation of relevant projected cash outflows. Historically, we utilized a single weighted-average discount rate applied to projected cash outflows. We made the change to provide a more precise measurement of service and interest costs by aligning the timing of the plan’s liability cash flows to the corresponding spot rate on the yield curve. The change does not impact the measurement of the plan’s obligations. We will account for this change as a change in accounting estimate. Changes in projected benefit obligations and plan assets were (in millions): U.S. and Puerto Rico Foreign For the Years Ended December 31, 2015 2014 2015 2014 Projected benefit obligation – beginning of year $ 386.6 $ 316.7 $ 423.7 $ 371.5 Obligation assumed from Biomet – – 159.4 – Service cost 11.8 10.9 18.9 14.7 Interest cost 15.8 15.5 8.8 9.2 Plan amendments (21.9 ) – – (7.0 ) Employee contributions – – 16.9 18.5 Benefits paid (12.3 ) (10.0 ) (24.1 ) (22.6 ) Actuarial (gain) loss (4.9 ) 53.5 (18.9 ) 77.9 Expenses paid – – (0.3 ) (0.2 ) Settlement – – (0.2 ) – Translation (gain) loss – – (15.6 ) (38.3 ) Projected benefit obligation – end of year $ 375.1 $ 386.6 $ 568.6 $ 423.7 Plan assets at fair market value – beginning of year $ 402.2 $ 398.6 $ 385.4 $ 372.3 Assets contributed by Biomet – – 129.4 – Actual return on plan assets (16.6 ) 10.9 (4.0 ) 38.0 Employer contributions 0.8 2.7 14.8 14.7 Employee contributions – – 16.9 18.5 Plan amendments – – (0.2 ) – Benefits paid (12.3 ) (10.0 ) (24.1 ) (22.6 ) Expenses paid – – (0.3 ) (0.2 ) Translation gain (loss) – – (12.3 ) (35.3 ) Plan assets at fair market value – end of year $ 374.1 $ 402.2 $ 505.6 $ 385.4 Funded status $ (1.0 ) $ 15.6 $ (63.0 ) $ (38.3 ) Amounts recognized in consolidated balance sheet: Prepaid pension $ 14.6 $ 29.4 $ 16.5 $ 12.4 Short-term accrued benefit liability (1.0 ) (0.7 ) (0.6 ) (0.5 ) Long-term accrued benefit liability (14.6 ) (13.1 ) (78.9 ) (50.2 ) Net amount recognized $ (1.0 ) $ 15.6 $ (63.0 ) $ (38.3 ) We estimate the following amounts recorded as part of accumulated other comprehensive income will be recognized as part of our net pension expense during 2016 (in millions): U.S. and Foreign Unrecognized prior service cost $ (5.9 ) $ (1.9 ) Unrecognized actuarial loss 17.1 2.9 $ 11.2 $ 1.0 The weighted average actuarial assumptions used to determine the projected benefit obligation for our defined benefit retirement plans were as follows: U.S. and Puerto Rico Foreign For the Years Ended December 31, 2015 2014 2013 2015 2014 2013 Discount rate 4.36 % 4.10 % 4.98 % 1.86 % 1.38 % 2.45 % Rate of compensation increase 3.29 % 3.29 % 3.29 % 2.02 % 1.43 % 1.52 % Plans with projected benefit obligations in excess of plan assets were as follows (in millions): U.S. and Puerto Rico Foreign As of December 31, 2015 2014 2015 2014 Projected benefit obligation $ 53.8 $ 54.6 $ 393.4 $ 365.2 Plan assets at fair market value 38.2 40.8 319.6 315.0 Total accumulated benefit obligations and plans with accumulated benefit obligations in excess of plan assets were as follows (in millions): U.S. and Puerto Rico Foreign As of December 31, 2015 2014 2015 2014 Total accumulated benefit obligations $ 354.6 $ 337.5 $ 556.8 $ 413.1 Plans with accumulated benefit obligations in excess of plan assets: Accumulated benefit obligation 34.8 32.8 380.1 358.6 Plan assets at fair market value 20.6 22.0 314.9 315.0 The benefits expected to be paid out in each of the next five years and for the five years combined thereafter are as follows (in millions): For the Years Ending December 31, U.S. and Foreign 2016 14.3 22.4 2017 15.8 22.5 2018 17.3 23.0 2019 19.1 24.0 2020 20.6 23.9 2021-2025 118.4 125.2 The U.S. and Puerto Rico defined benefit retirement plans’ overall investment strategy is to maximize total returns by emphasizing long-term growth of capital while mitigating risk. We have established target ranges of assets held by the plans of 40 to 45 percent for equity securities, 30 to 35 percent for debt securities and 20 to 25 percent in non-traditional investments. The plans strive to have sufficiently diversified assets so that adverse or unexpected results from one asset class will not have an unduly detrimental impact on the entire portfolio. We regularly review the investments in the plans and we may rebalance them from time-to-time based upon the target asset allocation of the plans. For the U.S. and Puerto Rico plans, we maintain an investment policy statement that guides the investment allocation in the plans. The investment policy statement describes the target asset allocation positions described above. Our benefits committee, along with our investment advisor, monitor compliance with and administer the investment policy statement and the plans’ assets and oversee the general investment strategy and objectives of the plans. Our benefits committee generally meets quarterly to review performance and to ensure that the current investment allocation is within the parameters of the investment policy statement. The investment strategies of foreign based plans vary according to the plan provisions and local laws. The majority of the assets in foreign based plans are located in Switzerland-based plans. These assets are held in trusts and are commingled with the assets of other Swiss companies with representatives of all the companies making the investment decisions. The overall strategy is to maximize total returns while avoiding risk. The trustees of the assets have established target ranges of assets held by the plans of 30 to 50 percent in debt securities, 20 to 37 percent in equity securities, 15 to 24 percent in real estate, 3 to 15 percent in cash funds and 0 to 12 percent in other funds. The fair value of our U.S. and Puerto Rico pension plan assets by asset category was as follows (in millions): As of December 31, 2015 Fair Value Measurements at Reporting Date Using: Asset Category Total Quoted Prices Significant Significant (Level 3) Cash and cash equivalents $ 2.5 $ 2.5 $ — $ — Equity securities: U.S. large-cap 79.2 — 79.2 — U.S. small-cap 25.6 — 25.6 — International 93.2 — 93.2 — Real estate 27.0 — 27.0 — Commodity-linked mutual funds 16.4 — 16.4 — Intermediate fixed income securities 130.2 — 130.2 — Total $ 374.1 $ 2.5 $ 371.6 $ — As of December 31, 2014 Fair Value Measurements at Reporting Date Using: Asset Category Total Quoted Prices Significant Significant (Level 3) Cash and cash equivalents $ 1.4 $ 1.4 $ — $ — Equity securities: U.S. large-cap 83.7 — 83.7 — U.S. small-cap 23.0 — 23.0 — International 83.0 — 83.0 — Real estate 49.1 — 49.1 — Commodity-linked mutual funds 36.0 — 36.0 — Intermediate fixed income securities 126.0 — 126.0 — Total $ 402.2 $ 1.4 $ 400.8 $ — The fair value of our foreign pension plan assets was as follows (in millions): As of December 31, 2015 Fair Value Measurements at Reporting Date Using: Asset Category Total Quoted Prices Significant Significant (Level 3) Cash and cash equivalents $ 34.0 $ 34.0 $ — $ — Equity securities: Energy 4.7 4.7 — — Materials 6.7 6.7 — — Industrials 8.2 8.2 — — Consumer discretionary 6.3 6.3 — — Consumer staples 8.5 8.5 — — Healthcare 8.6 8.6 — — Financials 17.4 17.4 — — Information technology 5.7 5.7 — — Telecommunication services 2.0 2.0 — — Utilities 3.3 3.3 — — Other 80.7 40.6 40.1 — Fixed income securities: Government bonds 104.0 — 104.0 — Corporate bonds 74.5 — 74.5 — Asset-backed securities 14.8 — 14.8 — Other debt 11.3 — 11.3 — Other types of investments: Mortgage loans 9.8 — 9.8 — Insurance contracts 5.8 — 5.8 — Other investments 14.7 — 14.7 — Real estate 84.6 — 10.7 73.9 Total $ 505.6 $ 146.0 $ 285.7 $ 73.9 As of December 31, 2014 Fair Value Measurements at Reporting Date Using: Asset Category Total Quoted Prices Significant Significant (Level 3) Cash and cash equivalents $ 31.0 $ 31.0 $ — $ — Equity securities: Energy 4.7 4.7 — — Materials 7.1 7.1 — — Industrials 7.5 7.5 — — Consumer discretionary 6.5 6.5 — — Consumer staples 7.5 7.5 — — Healthcare 6.8 6.8 — — Financials 16.3 16.3 — — Information technology 4.9 4.9 — — Telecommunication services 2.0 2.0 — — Utilities 3.4 3.4 — — Other 36.7 34.5 2.2 — Fixed income securities: Government bonds 72.5 — 72.5 — Corporate bonds 58.9 — 58.9 — Asset-backed securities 22.0 — 22.0 — Other debt 1.7 — 1.7 — Other types of investments: Mortgage loans 9.2 — 9.2 — Insurance contracts 6.1 — 6.1 — Other investments 12.0 — 12.0 — Real estate 68.6 — — 68.6 Total $ 385.4 $ 132.2 $ 184.6 $ 68.6 As of December 31, 2015 and 2014, our defined benefit pension plans’ assets did not hold any direct investment in Zimmer Biomet Holdings common stock. Equity securities are valued using a market approach, based on quoted prices for the specific security from transactions in active exchange markets (Level 1), or in some cases where we are invested in mutual or collective funds, based upon the net asset value per unit of the fund which is determined from quoted market prices of the underlying securities in the fund’s portfolio (Level 2). Fixed income securities are valued using a market approach, based upon quoted prices for the specific security or from institutional bid evaluations. Some fixed income securities are in funds with a net asset value per unit which is determined using similar techniques for the underlying securities in the fund’s portfolio. Real estate is valued by discounting to present value the cash flows expected to be generated by the specific properties. The following table provides a reconciliation of the beginning and ending balances of our foreign pension plan assets measured at fair value that used significant unobservable inputs (Level 3) (in millions): December 31, 2015 Beginning Balance $ 68.6 Gains on assets sold 0.2 Change in fair value of assets 2.2 Net purchases and sales 3.5 Translation loss (0.6 ) Ending Balance $ 73.9 We expect that we will have no legally required minimum funding requirements in 2016 for the qualified U.S. and Puerto Rico defined benefit retirement plans, nor do we expect to voluntarily contribute to these plans during 2016. Contributions to foreign defined benefit plans are estimated to be $15.1 million in 2016. We do not expect the assets in any of our plans to be returned to us in the next year. Defined Contribution Plans We also sponsor defined contribution plans for substantially all of the U.S. and Puerto Rico employees and certain employees in other countries. The benefits offered under these plans are reflective of local customs and practices in the countries concerned. We expensed $40.2 million, $32.8 million and $29.6 million related to these plans for the years ended December 31, 2015, 2014 and 2013, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes The components of earnings before income taxes consisted of the following (in millions): For the Years Ended December 31, 2015 2014 2013 United States operations $ (246.2 ) $ 403.3 $ 412.4 Foreign operations 399.4 536.1 595.7 Total $ 153.2 $ 939.4 $ 1,008.1 The provision for income taxes and the income taxes paid consisted of (in millions): Current: Federal $ 55.8 $ 178.2 $ 207.2 State 18.9 16.5 20.8 Foreign 96.3 116.0 127.7 171.0 310.7 355.7 Deferred: Federal (120.6 ) (54.8 ) (91.8 ) State (20.0 ) (6.6 ) (8.4 ) Foreign (23.4 ) (29.1 ) (26.0 ) (164.0 ) (90.5 ) (126.2 ) Provision for income taxes $ 7.0 $ 220.2 $ 229.5 Income taxes paid $ 193.6 $ 340.1 $ 272.3 A reconciliation of the U.S. statutory income tax rate to our effective tax rate is as follows: For the Years Ended December 31, 2015 2014 2013 U.S. statutory income tax rate 35.0 % 35.0 % 35.0 % State taxes, net of federal deduction (2.4 ) 0.7 0.8 Tax impact of foreign operations, (40.2 ) (11.7 ) (12.1 ) Change in valuation allowance (3.7 ) – – Non-deductible expenses 2.4 – – Tax impact of certain significant 21.6 1.4 1.6 Tax benefit relating to U.S. (6.2 ) (1.9 ) (1.8 ) R&D credit (2.5 ) (0.2 ) (0.6 ) Other 0.6 0.1 (0.1 ) Effective income tax rate 4.6 % 23.4 % 22.8 % Our operations in Puerto Rico and Switzerland benefit from various tax incentive grants. These grants expire between fiscal years 2019 and 2029. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Valuation allowances are recorded to reduce deferred income tax assets when it is more likely than not that an income tax benefit will not be realized. The components of deferred taxes consisted of the following (in millions): As of December 31, 2015 2014 Deferred tax assets: Inventory $ 159.7 $ 275.1 Net operating loss carryover 117.4 116.9 Tax credit carryover 207.8 185.5 Capital loss carryover 4.2 7.4 Accrued liabilities 190.2 106.7 Share-based compensation 59.0 59.9 Accounts receivable 23.7 – Unremitted earnings of foreign subsidiaries – 32.3 Other 133.6 50.3 Total deferred tax assets 895.6 834.1 Less: Valuation allowances (72.7 ) (122.8 ) Total deferred tax assets after valuation allowances 822.9 711.3 Deferred tax liabilities: Fixed assets $ (144.6 ) $ (104.3 ) Intangible assets (2,337.2 ) (95.9 ) Unremitted earnings of foreign subsidiaries (1,374.8 ) – Other (4.3 ) – Total deferred tax liabilities (3,860.9 ) (200.2 ) Total net deferred income taxes $ (3,038.0 ) $ 511.1 Net operating loss carryovers are available to reduce future federal, state and foreign taxable earnings. At December 31, 2015, $103.9 million of these net operating loss carryovers generally expire within a period of 1 to 20 years and $13.5 million of these net operating loss carryovers have an indefinite life. Valuation allowances for net operating loss carryovers have been established in the amount of $47.0 million and $99.0 million at December 31, 2015 and 2014, respectively. Deferred tax assets related to tax credit carryovers are available to offset future federal, state and foreign tax liabilities. At December 31, 2015, the Company’s total tax credit carryovers of $207.8 million generally expire within a period of 1 to 10 years. Valuation allowances for certain tax credit carryovers have been established in the amount of $14.4 million and $11.5 million at December 31, 2015 and 2014, respectively. Deferred tax assets related to capital loss carryovers are also available to reduce future federal capital gains. At December 31, 2015, the Company’s capital loss carryovers of $4.2 million generally expire within a period of 2 to 4 years. Valuation allowances for certain capital loss carryovers have been established in the amount of $4.2 million and $7.4 million at December 31, 2015 and 2014, respectively. The remaining valuation allowances booked against deferred tax assets of $7.1 million and $4.9 million at December 31, 2015 and 2014, respectively, relate primarily to intangible assets and potential capital losses that management believes, more likely than not, will not be realized. At December 31, 2015, we had an aggregate of approximately $3,853 million of unremitted earnings of foreign subsidiaries that have been, or are intended to be, indefinitely reinvested for continued use in foreign operations. If the total undistributed earnings of foreign subsidiaries were remitted, a significant amount of the additional tax would be offset by the allowable foreign tax credits. It is not practical for us to determine the additional tax related to remitting these earnings. The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions): For the Years Ended December 31, 2015 2014 2013 Balance at January 1 $ 321.7 $ 311.0 $ 293.9 Increase related to the merger* 247.6 – – Increases related to prior periods 1.3 0.9 16.5 Decreases related to prior periods – (3.8 ) (17.3 ) Increases related to current period 25.7 18.3 20.8 Decreases related to settlements with taxing authorities (1.4 ) (3.0 ) (2.9 ) Decreases related to lapse of statute of limitations (3.0 ) (1.7 ) – Balance at December 31 $ 591.9 $ 321.7 $ 311.0 Amounts impacting effective tax rate, if recognized balance at December 31* $ 526.6 $ 186.3 $ 191.2 * Subject to change during measurement period of the merger. We recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. During 2015, we accrued interest and penalties of $4.8 million, and as of December 31, 2015, had a recognized liability for interest and penalties of $82.9 million, which included a $29.8 million increase from December 31, 2014 related to the Biomet merger. During 2014, we accrued interest and penalties of $5.9 million, and as of December 31, 2014, had recognized a liability for interest and penalties of $48.3 million. During 2013, we accrued interest and penalties of $8.1 million, and as of December 31, 2013, had recognized a liability for interest and penalties of $42.4 million. We operate on a global basis and are subject to examinations by taxing authorities throughout the world, including major jurisdictions such as: Australia, Canada, China, France, Germany, Ireland, Italy, Japan, Luxembourg, the Netherlands, Puerto Rico, Spain, Switzerland, the United Kingdom and the United States. Our U.S. Federal income tax returns have been audited through 2009 and are currently under audit for years 2010-2014. The IRS has proposed adjustments for years 2005-2009, reallocating profits between certain of our U.S. and foreign subsidiaries. We have disputed these adjustments and intend to continue to vigorously defend our positions. For years 2005-2007, we have filed a petition with the U.S. Tax Court. For years 2008-2009, we are pursuing resolution through the IRS Administrative Appeals Process. The acquired Biomet consolidation group has been audited through financial year 2008. State income tax returns are generally subject to examination for a period of 3 to 5 years after filing of the respective return. The state impact of any federal changes generally remains subject to examination by various states for a period of up to one year after formal notification to the states. We have various state income tax return positions in the process of examination, administrative appeals or litigation. In other major jurisdictions, open years are generally 2008 or later. The net amount of tax liability for unrecognized tax benefits may change within the next twelve months due to changes in audit status, expiration of statutes of limitations, settlements of tax assessments and other events which could impact our determination of unrecognized tax benefits. Currently, we cannot reasonably estimate the amount by which our unrecognized tax benefits will change.

Capital Stock and Earnings per

Capital Stock and Earnings per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Capital Stock and Earnings per Share	17. Capital Stock and Earnings per Share We are authorized to issue 250.0 million shares of preferred stock, none of which were issued or outstanding as of December 31, 2015. The numerator for both basic and diluted earnings per share is net earnings available to common stockholders. The denominator for basic earnings per share is the weighted average number of common shares outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted for the effect of dilutive stock options and other equity awards. The following is a reconciliation of weighted average shares for the basic and diluted share computations (in millions): For the Years Ended December 31, 2015 2014 2013 Weighted average shares outstanding for basic net earnings per share 187.4 169.0 169.6 Effect of dilutive stock options and other equity awards 2.4 2.7 2.2 Weighted average shares outstanding for diluted net earnings per share 189.8 171.7 171.8 For the years ended December 31, 2015 and 2013, an average of 0.5 million and 3.1 million options, respectively, to purchase shares of common stock were not included in the computation of diluted earnings per share as the exercise prices of these options were greater than the average market price of the common stock. In the year ended December 31, 2014, all outstanding options to purchase shares of common stock were included in the computation of diluted earnings per share as the exercise prices of all options were less than the average market price of the common stock. During 2015, we repurchased 1.4 million shares of our common stock at an average price of $106.01 per share for a total cash outlay of $150.0 million, including commissions.

Segment Data

Segment Data	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Data	18. Segment Data We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Due to the Biomet merger, we changed our senior management organizational structure which has resulted in a change to our operating segments. We now allocate resources to achieve our operating profit goals through seven operating segments. Our operating segments are comprised of both geographic and product category business units. The geographic operating segments are the Americas, which is comprised principally of the U.S. and includes other North, Central and South American markets; EMEA, which is comprised principally of Europe and includes the Middle East and African markets; and Asia Pacific, which is comprised primarily of Japan and includes other Asian and Pacific markets. The product category operating segments are Americas Spine, Bone Healing, CMF and Dental. The geographic operating segments include results from all of our product categories except those in the product category operating segments. The Bone Healing, CMF and Dental product category operating segments reflect those respective product category results from all regions, whereas the Americas Spine operating segment only includes spine product results from the Americas. As it relates to the geographic operating segments, management evaluates performance based upon segment operating profit exclusive of operating expenses pertaining to inventory step-up and certain other inventory and manufacturing related charges, “Certain claims,” goodwill impairment, intangible asset amortization, “Special items,” and global operations and corporate functions. Global operations and corporate functions include research, development engineering, medical education, brand management, corporate legal, finance and human resource functions, manufacturing operations and logistics and share-based payment expense. As it relates to each product category operating segment, research, development engineering, medical education, brand management and other various costs that are specific to the product category operating segment’s operations are reflected in its operating profit results. Due to these additional costs included in the product category operating segments, profitability metrics between the geographic operating segments and product category operating segments are not comparable. Intercompany transactions have been eliminated from segment operating profit. Management reviews accounts receivable, inventory, and property, plant and equipment assets by reportable segment exclusive of manufacturing operations and logistics and corporate assets. These seven operating segments are the basis for our reportable segment information provided below. The four product category operating segments are individually insignificant to our consolidated results and therefore do not constitute a reporting segment either individually or combined. For presentation purposes, these product category operating segments have been aggregated. Prior period reportable segment financial information has been restated to conform to the current period. Net sales and other information by segment is as follows (in millions): Americas EMEA Asia Product Global Total As of and for the Year Ended December 31, 2015 Net sales $ 3,109.4 $ 1,302.9 $ 881.6 $ 703.9 $ – $ 5,997.8 Depreciation and amortization 110.0 61.1 37.9 21.0 482.4 712.4 Segment operating profit 1,647.0 445.3 421.9 167.9 (689.1 ) 1,993.0 Inventory step-up and certain other inventory and manufacturing related charges (348.8 ) Intangible asset amortization (337.4 ) Certain claims (7.7 ) Special items Biomet merger related (619.1 ) Other special items (212.7 ) Operating profit 467.3 Total assets 1,525.0 1,382.2 642.4 788.3 22,881.6 27,219.5 Additions to instruments 1.6 0.2 4.7 22.8 237.1 266.4 Additions to other property, plant and equipment 21.7 3.4 9.0 4.6 129.0 167.7 As of and for the Year Ended December 31, 2014 Net sales $ 2,320.2 $ 1,189.1 $ 789.2 $ 374.8 $ – $ 4,673.3 Depreciation and amortization 70.5 46.0 30.2 7.5 221.6 375.8 Segment operating profit 1,215.4 435.6 371.0 76.5 (569.8 ) 1,528.7 Inventory step-up and certain other inventory and manufacturing related charges (36.3 ) Intangible asset amortization (92.5 ) Certain claims (21.5 ) Special items Biomet merger related (61.9 ) Other special items (279.2 ) Operating profit 1,037.3 Total assets 1,012.0 924.0 380.3 295.1 7,046.6 9,658.0 Additions to instruments 0.2 0.1 6.0 16.3 174.8 197.4 Additions to other property, plant and equipment 8.6 2.1 9.1 2.6 122.5 144.9 As of and for the Year Ended December 31, 2013 Net sales $ 2,347.6 $ 1,134.0 $ 771.9 $ 369.9 $ – $ 4,623.4 Depreciation and amortization 62.6 48.2 30.0 7.7 210.0 358.5 Segment operating profit 1,293.5 401.2 335.6 79.9 (617.1 ) 1,493.1 Inventory step-up and certain other inventory and manufacturing related charges (88.7 ) Intangible asset amortization (78.5 ) Certain claims (47.0 ) Special items Biomet merger related – Other special items (210.3 ) Operating profit 1,068.6 Total assets 947.9 974.5 375.9 322.9 6,973.8 9,595.0 Additions to instruments 0.2 0.3 6.5 14.9 171.0 192.9 Additions to other property, plant and equipment 8.7 1.2 7.6 4.6 77.9 100.0 For segment reporting purposes, deployed instruments are included in the measurement of reportable segment assets while undeployed instruments at manufacturing operations and logistics are included in global operations and corporate functions. The majority of instruments are purchased by manufacturing operations and logistics and are deployed to the reportable segments as needed for the business. Therefore, the reportable segment assets include deployed instruments even though that reportable segment may not report the instrument addition. We conduct business in the following countries that hold 10 percent or more of our total consolidated Property, plant and equipment, net: As of December 31, 2015 2014 2013 United States $ 1,188.6 $ 794.4 $ 737.6 Switzerland 200.9 198.7 211.5 Other countries 673.1 292.2 280.4 Property, plant and equipment, net $ 2,062.6 $ 1,285.3 $ 1,229.5 U.S. sales were $3,447.2 million, $2,397.9 million and $2,418.2 million for the years ended December 31, 2015, 2014 and 2013, respectively. Sales within any other individual country were less than 10 percent of our consolidated sales in each of those years. Sales are attributable to a country based upon the customer’s country of domicile. Net sales by product category are as follows (in millions): For the Years Ended December 31, 2015 2014 2013 Knees $ 2,276.8 $ 1,895.2 $ 1,862.2 Hips 1,537.2 1,326.4 1,330.5 S.E.T. 1,214.9 863.2 847.2 Dental 335.7 242.8 239.3 Spine & CMF 404.4 207.2 202.3 Other 228.8 138.5 141.9 Total 5,997.8 4,673.3 4,623.4

Leases

Leases	12 Months Ended
	Dec. 31, 2015
Leases [Abstract]
Leases	19. Leases Total rent expense for the years ended December 31, 2015, 2014 and 2013 aggregated $60.1 million, $48.4 million and $49.2 million, respectively. Future minimum rental commitments under non-cancelable operating leases in effect as of December 31, 2015 were (in millions): For the Years Ending December 31, 2016 $ 59.1 2017 44.7 2018 33.9 2019 26.4 2020 21.8 Thereafter 45.9

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	20. Commitments and Contingencies On a quarterly and annual basis, we review relevant information with respect to loss contingencies and update our accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews. We establish liabilities for loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. For matters where a loss is believed to be reasonably possible, but not probable, no accrual has been made. Litigation Durom ® In Re: Zimmer Durom Hip Cup Products Liability Litigation Santas, et al. v. Zimmer, Inc., et al. McAllister, et al. v. Zimmer, Inc., et al. Santas McAllister Since 2008, we have recognized expense of $479.4 million for Durom Cup-related claims, including $7.7 million during the year ended December 31, 2015 that is reported on the “Certain claims” line of our consolidated statement of earnings. We recognized $21.5 million and $47.0 million in expense for Durom Cup-related claims during the years ended December 31, 2014 and 2013, respectively. We maintain insurance for product liability claims, subject to self-insurance retention requirements. As of December 31, 2015, we have exhausted our self-insured retention under our insurance program and have a claim for insurance proceeds for ultimate losses which exceed the self-insured retention amount, subject to a 20 percent co-payment requirement and a cap. We believe our contracts with the insurance carriers are enforceable for these claims and, therefore, it is probable that we will recover some amount from our insurance carriers. We have received a portion of the insurance proceeds we estimate we will recover. We have a $95.3 million receivable in “Other assets” remaining on our consolidated balance sheet as of December 31, 2015 for estimated insurance recoveries for Durom Cup-related claims. As is customary in this process, our insurance carriers have reserved all rights under their respective policies and could still ultimately deny coverage for some or all of our insurance claims. Our estimate as of December 31, 2015 of the remaining liability for all Durom Cup-related claims is $314.6 million, of which $50.0 million is classified as short-term in “Other current liabilities” and $264.6 million is classified as long-term in “Other long-term liabilities” on our consolidated balance sheet. We expect to pay the majority of the Durom Cup-related claims within the next few years. Our understanding of clinical outcomes with the Durom Cup and other large diameter hip cups continues to evolve. We rely on significant estimates in determining the provisions for Durom Cup-related claims, including our estimate of the number of claims that we will receive and the average amount we will pay per claim. The actual number of claims and the actual amount we pay per claim may differ from our estimates. Among other factors, since our understanding of the clinical outcomes is still evolving, we cannot reasonably estimate the possible loss or range of loss that may result from Durom Cup-related claims in excess of the losses we have accrued. Margo and Daniel Polett v. Zimmer, Inc. et al. NexGen Knee System claims In Re: Zimmer NexGen Knee Implant Products Liability Litigation Biomet metal-on-metal hip implant claims (In Re: Biomet M2a Magnum Hip Implant Product Liability Litigation) On February 3, 2014, Biomet announced the settlement of the MDL. Lawsuits filed in the MDL by April 15, 2014 may participate in the settlement. Biomet continues to evaluate the inventory of lawsuits in the MDL pursuant to the categories and procedures set forth in the settlement agreement. The final amount of payments under the settlement is uncertain. The settlement does not affect certain other claims relating to Biomet’s metal-on-metal hip products that are pending in various state and foreign courts, or other claims that may be filed in the future. Our estimate as of December 31, 2015 of the remaining liability for all Biomet metal-on-metal hip implant claims is $33.4 million. Biomet has exhausted the self-insured retention in its insurance program and has been reimbursed for claims related to its metal-on-metal products up to its policy limits in the program. Zimmer Biomet will be responsible for any amounts by which the ultimate losses exceed the amount of Biomet’s third-party insurance coverage. As of December 31, 2015, Biomet had received all of the insurance proceeds it expects to recover under the excess policies. Heraeus trade secret misappropriation lawsuits Following an appeal by Heraeus, on June 5, 2014, the German appeals court (i) enjoined Biomet, Inc., Biomet Europe BV and Biomet Deutschland GmbH from manufacturing, selling or offering the European Cements to the extent they contain certain raw materials in particular specifications; (ii) held the defendants jointly and severally liable to Heraeus for any damages from the sale of European Cements since 2005; and (iii) ruled that no further review may be sought. Damages have not been determined. The judgment is not final and the defendants are seeking review (including review of the appeals court ruling that no further review may be sought) from Germany’s Supreme Court. No prediction can be made as to the likelihood of review being granted by Germany’s Supreme Court. As a result, Biomet Europe BV and Biomet Deutschland GmbH are enjoined from the manufacture, marketing, sale and offering of European Cements in Germany. While Heraeus has indicated that it intends to take the position that the judgment would prohibit the manufacture, marketing, sale and offering of European Cements outside of Germany as well and is attempting to enforce the judgment in a limited number of other European jurisdictions, Biomet, Inc., Biomet Europe BV and Biomet Deutschland GmbH are vigorously contesting any enforcement of the judgment beyond Germany. Biomet, Inc., Biomet Europe BV and Biomet Deutschland GmbH thus filed a declaratory action in Germany on August 3, 2014 to have the court determine the reach of the appeals court decision. On September 8, 2014, Heraeus filed a complaint against a Biomet supplier, Esschem, Inc. (“Esschem”), in the United States District Court for the Eastern District of Pennsylvania. The lawsuit contains allegations that focus on two copolymer compounds that Esschem sells to Biomet, which Biomet incorporates into certain bone cement products that compete with Heraeus’ bone cement products. The complaint alleges that Biomet helped Esschem to develop these copolymers, using Heraeus trade secrets that Biomet allegedly misappropriated. The complaint asserts a claim under the Pennsylvania Trade Secrets Act, as well as other various common law tort claims, all based upon the same trade secret misappropriation theory. Heraeus is seeking to enjoin Esschem from supplying the copolymers to any third party and actual damages in an unspecified amount. The complaint also seeks punitive damages, costs and attorneys’ fees. If Esschem is enjoined, Biomet may not be able to obtain the copolymers from another supplier and as a result may not be able to continue to manufacture the subject bone cement products. Although Heraeus has not named Biomet as a party to this lawsuit, Biomet has agreed, at Esschem’s request and subject to certain limitations, to indemnify Esschem for any liability, damages and legal costs related to this matter. On November 3, 2014, the court entered an order denying Heraeus’ motion for a temporary restraining order. On October 15, 2015, Heraeus initiated expedited proceedings against Biomet France, Biomet SAS, Biomet Europe BV, Biomet, Inc., Biomet Orthopedics Switzerland GmbH and Biomet Global Supply Chain Center BV before the Commercial Court in Paris seeking to enjoin these entities from importing the certain raw materials subject to the rulings in Germany and from manufacturing, selling or exporting the bone cements made from those raw materials, including under the names of the European Cements. On November 16, 2015, the presiding judge ruled that it had no jurisdiction over Biomet, Inc. and on December 4, 2015, the judge denied the preliminary measures requested by Heraeus. Heraeus has not appealed this ruling or filed an action on the merits before the Commercial Court in Paris. On December 8, 2015, Heraeus filed separate proceedings against Biomet France, Biomet SAS and Biomet France Holding before the Commercial Court of Roman-Sur-Isere seeking to gain access to certain documents which had been seized during searches of Biomet France’s premises in June 2015. Biomet is defending itself vigorously in this proceeding, which is still ongoing. Heraeus continues to initiate other related legal proceedings in Europe seeking various forms of relief, including injunctive relief and damages, against Biomet-related entities relating to the European Cements. No assurance can be made as to the time or resources that will be needed to devote to this litigation or its final outcome. Stryker patent infringement lawsuit ® Bonutti patent infringement lawsuits On September 10, 2012, Bonutti Skeletal filed suit against Zimmer in the U.S. District Court for the District of Delaware, alleging infringement of three U.S. patents. An amended complaint was filed on January 15, 2013, alleging infringement of three additional patents. Zimmer requested an Inter Partes Review (“IPR”) of three of the patents at issue. IPRs were granted for two of the patents. Zimmer moved for a stay of the case during the pendency of the IPRs, and on April 7, 2014, the court granted the stay. In May 2015, the U.S. Patent and Trademark Office issued its decision in the IPRs, invalidating all of the challenged patent claims in both patents. Bonutti Skeletal decided not to appeal that decision. On June 30, 2015, the court lifted the stay and the litigation then proceeded with respect to the remaining patents at issue. On October 30, 2015, the Bonutti litigation was settled in a joint settlement of the legacy Biomet litigation and legacy Zimmer litigation related to the same entity. Regulatory Matters, Government Investigations and Other Matters FDA warning letters Biomet DPA and Consent In October 2013, Biomet became aware of certain alleged improprieties regarding its operations in Brazil and Mexico, including alleged improprieties that predated the entry of the DPA. Biomet retained counsel and other experts to investigate both matters. Based on the results of the ongoing investigations, Biomet has terminated, suspended or otherwise disciplined certain of the employees and executives involved in these matters, and has taken certain other remedial measures. Additionally, pursuant to the terms of the DPA, in April 2014 and thereafter, Biomet disclosed these matters to and discussed these matters with the independent compliance monitor and the DOJ and SEC. On July 2, 2014 and July 13, 2015, the SEC issued subpoenas to Biomet requiring that Biomet produce certain documents relating to such matters. These matters remain under investigation by the DOJ. On March 13, 2015, the DOJ informed Biomet that the DPA and the independent compliance monitor’s appointment have been extended for an additional year. On April 2, 2015, at the request of the staff of the SEC, Biomet consented to an amendment to the Final Judgment to extend the term of the compliance monitor’s appointment for one year from the date of entry of the Amended Final Judgment. Pursuant to the DPA, the DOJ has sole discretion to determine whether conduct by Biomet constitutes a violation or breach of the DPA. The DOJ has informed Biomet that it retains its rights under the DPA to bring further action against Biomet relating to the conduct in Brazil and Mexico referenced above or the violations set forth in the DPA. The DOJ could, among other things, revoke the DPA or prosecute Biomet and/or the involved former employees and executives. Biomet continues to cooperate with the SEC and DOJ and expects that discussions with the SEC and the DOJ will continue. While we are devoting significant time and resources to these matters, we can give no assurances as to their final outcome. Other Government Investigations and Document Requests In July 2011, Biomet received an administrative subpoena from the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) requesting documents concerning the export of products to Iran. OFAC informed Biomet that the subpoena related to allegations that Biomet may have been involved in unauthorized sales of dental products to Iran. Biomet is fully cooperating in the investigation and submitted its response to the subpoena in October 2011. We may need to devote significant time and resources to this inquiry and can give no assurances as to its final outcome. In February 2010, Biomet received a subpoena from the Office of the Inspector General of the U.S. Department of Health and Human Services requesting various documents relating to agreements or arrangements between physicians and Biomet’s Interpore Cross subsidiary for the period from 1999 through the date of the subpoena and the marketing and sales activities associated with Interpore Cross’ spinal products. Biomet is fully cooperating in the investigation. We may need to devote significant time and resources to this inquiry and can give no assurances as to its final outcome.

Quarterly Financial Information

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	21. Quarterly Financial Information (Unaudited) (in millions, except per share data) 2015 Quarter Ended 2014 Quarter Ended Mar Jun Sep Dec Mar Jun Sep Dec Net sales $ 1,134.4 $ 1,167.6 $ 1,762.2 $ 1,933.6 $ 1,161.5 $ 1,182.9 $ 1,106.0 $ 1,222.9 Gross profit 829.1 840.3 1,087.5 1,102.9 826.8 833.1 789.5 888.6 Net earnings of Zimmer Biomet Holdings, Inc. 171.4 (173.6 ) 22.2 127.0 221.0 172.4 173.1 153.8 Earnings per common share Basic 1.01 (1.00 ) 0.11 0.62 1.31 1.02 1.02 0.91 Diluted 0.99 (1.00 ) 0.11 0.62 1.29 1.01 1.01 0.89

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	SCHEDULE II ZIMMER HOLDINGS, INC. VALUATION AND QUALIFYING ACCOUNTS (in millions) Description Balance at Additions Deductions Effects of Acquired Balance at Period Allowance for Doubtful Accounts: Year Ended December 31, 2013 22.8 1.9 (1.5 ) (0.5 ) – 22.7 Year Ended December 31, 2014 22.7 2.0 (1.4 ) (1.0 ) – 22.3 Year Ended December 31, 2015 22.3 13.5 (0.4 ) (1.3 ) – 34.1 Deferred Tax Asset Valuation Allowances: Year End December 31, 2013 41.3 1.5 (0.1 ) – – 42.7 Year End December 31, 2014 42.7 74.7 (9.2 ) – 14.6 122.8 Year End December 31, 2015 122.8 (53.7 ) (5.6 ) (1.6 ) 10.8 72.7

Significant Accounting Polici30

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
Use of Estimates	Use of Estimates
Foreign Currency Translation	Foreign Currency Translation
Revenue Recognition	Revenue Recognition Sales to stocking distributors, healthcare dealers, dental practices and dental laboratories accounted for approximately 20 percent of our net sales in 2015. With these types of sales, revenue is recognized when title to product passes, either upon shipment of the product or in some cases upon implantation of the product. Product is generally sold at contractually fixed prices for specified periods. Payment terms vary by customer, but are typically less than 90 days. If sales incentives are earned by a customer for purchasing a specified amount of our product, we estimate whether such incentives will be achieved and, if so, recognize these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. Occasionally products are returned and, accordingly, we maintain an estimated sales return reserve that is recorded as a reduction in revenue. Product returns were not significant for the years ended December 31, 2015, 2014 and 2013. Taxes collected from customers and remitted to governmental authorities are presented on a net basis and excluded from revenues.
Shipping and Handling	Shipping and Handling
Research and Development	Research and Development
Litigation	Litigation
Special Items	Special Items For the Years Ended December 31, 2015 2014 2013 Biomet-related Merger compensation expense $ 90.4 $ – $ – Retention plans 73.0 – – Employee termination benefits 101.0 – – Consulting and professional fees 167.4 61.5 – Dedicated project personnel 62.3 0.4 – Relocated facilities 5.6 – – Contract terminations 95.0 – – Information technology integration 5.2 – – Other 19.2 – – Other Employee termination benefits 1.9 0.9 14.2 Consulting and professional fees 114.8 115.2 99.1 Dedicated project personnel 31.8 50.4 34.0 Impairment/loss on disposal of assets 2.3 24.0 10.9 Certain R&D agreements – 4.5 0.8 Relocated facilities – 0.7 3.6 Distributor acquisitions – 0.6 0.4 Certain litigation matters 31.2 70.0 26.9 Contract terminations – 1.8 3.9 Information technology integration 1.8 – – Contingent consideration adjustments 2.4 0.6 9.0 Accelerated software amortization 1.5 6.0 6.0 Other 25.0 4.5 1.5 Special items $ 831.8 $ 341.1 $ 210.3 Pursuant to the Biomet merger agreement, all outstanding LVB stock options and LVB stock-based awards vested immediately prior to the effective time of the merger, and holders of these options and awards received a portion of the aggregate merger consideration. Some of these options and awards were already vested under the terms of LVB’s equity incentive plans. We accounted for the fair value of the consideration we paid in exchange for previously vested options and awards as consideration to complete the merger. As part of the merger agreement terms, all previously unvested options and awards vested immediately prior to the effective time of the merger. Under LVB’s equity incentive plans, unvested options and awards would have otherwise been forfeited. We have concluded that the discretionary accelerated vesting of these unvested options and awards was for the economic benefit of the combined company, and, therefore, we classified the fair value of the merger consideration we paid to holders of such unvested options and awards of $90.4 million as compensation expense. Pursuant to the LVB merger agreement, retention plans were established for certain Biomet employees and third-party sales agents. Retention payments were earned by employees and third-party sales agents who remained with Biomet through the Closing Date. We recognized $73.0 million of expense resulting from these retention plans. After the Closing Date, we started to implement our integration plans to drive operational synergies. Part of these integration plans included termination of employees and certain contracts. Expenses attributable to the initial phase of these integration plans that were recognized in 2015 as part of “Special items” related to employee termination benefits and contract termination expense associated with agreements with independent agents, distributors, suppliers and lessors. Our integration plans are expected to last through 2018 and we expect to incur a total of $170.0 million for employee termination benefits and $130.0 million for contract termination expense in that time period. The following table summarizes the liabilities related to these integration plans (in millions): Employee Contract Total Balance, Closing Date $ – $ – $ – Additions 101.0 95.0 196.0 Cash payments (54.1 ) (39.0 ) (93.1 ) Foreign currency exchange rate changes (0.1 ) – (0.1 ) Balance, December 31, 2015 $ 46.8 $ 56.0 $ 102.8 Consulting and professional fees relate to third-party consulting, professional fees and contract labor related to our quality and operational excellence initiatives, third-party consulting fees related to certain information system implementations, third-party integration consulting performed in a variety of areas such as tax, compliance, logistics and human resources for our business combinations and merger with Biomet, third-party fees related to severance and termination benefits matters and legal fees related to certain litigation matters. Our quality and operational excellence initiatives are company-wide and include improvements in quality, distribution, sourcing, manufacturing and information technology, among other areas. Dedicated project personnel expenses include the salary, benefits, travel expenses and other costs directly associated with employees who are 100 percent dedicated to our quality and operational excellence initiatives or integration of acquired businesses. Impairment/loss on disposal of assets relates to impairment of intangible assets that were acquired in business combinations or impairment of or a loss on the disposal of other assets. This caption also includes the effect of reducing the estimated useful life of certain intangible assets to zero, which resulted in the remaining net book values of those assets being amortized immediately. Certain R&D agreements relate to agreements with upfront payments to obtain intellectual property to be used in R&D projects that have no alternative future use in other projects. Relocated facilities expenses are the moving costs and the lease expenses incurred during the relocation period in connection with relocating certain facilities. Over the past few years we have acquired a number of U.S. and foreign-based distributors. We have incurred various costs related to the consummation and integration of those businesses. Certain litigation matters relate to net expenses recognized during the year for the estimated or actual settlement of certain pending litigation and similar claims, including matters where we recognized income from a settlement on more favorable terms than our previous estimate, or we reduced our estimate of a previously recorded contingent liability. These litigation matters have included royalty disputes, patent litigation matters and commercial litigation matters. Contract termination costs relate to terminated agreements in connection with the integration of acquired companies and changes to our distribution model as part of business restructuring and operational excellence initiatives. The terminated contracts primarily relate to sales agents and distribution agreements. Information technology integration costs are non-capitalizable costs incurred related to integrating information technology platforms of acquired companies or other significant software implementations as part of our quality and operational excellence initiatives. Contingent consideration adjustments represent the changes in the fair value of contingent consideration obligations to be paid to the prior owners of acquired businesses. Accelerated software amortization is the incremental amortization resulting from a reduction in the estimated life of certain software. Due to an approved plan to replace certain software, the estimated economic useful life of the existing software was decreased to represent the period of time expected to implement replacement software. As a result, the amortization from the shortened life of this software is substantially higher than the previous amortization being recognized.
Cash and Cash Equivalents	Cash and Cash Equivalents
Investments	Investments
Accounts Receivable	Accounts Receivable
Inventories	Inventories
Property, Plant and Equipment	Property, Plant and Equipment
Software Costs	Software Costs
Instruments	Instruments
Goodwill	Goodwill
Intangible Assets	Intangible Assets In determining the useful lives of intangible assets, we consider the expected use of the assets and the effects of obsolescence, demand, competition, anticipated technological advances, changes in surgical techniques, market influences and other economic factors. For technology-based intangible assets, we consider the expected life cycles of products, absent unforeseen technological advances, which incorporate the corresponding technology. Trademarks and trade names that do not have a wasting characteristic (i.e., there are no legal, regulatory, contractual, competitive, economic or other factors which limit the useful life) are assigned an indefinite life. Trademarks and trade names that are related to products expected to be phased out are assigned lives consistent with the period in which the products bearing each brand are expected to be sold. For customer relationship intangible assets, we assign useful lives based upon historical levels of customer attrition. Intellectual property rights are assigned useful lives that approximate the contractual life of any related patent or the period for which we maintain exclusivity over the intellectual property.
Income Taxes	Income Taxes – We reduce our deferred tax assets by a valuation allowance if it is more likely than not that we will not realize some portion or all of the deferred tax assets. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. We operate on a global basis and are subject to numerous and complex tax laws and regulations. Our income tax filings are regularly under audit in multiple federal, state and foreign jurisdictions. Income tax audits may require an extended period of time to reach resolution and may result in significant income tax adjustments when interpretation of tax laws or allocation of company profits is disputed. Because income tax adjustments in certain jurisdictions can be significant, we record accruals representing management’s best estimate of the probable resolution of these matters. To the extent additional information becomes available, such accruals are adjusted to reflect the revised estimated probable outcome.
Derivative Financial Instruments	Derivative Financial Instruments
Other Comprehensive Income	Other Comprehensive Income (Loss)
Treasury Stock	Treasury Stock
Noncontrolling Interest	Noncontrolling Interest
Accounting Pronouncements	Accounting Pronouncements Revenue from Contracts with Customers (Topic 606) In April 2015, the FASB issued ASU 2015-03 – Simplifying the Presentation of Debt Issuance Costs In September 2015, the FASB issued ASU 2015-16 – Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments On November 20, 2015, the FASB issued ASU 2015-17 – Balance Sheet Classification of Deferred Taxes There are no other recently issued accounting pronouncements that we have not yet adopted that are expected to have a material effect on our financial position, results of operations or cash flows.

Revision of Prior Period Fina31

Revision of Prior Period Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Schedule of Prior Period Adjustments	Following is a summary of the financial statement line items impacted by these revisions for the periods presented in this Form 10-K (in millions, except per share amounts). Revisions to the Consolidated Statements of Earnings and Comprehensive Income (Loss) Year Ended December 31, 2014 Year Ended December 31, 2013 As Reported Adjustments As Revised As Reported Adjustments As Revised Cost of products sold, excluding intangible asset amortization $ 1,242.7 $ 0.1 $ 1,242.8 $ 1,280.1 $ (13.4 ) $ 1,266.7 Research and development 187.9 (0.5 ) 187.4 203.4 (0.4 ) 203.0 Selling, general and administrative 1,744.4 6.3 1,750.7 1,758.8 (9.5 ) 1,749.3 Special items 342.5 (1.4 ) 341.1 214.0 (3.7 ) 210.3 Operating expenses 3,631.5 4.5 3,636.0 3,581.8 (27.0 ) 3,554.8 Earnings before income taxes 943.9 (4.5 ) 939.4 981.1 27.0 1,008.1 Provision for income taxes 224.9 (4.7 ) 220.2 221.9 7.6 229.5 Net earnings 719.0 0.2 719.2 759.2 19.4 778.6 Net Earnings of Zimmer Holdings, Inc. $ 720.1 $ 0.2 $ 720.3 $ 761.0 $ 19.4 $ 780.4 Earnings Per Common Share - Basic $ 4.26 $ – $ 4.26 $ 4.49 $ 0.11 $ 4.60 Earnings Per Common Share - Diluted $ 4.19 $ 0.01 $ 4.20 $ 4.43 $ 0.11 $ 4.54 Foreign currency cumulative translation adjustments $ (241.5 ) $ 18.4 $ (223.1 ) $ (44.4 ) $ 9.4 $ (35.0 ) Total Other Comprehensive Income (Loss) (281.2 ) 18.4 (262.8 ) 23.2 9.4 32.6 Comprehensive Income 437.8 18.6 456.4 782.4 28.8 811.2 Comprehensive Income Attributable to Zimmer Holdings, Inc. 438.8 18.6 457.4 784.4 28.8 813.2 Revisions to the Consolidated Balance Sheet December 31, 2014 As Reported Adjustments As Revised Inventories $ 1,169.0 $ 24.3 $ 1,193.3 Total Current Assets 4,289.0 24.3 4,313.3 Property, plant and equipment, net 1,288.8 (3.5 ) 1,285.3 Other assets 939.2 2.5 941.7 Total Assets 9,634.7 23.3 9,658.0 Accounts payable 167.1 (21.9 ) 145.2 Income taxes payable 72.4 7.9 80.3 Other current liabilities 798.5 – 798.5 Total Current Liabilities 1,038.0 (14.0 ) 1,024.0 Long-term income tax payable 181.7 8.2 189.9 Total Liabilities 3,112.1 (5.8 ) 3,106.3 Retained earnings 8,285.2 76.9 8,362.1 Accumulated other comprehensive income 85.9 (47.8 ) 38.1 Total Zimmer Holdings, Inc. stockholders’ equity 6,520.8 29.1 6,549.9 Total Stockholders’ Equity 6,522.6 29.1 6,551.7 Total Liabilities and Stockholders’ Equity 9,634.7 23.3 9,658.0 Revisions to the Consolidated Statements of Cash Flows Year ended December 31, 2014 Year ended December 31, 2013 As Reported Adjustments As Revised As Reported Adjustments As Revised Net earnings $ 719.0 $ 0.2 $ 719.2 $ 759.2 $ 19.4 $ 778.6 Deferred income tax provision (84.2 ) (6.3 ) (90.5 ) (126.2 ) – (126.2 ) Changes in operating assets and liabilities, net of effect of acquisitions: Income taxes payable (51.9 ) 1.5 (50.4 ) 96.8 7.6 104.4 Inventories (154.1 ) (10.5 ) (164.6 ) (128.4 ) (19.7 ) (148.1 ) Accounts payable and accrued expenses 120.1 (11.7 ) 108.4 38.3 (4.7 ) 33.6 Other assets and liabilities 87.6 26.8 114.4 (47.1 ) (2.6 ) (49.7 )

Significant Accounting Polici32

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Expenses in Special Items	“Special items” included (in millions): For the Years Ended December 31, 2015 2014 2013 Biomet-related Merger compensation expense $ 90.4 $ – $ – Retention plans 73.0 – – Employee termination benefits 101.0 – – Consulting and professional fees 167.4 61.5 – Dedicated project personnel 62.3 0.4 – Relocated facilities 5.6 – – Contract terminations 95.0 – – Information technology integration 5.2 – – Other 19.2 – – Other Employee termination benefits 1.9 0.9 14.2 Consulting and professional fees 114.8 115.2 99.1 Dedicated project personnel 31.8 50.4 34.0 Impairment/loss on disposal of assets 2.3 24.0 10.9 Certain R&D agreements – 4.5 0.8 Relocated facilities – 0.7 3.6 Distributor acquisitions – 0.6 0.4 Certain litigation matters 31.2 70.0 26.9 Contract terminations – 1.8 3.9 Information technology integration 1.8 – – Contingent consideration adjustments 2.4 0.6 9.0 Accelerated software amortization 1.5 6.0 6.0 Other 25.0 4.5 1.5 Special items $ 831.8 $ 341.1 $ 210.3
Summary of Liabilities Related to Integration Plans	The following table summarizes the liabilities related to these integration plans (in millions): Employee Contract Total Balance, Closing Date $ – $ – $ – Additions 101.0 95.0 196.0 Cash payments (54.1 ) (39.0 ) (93.1 ) Foreign currency exchange rate changes (0.1 ) – (0.1 ) Balance, December 31, 2015 $ 46.8 $ 56.0 $ 102.8

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Summary of Preliminary Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes our estimate of the preliminary fair values of the assets acquired and liabilities assumed at the Closing Date, including measurement period adjustments recognized from our initial purchase price allocation through December 31, 2015 (in millions): Closing Date Adjustments Closing Date Cash $ 494.8 $ – $ 494.8 Accounts receivable, net 544.7 (15.7 ) 529.0 Inventory 1,161.7 84.0 1,245.7 Other current assets 123.4 (97.0 ) 26.4 Property, plant and equipment 699.4 92.0 791.4 Intangible assets not subject to amortization: Trademarks and trade names 515.0 (36.0 ) 479.0 In-process research and development (IPR&D) – 246.0 246.0 Intangible assets subject to amortization: Technology 3,075.3 (583.2 ) 2,492.1 Customer relationships 5,829.0 (873.0 ) 4,956.0 Trademarks and trade names – 389.0 389.0 Other assets 29.5 211.6 241.1 Goodwill 5,270.2 2,303.7 7,573.9 Total assets acquired 17,743.0 1,721.4 19,464.4 Current liabilities 588.9 39.2 628.1 Long-term debt 2,740.0 – 2,740.0 Deferred taxes 2,489.7 1,607.8 4,097.5 Other long-term liabilities 58.2 0.7 58.9 Total liabilities assumed 5,876.8 1,647.7 7,524.5 Net assets acquired $ 11,866.2 $ 73.7 $ 11,939.9
Pro forma Financial Information Adjusted to Give Effect to the Merger	The pro forma financial information has been adjusted to give effect to the merger as if it had occurred on January 1, 2014. Pro Forma Financial Information (Unaudited) Year Ended December 31, 2015 2014 (in millions) Net Sales $ 7,517.7 $ 7,965.2 Net Earnings $ 327.4 $ 314.5

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation Expense	Share-based compensation expense was as follows (in millions): For the Years Ended December 31, 2015 2014 2013 Total expense, pre-tax $ 46.4 $ 49.4 $ 48.5 Tax benefit related to awards (14.5 ) (15.5 ) (15.6 ) Total expense, net of tax $ 31.9 $ 33.9 $ 32.9
Summary of Stock Option Activity	A summary of stock option activity for the year ended December 31, 2015 is as follows (options in thousands): Stock Options Weighted Weighted Intrinsic (in millions) Outstanding at January 1, 2015 7,846 $ 71.94 Options granted 1,717 107.10 Options exercised (1,404 ) 73.09 Options forfeited (185 ) 97.02 Options expired (43 ) 80.59 Outstanding at December 31, 2015 7,931 $ 78.73 5.7 $ 201.1 Vested or expected to vest as of December 31, 2015 7,497 $ 77.59 5.5 $ 197.4 Exercisable at December 31, 2015 4,969 $ 68.67 3.9 $ 168.6
Weighted Average Fair Value for Stock Options Granted	The following table presents information regarding the weighted average fair value for stock options granted, the assumptions used to determine fair value, and the intrinsic value of options exercised in the indicated year: For the Years Ended December 31, 2015 2014 2013 Dividend yield 0.8 % 0.9 % 1.1 % Volatility 22.2 % 25.2 % 24.5 % Risk-free interest rate 1.7 % 1.8 % 1.1 % Expected life (years) 5.3 5.5 6.1 Weighted average fair value of options granted $ 22.30 $ 22.59 $ 16.33 Intrinsic value of options exercised (in millions) $ 49.4 $ 99.6 $ 97.9
Summary of Nonvested RSU Activity	A summary of nonvested RSU activity for the year ended December 31, 2015 is as follows (RSUs in thousands): RSUs Weighted Average Grant Date Fair Value Outstanding at January 1, 2015 1,475 $ 76.60 Granted 556 104.77 Vested (347 ) 67.50 Forfeited (384 ) 74.82 Outstanding at December 31, 2015 1,300 91.64

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories consisted of the following (in millions): As of December 31, 2015 2014 Finished goods $ 1,827.9 $ 924.2 Work in progress 146.1 87.8 Raw materials 280.1 181.3 Inventories $ 2,254.1 $ 1,193.3

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment	Property, plant and equipment consisted of the following (in millions): As of December 31, 2015 2014 Land $ 39.6 $ 20.4 Building and equipment 1,789.3 1,283.4 Capitalized software costs 330.1 294.7 Instruments 2,160.5 1,692.8 Construction in progress 108.4 115.8 4,427.9 3,407.1 Accumulated depreciation (2,365.3 ) (2,121.8 ) Property, plant and equipment, net $ 2,062.6 $ 1,285.3

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Investments in Short and Long-Term Classified as Available-for-Sale Securities	We invest in short and long-term investments classified as available-for-sale securities. Information regarding our investments is as follows (in millions): Gross Unrealized Amortized Cost Gains Losses Fair As of December 31, 2015 Corporate debt securities $ 245.7 $ 0.1 $ (0.4 ) $ 245.4 U.S. government and agency debt securities 21.6 – (0.1 ) 21.5 Commercial paper 4.2 – – 4.2 Certificates of deposit 2.0 – – 2.0 Total short and long-term investments $ 273.5 $ 0.1 $ (0.5 ) $ 273.1 As of December 31, 2014 Corporate debt securities $ 516.9 $ 0.1 $ (0.5 ) $ 516.5 U.S. government and agency debt securities 194.3 – – 194.3 Commercial paper 57.8 – – 57.8 Certificates of deposit 100.3 – – 100.3 Total short and long-term investments $ 869.3 $ 0.1 $ (0.5 ) $ 868.9
Cost and Fair Value of Available-for-Sale Fixed-Maturity Securities by Contractual Maturity	The amortized cost and fair value of our available-for-sale fixed-maturity securities by contractual maturity are as follows (in millions): As of December 31, 2015 Amortized Cost Fair Due in one year or less $ 164.7 $ 164.6 Due after one year through two years 108.8 108.5 Total $ 273.5 $ 273.1

Fair Value Measurements of As38

Fair Value Measurements of Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurement of Assets and Liabilities	The following financial assets and liabilities are recorded at fair value on a recurring basis (in millions): As of December 31, 2015 Fair Value Measurements at Reporting Date Using: Description Recorded Quoted Prices Significant Other (Level 2) Significant (Level 3) Assets Available-for-sale securities Corporate debt securities $ 245.4 $ – $ 245.4 $ – U.S. government and agency debt securities 21.5 – 21.5 – Commercial paper 4.2 – 4.2 – Certificates of deposit 2.0 – 2.0 – Total available-for-sale securities 273.1 – 273.1 – Derivatives, current and long-term Foreign currency forward contracts 96.9 – 96.9 – Interest rate swaps 26.8 – 26.8 – $ 396.8 $ – $ 396.8 $ – Liabilities Derivatives, current and long-term Foreign currency forward contracts 1.6 – 1.6 – $ 1.6 $ – $ 1.6 $ – As of December 31, 2014 Fair Value Measurements at Reporting Date Using: Description Recorded Quoted Prices Significant Other (Level 2) Significant (Level 3) Assets Available-for-sale securities Corporate debt securities $ 516.5 $ – $ 516.5 $ – U.S. government and agency debt securities 194.3 – 194.3 – Commercial paper 57.8 – 57.8 – Certificates of deposit 100.3 – 100.3 – Total available-for-sale securities 868.9 – 868.9 – Derivatives, current and long-term Foreign currency forward contracts 125.5 – 125.5 – Interest rate swaps 24.0 – 24.0 – $ 1,018.4 $ – $ 1,018.4 $ – Liabilities Derivatives, current and long-term Foreign currency forward contracts 1.7 – 1.7 – Forward starting interest rate swaps 59.3 – 59.3 – $ 61.0 $ – $ 61.0 $ –

Goodwill and Other Intangible39

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The following table summarizes the changes in the carrying amount of goodwill (in millions): Americas EMEA Asia Product Category Total Balance at January 1, 2014 Goodwill $ 894.8 $ 1,271.9 $ 161.8 $ 655.7 $ 2,984.2 Accumulated impairment losses – – – (373.0 ) (373.0 ) 894.8 1,271.9 161.8 282.7 2,611.2 Acquisitions 40.6 – – – 40.6 Currency translation (4.3 ) (114.6 ) (13.6 ) (5.1 ) (137.6 ) Balance at December 31, 2014 Goodwill 931.1 1,157.3 148.2 650.6 2,887.2 Accumulated impairment losses – – – (373.0 ) (373.0 ) 931.1 1,157.3 148.2 277.6 2,514.2 Biomet Merger 6,445.2 225.6 408.1 495.0 7,573.9 Currency translation (48.3 ) (91.9 ) (7.4 ) (6.3 ) (153.9 ) Balance at December 31, 2015 Goodwill 7,328.0 1,291.0 548.9 1,139.3 10,307.2 Accumulated impairment losses – – – (373.0 ) (373.0 ) $ 7,328.0 $ 1,291.0 $ 548.9 $ 766.3 $ 9,934.2
Components of Identifiable Intangible Assets	The components of identifiable intangible assets were as follows (in millions): Technology Intellectual Trademarks Customer IPR&D Other Total As of December 31, 2015: Intangible assets subject to amortization: Gross carrying amount $ 3,161.6 $ 181.0 $ 583.3 $ 5,133.0 $ – $ 101.8 $ 9,160.7 Accumulated amortization (591.9 ) (164.8 ) (50.9 ) (269.6 ) – (64.8 ) (1,142.0 ) Intangible assets not subject to amortization: Gross carrying amount – – 479.0 – 248.6 – 727.6 Total identifiable intangible assets $ 2,569.7 $ 16.2 $ 1,011.4 $ 4,863.4 $ 248.6 $ 37.0 $ 8,746.3 As of December 31, 2014: Intangible assets subject to amortization: Gross carrying amount $ 727.2 $ 173.4 $ 74.2 $ 213.8 $ – $ 93.9 $ 1,282.5 Accumulated amortization (458.3 ) (157.7 ) (34.1 ) (99.6 ) – (58.3 ) (808.0 ) Intangible assets not subject to amortization: Gross carrying amount – – 129.0 – – – 129.0 Total identifiable intangible assets $ 268.9 $ 15.7 $ 169.1 $ 114.2 $ – $ 35.6 $ 603.5
Estimated Annual Amortization Expense Based on Intangible Assets Recognized	Estimated annual amortization expense based upon intangible assets recognized as of December 31, 2015 for the years ending December 31, 2016 through 2020 is (in millions): For the Years Ending December 31, 2016 $ 559.9 2017 546.2 2018 529.3 2019 516.1 2020 514.4

Other Current and Long-term L40

Other Current and Long-term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Summary of Other Current and Long-Term Liabilities	Other current and long-term liabilities consisted of the following (in millions): As of December 31, 2015 2014 Other current liabilities: License and service agreements $ 144.1 $ 100.2 Certain claims accrual (Note 20) 50.0 50.0 Litigation settlement accrual (Note 20) – 70.0 Forward starting interest rate swaps – 59.3 Salaries, wages and benefits 265.9 167.7 Accrued liabilities 725.9 351.3 Total other current liabilities $ 1,185.9 $ 798.5 Other long-term liabilities: Long-term income tax payable $ 478.1 $ 189.9 Certain claims accrual (Note 20) 264.6 307.2 Other long-term liabilities 263.0 113.8 Total other long-term liabilities $ 1,005.7 $ 610.9

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Summary of Debt Instruments	Our debt consisted of the following (in millions): As of December 31, 2015 2014 Long-term debt 1.450% Senior Notes due 2017 $ 500.0 $ – 2.000% Senior Notes due 2018 1,150.0 – 4.625% Senior Notes due 2019 500.0 500.0 2.700% Senior Notes due 2020 1,500.0 – 3.375% Senior Notes due 2021 300.0 300.0 3.150% Senior Notes due 2022 750.0 – 3.550% Senior Notes due 2025 2,000.0 – 4.250% Senior Notes due 2035 500.0 – 5.750% Senior Notes due 2039 500.0 500.0 4.450% Senior Notes due 2045 1,250.0 – U.S. Term Loan 2,500.0 – Japan Term Loan 96.8 98.0 Other long-term debt 4.6 4.9 Debt discount (21.9 ) (1.4 ) Adjustment related to interest rate swaps 26.8 24.0 Total long-term debt $ 11,556.3 $ 1,425.5

Accumulated Other Comprehensi42

Accumulated Other Comprehensive (Loss) Income (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Changes in Components of Other Comprehensive Income, Net of Tax	The following table shows the changes in the components of OCI, net of tax (in millions): Foreign Cash Unrealized Defined Balance December 31, 2014 $ 111.8 $ 70.1 $ (0.4 ) $ (143.4 ) OCI before reclassifications (305.2 ) 52.7 (0.2 ) (30.6 ) Reclassifications – (93.0 ) – 9.2 Balance December 31, 2015 $ (193.4 ) $ 29.8 $ (0.6 ) $ (164.8 )
Reclassification Adjustments from Accumulated Other Comprehensive Income	The following table shows the reclassification adjustments from OCI (in millions): Amount of Gain / (Loss) Reclassified from OCI Location on Statement of Earnings For the Years Ended December 31, Component of OCI 2015 2014 2013 Cash flow hedges Foreign exchange forward contracts $ 122.3 $ 33.3 $ 8.0 Cost of products sold Foreign exchange options – – (0.2 ) Cost of products sold Forward starting interest rate swaps (1.3 ) – – Interest expense 121.0 33.3 7.8 Total before tax 28.0 14.4 3.4 Provision for income taxes $ 93.0 $ 18.9 $ 4.4 Net of tax Investments Realized gains on securities $ – $ 0.4 $ – Interest income – 0.4 – Total before tax – – – Provision for income taxes $ – $ 0.4 $ – Net of tax Defined benefit plans Prior service cost $ 5.6 $ 3.9 $ 3.9 * Unrecognized actuarial (loss) (20.1 ) (11.1 ) (16.6 ) * (14.5 ) (7.2 ) (12.7 ) Total before tax (5.3 ) (3.0 ) (4.8 ) Provision for income taxes $ (9.2 ) $ (4.2 ) $ (7.9 ) Net of tax Total reclassifications $ 83.8 $ 15.1 $ (3.5 ) Net of tax * These OCI components are included in the computation of net periodic pension expense (see Note 15).
Tax Effects on Each Component of Other Comprehensive Income Recognized in Statements of Comprehensive Income	The following table shows the tax effects on each component of OCI recognized in our consolidated statements of comprehensive income (in millions): Before Tax Tax Net of Tax For the Years Ended December 31, 2015 2014 2013 2015 2014 2013 2015 2014 2013 Foreign currency cumulative translation adjustments $ (305.2 ) $ (223.1 ) $ (35.0 ) $ – $ – $ – $ (305.2 ) $ (223.1 ) $ (35.0 ) Unrealized cash flow hedge gains 59.1 60.5 63.6 6.4 4.6 30.2 52.7 55.9 33.4 Reclassification adjustments on foreign currency hedges (121.0 ) (33.3 ) (7.8 ) (28.0 ) (14.4 ) (3.4 ) (93.0 ) (18.9 ) (4.4 ) Reclassification adjustments on securities – (0.4 ) – – – – – (0.4 ) – Unrealized gains/(losses) on securities (0.2 ) (0.5 ) 0.1 – – – (0.2 ) (0.5 ) 0.1 Adjustments to prior service cost and unrecognized actuarial assumptions (25.0 ) (104.8 ) 50.3 (3.6 ) (29.0 ) 11.8 (21.4 ) (75.8 ) 38.5 Total Other Comprehensive (Loss) Income $ (392.3 ) $ (301.6 ) $ 71.2 $ (25.2 ) $ (38.8 ) $ 38.6 $ (367.1 ) $ (262.8 ) $ 32.6

Derivative Instruments and He43

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments Designated as Fair Value Hedges	Derivative instruments designated as fair value hedges had the following effects on our consolidated statements of earnings (in millions): Gain /(Loss) on Instrument Gain /(Loss) on Hedged Item Derivative Instrument Location on Statement of Earnings Year Ended December 31, Year Ended December 31, 2015 2014 2013 2015 2014 2013 Interest rate swaps Interest expense $ 2.8 $ 14.7 $ (24.6 ) $ (2.8 ) $ (14.7 ) $ 24.6
Gross Unrealized Losses from Derivative Instruments	Derivative instruments designated as cash flow hedges had the following effects, before taxes, on OCI and net earnings on our consolidated statements of earnings, consolidated statements of comprehensive income and consolidated balance sheets (in millions): Amount of Gain / (Loss) Amount of Gain / (Loss) Year Ended December 31, Year Ended December 31, Derivative Instrument 2015 2014 2013 Location on Statement of Earnings 2015 2014 2013 Foreign exchange forward contracts $ 97.4 $ 119.8 $ 63.9 Cost of products sold $ 122.3 $ 33.3 $ 8.0 Foreign exchange options – – (0.3 ) Cost of products sold – – (0.2 ) Forward starting interest rate swaps (38.3 ) (59.3 ) – Interest expense (1.3 ) – – $ 59.1 $ 60.5 $ 63.6 $ 121.0 $ 33.3 $ 7.8
Derivative Instruments Not Designated as Hedging Instruments	The following gains from these derivative instruments were recognized on our consolidated statements of earnings (in millions): Derivative Instrument Location on Year Ended December 31, Statement of Earnings 2015 2014 2013 Foreign exchange forward contracts Other expense, net $ 28.8 $ 15.3 $ –
Fair Value of Derivative Instruments on Gross Basis	The fair value of derivative instruments on a gross basis is as follows (in millions): As of December 31, 2015 As of December 31, 2014 Balance Sheet Location Fair Value Balance Sheet Location Fair Value Asset Derivatives Foreign exchange forward contracts Other current assets $ 100.5 Other current assets $ 98.7 Foreign exchange forward contracts Other assets 19.8 Other assets 53.1 Interest rate swaps Other assets 26.8 Other assets 24.0 Total asset derivatives $ 147.1 $ 175.8 Liability Derivatives Foreign exchange forward contracts Other current liabilities $ 16.7 Other current liabilities $ 16.4 Forward starting interest rate swaps Other current liabilities – Other current liabilities 59.3 Foreign exchange forward contracts Other long-term liabilities 8.3 Other long-term liabilities 11.6 Total liability derivatives $ 25.0 $ 87.3
Schedule of Effects of Master Netting Agreements on Consolidated Balance Sheets	The table below presents the effects of our master netting agreements on our consolidated balance sheets (in millions): As of December 31, 2015 As of December 31, 2014 Description Location Gross Offset Net Amount Gross Offset Net Amount Asset Derivatives Cash flow hedges Other current assets $ 100.5 $ 16.3 $ 84.2 $ 98.7 $ 15.9 $ 82.8 Cash flow hedges Other assets 19.8 7.1 12.7 53.1 10.4 42.7 Liability Derivatives Cash flow hedges Other current liabilities 16.7 16.3 0.4 16.4 15.9 0.5 Cash flow hedges Other long-term liabilities 8.3 7.1 1.2 11.6 10.4 1.2

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2015
Components of Net Pension Expense	The components of net pension expense for our defined benefit retirement plans were as follows (in millions): U.S. and Puerto Rico Foreign For the Years Ended December 31, 2015 2014 2013 2015 2014 2013 Service cost $ 11.8 $ 10.9 $ 11.9 $ 18.9 $ 14.7 $ 16.1 Interest cost 15.8 15.5 13.2 8.8 9.2 5.6 Expected return on plan assets (31.8 ) (30.8 ) (28.7 ) (13.9 ) (11.0 ) (6.7 ) Amortization of prior service cost (3.7 ) (2.6 ) (2.6 ) (1.9 ) (1.3 ) (1.3 ) Amortization of unrecognized actuarial loss 17.4 10.6 14.8 2.7 0.5 1.8 Net periodic benefit cost $ 9.5 $ 3.6 $ 8.6 $ 14.6 $ 12.1 $ 15.5
Weighted Average Actuarial Assumptions Used to Determine Net Pension Expense for Our Defined Benefit Retirement Plans	The weighted average actuarial assumptions used to determine net pension expense for our defined benefit retirement plans were as follows: U.S. and Puerto Rico Foreign For the Years Ended December 31, 2015 2014 2013 2015 2014 2013 Discount rate 4.56% 4.98% 4.32% 1.94% 2.46% 2.13% Rate of compensation increase 3.29% 3.29% 3.29% 2.00% 1.48% 2.29% Expected long-term rate of return on plan assets 7.75% 7.75% 7.75% 3.05% 2.88% 2.74%
Changes in Projected Benefit Obligations	Changes in projected benefit obligations and plan assets were (in millions): U.S. and Puerto Rico Foreign For the Years Ended December 31, 2015 2014 2015 2014 Projected benefit obligation – beginning of year $ 386.6 $ 316.7 $ 423.7 $ 371.5 Obligation assumed from Biomet – – 159.4 – Service cost 11.8 10.9 18.9 14.7 Interest cost 15.8 15.5 8.8 9.2 Plan amendments (21.9 ) – – (7.0 ) Employee contributions – – 16.9 18.5 Benefits paid (12.3 ) (10.0 ) (24.1 ) (22.6 ) Actuarial (gain) loss (4.9 ) 53.5 (18.9 ) 77.9 Expenses paid – – (0.3 ) (0.2 ) Settlement – – (0.2 ) – Translation (gain) loss – – (15.6 ) (38.3 ) Projected benefit obligation – end of year $ 375.1 $ 386.6 $ 568.6 $ 423.7
Changes in Fair Value of Plan Assets	For the Years Ended December 31, U.S. and Puerto Rico Foreign 2015 2014 2015 2014 Plan assets at fair market value - beginning of year $ 402.2 $ 398.6 $ 385.4 $ 372.3 Assets contributed by Biomet – – 129.4 – Actual return on plan assets (16.6 ) 10.9 (4.0 ) 38.0 Employer contributions 0.8 2.7 14.8 14.7 Employee contributions – – 16.9 18.5 Plan amendments – – (0.2 ) – Benefits paid (12.3 ) (10.0 ) (24.1 ) (22.6 ) Expenses paid – – (0.3 ) (0.2 ) Translation gain (loss) – – (12.3 ) (35.3 ) Plan assets at fair market value - end of year $ 374.1 $ 402.2 $ 505.6 $ 385.4 Funded status $ (1.0 ) $ 15.6 $ (63.0 ) $ (38.3 )
Summary of Amounts Recognized in Balance Sheet	For the Years Ended December 31, U.S. and Puerto Rico Foreign 2015 2014 2015 2014 Amounts recognized in consolidated balance sheet: Prepaid pension $ 14.6 $ 29.4 $ 16.5 $ 12.4 Short-term accrued benefit liability (1.0 ) (0.7 ) (0.6 ) (0.5 ) Long-term accrued benefit liability (14.6 ) (13.1 ) (78.9 ) (50.2 ) Net amount recognized $ (1.0 ) $ 15.6 $ (63.0 ) $ (38.3 )
Summary of Amounts Recognized in Other Comprehensive Income Loss	We estimate the following amounts recorded as part of accumulated other comprehensive income will be recognized as part of our net pension expense during 2016 (in millions): U.S. and Foreign Unrecognized prior service cost $ (5.9 ) $ (1.9 ) Unrecognized actuarial loss 17.1 2.9 $ 11.2 $ 1.0
Weighted Average Actuarial Assumptions Used to Determine Projected Benefit Obligation for Defined Benefit Retirement Plans	The weighted average actuarial assumptions used to determine the projected benefit obligation for our defined benefit retirement plans were as follows: U.S. and Puerto Rico Foreign For the Years Ended December 31, 2015 2014 2013 2015 2014 2013 Discount rate 4.36 % 4.10 % 4.98 % 1.86 % 1.38 % 2.45 % Rate of compensation increase 3.29 % 3.29 % 3.29 % 2.02 % 1.43 % 1.52 %
Plans with Benefit Obligations in Excess of Plan Assets	Plans with projected benefit obligations in excess of plan assets were as follows (in millions): U.S. and Puerto Rico Foreign As of December 31, 2015 2014 2015 2014 Projected benefit obligation $ 53.8 $ 54.6 $ 393.4 $ 365.2 Plan assets at fair market value 38.2 40.8 319.6 315.0
Total Accumulated Benefit Obligations and Plans with Accumulated Benefit Obligations in Excess of Plan Assets	Total accumulated benefit obligations and plans with accumulated benefit obligations in excess of plan assets were as follows (in millions): U.S. and Puerto Rico Foreign As of December 31, 2015 2014 2015 2014 Total accumulated benefit obligations $ 354.6 $ 337.5 $ 556.8 $ 413.1 Plans with accumulated benefit obligations in excess of plan assets: Accumulated benefit obligation 34.8 32.8 380.1 358.6 Plan assets at fair market value 20.6 22.0 314.9 315.0
Summary of Benefits Expected to be Paid Out	The benefits expected to be paid out in each of the next five years and for the five years combined thereafter are as follows (in millions): For the Years Ending December 31, U.S. and Foreign 2016 14.3 22.4 2017 15.8 22.5 2018 17.3 23.0 2019 19.1 24.0 2020 20.6 23.9 2021-2025 118.4 125.2
Reconciliation of Beginning and Ending Balances of Foreign Pension Plan Assets Measured at Fair Value	The following table provides a reconciliation of the beginning and ending balances of our foreign pension plan assets measured at fair value that used significant unobservable inputs (Level 3) (in millions): December 31, 2015 Beginning Balance $ 68.6 Gains on assets sold 0.2 Change in fair value of assets 2.2 Net purchases and sales 3.5 Translation loss (0.6 ) Ending Balance $ 73.9
U.S. and Puerto Rico [Member]
Fair Value of Pension Plan Assets	The fair value of our U.S. and Puerto Rico pension plan assets by asset category was as follows (in millions): As of December 31, 2015 Fair Value Measurements at Reporting Date Using: Asset Category Total Quoted Prices Significant Significant (Level 3) Cash and cash equivalents $ 2.5 $ 2.5 $ — $ — Equity securities: U.S. large-cap 79.2 — 79.2 — U.S. small-cap 25.6 — 25.6 — International 93.2 — 93.2 — Real estate 27.0 — 27.0 — Commodity-linked mutual funds 16.4 — 16.4 — Intermediate fixed income securities 130.2 — 130.2 — Total $ 374.1 $ 2.5 $ 371.6 $ — As of December 31, 2014 Fair Value Measurements at Reporting Date Using: Asset Category Total Quoted Prices Significant Significant (Level 3) Cash and cash equivalents $ 1.4 $ 1.4 $ — $ — Equity securities: U.S. large-cap 83.7 — 83.7 — U.S. small-cap 23.0 — 23.0 — International 83.0 — 83.0 — Real estate 49.1 — 49.1 — Commodity-linked mutual funds 36.0 — 36.0 — Intermediate fixed income securities 126.0 — 126.0 — Total $ 402.2 $ 1.4 $ 400.8 $ —
Foreign-based Defined Benefit Plans [Member]
Fair Value of Pension Plan Assets	The fair value of our foreign pension plan assets was as follows (in millions): As of December 31, 2015 Fair Value Measurements at Reporting Date Using: Asset Category Total Quoted Prices Significant Significant (Level 3) Cash and cash equivalents $ 34.0 $ 34.0 $ — $ — Equity securities: Energy 4.7 4.7 — — Materials 6.7 6.7 — — Industrials 8.2 8.2 — — Consumer discretionary 6.3 6.3 — — Consumer staples 8.5 8.5 — — Healthcare 8.6 8.6 — — Financials 17.4 17.4 — — Information technology 5.7 5.7 — — Telecommunication services 2.0 2.0 — — Utilities 3.3 3.3 — — Other 80.7 40.6 40.1 — Fixed income securities: Government bonds 104.0 — 104.0 — Corporate bonds 74.5 — 74.5 — Asset-backed securities 14.8 — 14.8 — Other debt 11.3 — 11.3 — Other types of investments: Mortgage loans 9.8 — 9.8 — Insurance contracts 5.8 — 5.8 — Other investments 14.7 — 14.7 — Real estate 84.6 — 10.7 73.9 Total $ 505.6 $ 146.0 $ 285.7 $ 73.9 As of December 31, 2014 Fair Value Measurements at Reporting Date Using: Asset Category Total Quoted Prices Significant Significant (Level 3) Cash and cash equivalents $ 31.0 $ 31.0 $ — $ — Equity securities: Energy 4.7 4.7 — — Materials 7.1 7.1 — — Industrials 7.5 7.5 — — Consumer discretionary 6.5 6.5 — — Consumer staples 7.5 7.5 — — Healthcare 6.8 6.8 — — Financials 16.3 16.3 — — Information technology 4.9 4.9 — — Telecommunication services 2.0 2.0 — — Utilities 3.4 3.4 — — Other 36.7 34.5 2.2 — Fixed income securities: Government bonds 72.5 — 72.5 — Corporate bonds 58.9 — 58.9 — Asset-backed securities 22.0 — 22.0 — Other debt 1.7 — 1.7 — Other types of investments: Mortgage loans 9.2 — 9.2 — Insurance contracts 6.1 — 6.1 — Other investments 12.0 — 12.0 — Real estate 68.6 — — 68.6 Total $ 385.4 $ 132.2 $ 184.6 $ 68.6

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Components of Earnings Before Income Taxes	The components of earnings before income taxes consisted of the following (in millions): For the Years Ended December 31, 2015 2014 2013 United States operations $ (246.2 ) $ 403.3 $ 412.4 Foreign operations 399.4 536.1 595.7 Total $ 153.2 $ 939.4 $ 1,008.1
Provision for Income Taxes and Income Taxes Paid	The provision for income taxes and the income taxes paid consisted of (in millions): Current: Federal $ 55.8 $ 178.2 $ 207.2 State 18.9 16.5 20.8 Foreign 96.3 116.0 127.7 171.0 310.7 355.7 Deferred: Federal (120.6 ) (54.8 ) (91.8 ) State (20.0 ) (6.6 ) (8.4 ) Foreign (23.4 ) (29.1 ) (26.0 ) (164.0 ) (90.5 ) (126.2 ) Provision for income taxes $ 7.0 $ 220.2 $ 229.5 Income taxes paid $ 193.6 $ 340.1 $ 272.3
Reconciliation of U.S. Statutory Income Tax Rate to Our Effective Tax Rate	A reconciliation of the U.S. statutory income tax rate to our effective tax rate is as follows: For the Years Ended December 31, 2015 2014 2013 U.S. statutory income tax rate 35.0 % 35.0 % 35.0 % State taxes, net of federal deduction (2.4 ) 0.7 0.8 Tax impact of foreign operations, (40.2 ) (11.7 ) (12.1 ) Change in valuation allowance (3.7 ) – – Non-deductible expenses 2.4 – – Tax impact of certain significant 21.6 1.4 1.6 Tax benefit relating to U.S. (6.2 ) (1.9 ) (1.8 ) R&D credit (2.5 ) (0.2 ) (0.6 ) Other 0.6 0.1 (0.1 ) Effective income tax rate 4.6 % 23.4 % 22.8 %
Components of Deferred Taxes	The components of deferred taxes consisted of the following (in millions): As of December 31, 2015 2014 Deferred tax assets: Inventory $ 159.7 $ 275.1 Net operating loss carryover 117.4 116.9 Tax credit carryover 207.8 185.5 Capital loss carryover 4.2 7.4 Accrued liabilities 190.2 106.7 Share-based compensation 59.0 59.9 Accounts receivable 23.7 – Unremitted earnings of foreign subsidiaries – 32.3 Other 133.6 50.3 Total deferred tax assets 895.6 834.1 Less: Valuation allowances (72.7 ) (122.8 ) Total deferred tax assets after valuation allowances 822.9 711.3 Deferred tax liabilities: Fixed assets $ (144.6 ) $ (104.3 ) Intangible assets (2,337.2 ) (95.9 ) Unremitted earnings of foreign subsidiaries (1,374.8 ) – Other (4.3 ) – Total deferred tax liabilities (3,860.9 ) (200.2 ) Total net deferred income taxes $ (3,038.0 ) $ 511.1
Tabular Reconciliation of Total Amounts of Unrecognized Tax Benefits	The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions): For the Years Ended December 31, 2015 2014 2013 Balance at January 1 $ 321.7 $ 311.0 $ 293.9 Increase related to the merger* 247.6 – – Increases related to prior periods 1.3 0.9 16.5 Decreases related to prior periods – (3.8 ) (17.3 ) Increases related to current period 25.7 18.3 20.8 Decreases related to settlements with taxing authorities (1.4 ) (3.0 ) (2.9 ) Decreases related to lapse of statute of limitations (3.0 ) (1.7 ) – Balance at December 31 $ 591.9 $ 321.7 $ 311.0 Amounts impacting effective tax rate, if recognized balance at December 31* $ 526.6 $ 186.3 $ 191.2 * Subject to change during measurement period of the merger.

Capital Stock and Earnings pe46

Capital Stock and Earnings per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Reconciliation of Weighted Average Shares for Basic and Diluted Share Computations	The following is a reconciliation of weighted average shares for the basic and diluted share computations (in millions): For the Years Ended December 31, 2015 2014 2013 Weighted average shares outstanding for basic net earnings per share 187.4 169.0 169.6 Effect of dilutive stock options and other equity awards 2.4 2.7 2.2 Weighted average shares outstanding for diluted net earnings per share 189.8 171.7 171.8

Segment Data (Tables)

Segment Data (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Summary of Net Sales and Other Information by Segment	Net sales and other information by segment is as follows (in millions): Americas EMEA Asia Product Global Total As of and for the Year Ended December 31, 2015 Net sales $ 3,109.4 $ 1,302.9 $ 881.6 $ 703.9 $ – $ 5,997.8 Depreciation and amortization 110.0 61.1 37.9 21.0 482.4 712.4 Segment operating profit 1,647.0 445.3 421.9 167.9 (689.1 ) 1,993.0 Inventory step-up and certain other inventory and manufacturing related charges (348.8 ) Intangible asset amortization (337.4 ) Certain claims (7.7 ) Special items Biomet merger related (619.1 ) Other special items (212.7 ) Operating profit 467.3 Total assets 1,525.0 1,382.2 642.4 788.3 22,881.6 27,219.5 Additions to instruments 1.6 0.2 4.7 22.8 237.1 266.4 Additions to other property, plant and equipment 21.7 3.4 9.0 4.6 129.0 167.7 As of and for the Year Ended December 31, 2014 Net sales $ 2,320.2 $ 1,189.1 $ 789.2 $ 374.8 $ – $ 4,673.3 Depreciation and amortization 70.5 46.0 30.2 7.5 221.6 375.8 Segment operating profit 1,215.4 435.6 371.0 76.5 (569.8 ) 1,528.7 Inventory step-up and certain other inventory and manufacturing related charges (36.3 ) Intangible asset amortization (92.5 ) Certain claims (21.5 ) Special items Biomet merger related (61.9 ) Other special items (279.2 ) Operating profit 1,037.3 Total assets 1,012.0 924.0 380.3 295.1 7,046.6 9,658.0 Additions to instruments 0.2 0.1 6.0 16.3 174.8 197.4 Additions to other property, plant and equipment 8.6 2.1 9.1 2.6 122.5 144.9 As of and for the Year Ended December 31, 2013 Net sales $ 2,347.6 $ 1,134.0 $ 771.9 $ 369.9 $ – $ 4,623.4 Depreciation and amortization 62.6 48.2 30.0 7.7 210.0 358.5 Segment operating profit 1,293.5 401.2 335.6 79.9 (617.1 ) 1,493.1 Inventory step-up and certain other inventory and manufacturing related charges (88.7 ) Intangible asset amortization (78.5 ) Certain claims (47.0 ) Special items Biomet merger related – Other special items (210.3 ) Operating profit 1,068.6 Total assets 947.9 974.5 375.9 322.9 6,973.8 9,595.0 Additions to instruments 0.2 0.3 6.5 14.9 171.0 192.9 Additions to other property, plant and equipment 8.7 1.2 7.6 4.6 77.9 100.0
Disclosure on Geographic Areas, Long-Lived Assets	We conduct business in the following countries that hold 10 percent or more of our total consolidated Property, plant and equipment, net: As of December 31, 2015 2014 2013 United States $ 1,188.6 $ 794.4 $ 737.6 Switzerland 200.9 198.7 211.5 Other countries 673.1 292.2 280.4 Property, plant and equipment, net $ 2,062.6 $ 1,285.3 $ 1,229.5
Summary of Net Sales by Product Category	Net sales by product category are as follows (in millions): For the Years Ended December 31, 2015 2014 2013 Knees $ 2,276.8 $ 1,895.2 $ 1,862.2 Hips 1,537.2 1,326.4 1,330.5 S.E.T. 1,214.9 863.2 847.2 Dental 335.7 242.8 239.3 Spine & CMF 404.4 207.2 202.3 Other 228.8 138.5 141.9 Total 5,997.8 4,673.3 4,623.4

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2015
Leases [Abstract]
Schedule of Future Minimum Rental Commitments Under Non-Cancelable Operating Leases	Future minimum rental commitments under non-cancelable operating leases in effect as of December 31, 2015 were (in millions): For the Years Ending December 31, 2016 $ 59.1 2017 44.7 2018 33.9 2019 26.4 2020 21.8 Thereafter 45.9

Quarterly Financial Informati49

Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	(in millions, except per share data) 2015 Quarter Ended 2014 Quarter Ended Mar Jun Sep Dec Mar Jun Sep Dec Net sales $ 1,134.4 $ 1,167.6 $ 1,762.2 $ 1,933.6 $ 1,161.5 $ 1,182.9 $ 1,106.0 $ 1,222.9 Gross profit 829.1 840.3 1,087.5 1,102.9 826.8 833.1 789.5 888.6 Net earnings of Zimmer Biomet Holdings, Inc. 171.4 (173.6 ) 22.2 127.0 221.0 172.4 173.1 153.8 Earnings per common share Basic 1.01 (1.00 ) 0.11 0.62 1.31 1.02 1.02 0.91 Diluted 0.99 (1.00 ) 0.11 0.62 1.29 1.01 1.01 0.89

Revision of Prior Period Fina50

Revision of Prior Period Financial Statements - Additional Information (Detail) - USD ($) $ in Millions	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2015	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Biomet merger consideration compensation expense			$ 90.4	$ 0	$ 0
Biomet acquisition, net of acquired cash			7,760.1
Immaterial Interim Periods Error Correction Adjustments [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Biomet merger consideration compensation expense			$ 52.8
Biomet acquisition, net of acquired cash	$ 52.8	$ 52.8

Revision of Prior Period Fina51

Revision of Prior Period Financial Statements - Revisions to the Consolidated Statements of Earnings and Comprehensive Income (Loss) (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of products sold, excluding intangible asset amortization									$ 1,800.6	$ 1,242.8	$ 1,266.7
Research and development									268.8	187.4	203
Selling, general and administrative									2,284.2	1,750.7	1,749.3
Special items									831.8	341.1	210.3
Operating expenses									5,530.5	3,636	3,554.8
Earnings before income taxes									153.2	939.4	1,008.1
Provision for income taxes									7	220.2	229.5
Net earnings									146.2	719.2	778.6
Net Earnings of Zimmer Holdings, Inc.	$ 127	$ 22.2	$ (173.6)	$ 171.4	$ 153.8	$ 173.1	$ 172.4	$ 221	$ 147	$ 720.3	$ 780.4
Earnings Per Common Share - Basic	$ 0.62	$ 0.11	$ (1)	$ 1.01	$ 0.91	$ 1.02	$ 1.02	$ 1.31	$ 0.78	$ 4.26	$ 4.60
Earnings Per Common Share - Diluted	$ 0.62	$ 0.11	$ (1)	$ 0.99	$ 0.89	$ 1.01	$ 1.01	$ 1.29	$ 0.77	$ 4.20	$ 4.54
Foreign currency cumulative translation adjustments									$ (305.2)	$ (223.1)	$ (35)
Total Other Comprehensive Income (Loss)									(367.1)	(262.8)	32.6
Comprehensive Income									(220.9)	456.4	811.2
Comprehensive Income Attributable to Zimmer Holdings, Inc.									$ (220.6)	457.4	813.2
As Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of products sold, excluding intangible asset amortization										1,242.7	1,280.1
Research and development										187.9	203.4
Selling, general and administrative										1,744.4	1,758.8
Special items										342.5	214
Operating expenses										3,631.5	3,581.8
Earnings before income taxes										943.9	981.1
Provision for income taxes										224.9	221.9
Net earnings										719	759.2
Net Earnings of Zimmer Holdings, Inc.										$ 720.1	$ 761
Earnings Per Common Share - Basic										$ 4.26	$ 4.49
Earnings Per Common Share - Diluted										$ 4.19	$ 4.43
Foreign currency cumulative translation adjustments										$ (241.5)	$ (44.4)
Total Other Comprehensive Income (Loss)										(281.2)	23.2
Comprehensive Income										437.8	782.4
Comprehensive Income Attributable to Zimmer Holdings, Inc.										438.8	784.4
Adjustments [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of products sold, excluding intangible asset amortization										0.1	(13.4)
Research and development										(0.5)	(0.4)
Selling, general and administrative										6.3	(9.5)
Special items										(1.4)	(3.7)
Operating expenses										4.5	(27)
Earnings before income taxes										(4.5)	27
Provision for income taxes										(4.7)	7.6
Net earnings										0.2	19.4
Net Earnings of Zimmer Holdings, Inc.										$ 0.2	$ 19.4
Earnings Per Common Share - Basic											$ 0.11
Earnings Per Common Share - Diluted										$ 0.01	$ 0.11
Foreign currency cumulative translation adjustments										$ 18.4	$ 9.4
Total Other Comprehensive Income (Loss)										18.4	9.4
Comprehensive Income										18.6	28.8
Comprehensive Income Attributable to Zimmer Holdings, Inc.										$ 18.6	$ 28.8

Revision of Prior Period Fina52

Revision of Prior Period Financial Statements - Revisions to the Consolidated Balance Sheet (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Inventories	$ 2,254.1	$ 1,193.3
Total Current Assets	5,862.9	4,313.3
Property, plant and equipment, net	2,062.6	1,285.3	$ 1,229.5
Other assets	613.5	941.7
Total Assets	27,219.5	9,658	9,595
Accounts payable	284.8	145.2
Income taxes payable	147.2	80.3
Other current liabilities	1,185.9	798.5
Total Current Liabilities	1,617.9	1,024
Long-term income tax payable	478.1	189.9
Total Liabilities	17,330.1	3,106.3
Retained earnings	8,347.7	8,362.1
Accumulated other comprehensive income	(329)	38.1
Total Zimmer Holdings, Inc. stockholders' equity	9,887.9	6,549.9
Total Stockholders' Equity	9,889.4	6,551.7	$ 6,310.6	$ 5,848
Total Liabilities and Stockholders' Equity	$ 27,219.5	9,658
As Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Inventories		1,169
Total Current Assets		4,289
Property, plant and equipment, net		1,288.8
Other assets		939.2
Total Assets		9,634.7
Accounts payable		167.1
Income taxes payable		72.4
Other current liabilities		798.5
Total Current Liabilities		1,038
Long-term income tax payable		181.7
Total Liabilities		3,112.1
Retained earnings		8,285.2
Accumulated other comprehensive income		85.9
Total Zimmer Holdings, Inc. stockholders' equity		6,520.8
Total Stockholders' Equity		6,522.6
Total Liabilities and Stockholders' Equity		9,634.7
Adjustments [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Inventories		24.3
Total Current Assets		24.3
Property, plant and equipment, net		(3.5)
Other assets		2.5
Total Assets		23.3
Accounts payable		(21.9)
Income taxes payable		7.9
Total Current Liabilities		(14)
Long-term income tax payable		8.2
Total Liabilities		(5.8)
Retained earnings		76.9
Accumulated other comprehensive income		(47.8)
Total Zimmer Holdings, Inc. stockholders' equity		29.1
Total Stockholders' Equity		29.1
Total Liabilities and Stockholders' Equity		$ 23.3

Revision of Prior Period Fina53

Revision of Prior Period Financial Statements - Revisions to the Consolidated Statements of Cash Flows (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net earnings	$ 146.2	$ 719.2	$ 778.6
Deferred income tax provision	(164)	(90.5)	(126.2)
Changes in operating assets and liabilities, net of effect of acquisitions:
Income taxes payable	163.3	(50.4)	104.4
Inventories	(205.4)	(164.6)	(148.1)
Accounts payable and accrued expenses	(263.1)	108.4	33.6
Other assets and liabilities	$ (21.8)	114.4	(49.7)
As Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net earnings		719	759.2
Deferred income tax provision		(84.2)	(126.2)
Changes in operating assets and liabilities, net of effect of acquisitions:
Income taxes payable		(51.9)	96.8
Inventories		(154.1)	(128.4)
Accounts payable and accrued expenses		120.1	38.3
Other assets and liabilities		87.6	(47.1)
Adjustments [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net earnings		0.2	19.4
Deferred income tax provision		(6.3)
Changes in operating assets and liabilities, net of effect of acquisitions:
Income taxes payable		1.5	7.6
Inventories		(10.5)	(19.7)
Accounts payable and accrued expenses		(11.7)	(4.7)
Other assets and liabilities		$ 26.8	$ (2.6)

Significant Accounting Polici54

Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business And Significant Accounting Policies [Line Items]
Percentage of sales through direct channel	80.00%
Percentage of sales through indirect channel	20.00%
Period terms for payment	90 days
Expenses incurred related to shipping and handling of products	$ 214.2	$ 181.9	$ 163.6
Fair value of merger consideration transferred, classified as compensation expense	90.4	0	$ 0
Merger retention plans, expenses recognized	$ 73
Employees dedication percentage to quality and operational excellence for dedicated project personnel expenses	100.00%
Allowance for doubtful accounts	$ 34.1	$ 22.3
Reclassification of other current assets to debt	11.7
Reclassification of other assets to debt	60.6
Employee Severance [Member]
Business And Significant Accounting Policies [Line Items]
Restructuring Cost	170
Contract Terminations [Member]
Business And Significant Accounting Policies [Line Items]
Restructuring Cost	130
LVB Acquisition Inc [Member]
Business And Significant Accounting Policies [Line Items]
Fair value of merger consideration transferred, classified as compensation expense	90.4
Merger retention plans, expenses recognized	73
Deferred Compensation, Share-based Payments [Member] | LVB Acquisition Inc [Member]
Business And Significant Accounting Policies [Line Items]
Fair value of merger consideration transferred, classified as compensation expense	$ 90.4
Instruments [Member]
Business And Significant Accounting Policies [Line Items]
Average estimated useful life	5 years
Minimum [Member]
Business And Significant Accounting Policies [Line Items]
Useful life of finite lived intangibles	1 year
Minimum [Member] | Building and Building Improvements [Member]
Business And Significant Accounting Policies [Line Items]
Average estimated useful life	10 years
Minimum [Member] | Machinery and Equipment [Member]
Business And Significant Accounting Policies [Line Items]
Average estimated useful life	3 years
Minimum [Member] | Capitalized Software Costs [Member]
Business And Significant Accounting Policies [Line Items]
Average estimated useful life	3 years
Maximum [Member]
Business And Significant Accounting Policies [Line Items]
Useful life of finite lived intangibles	20 years
Maximum [Member] | Building and Building Improvements [Member]
Business And Significant Accounting Policies [Line Items]
Average estimated useful life	40 years
Maximum [Member] | Machinery and Equipment [Member]
Business And Significant Accounting Policies [Line Items]
Average estimated useful life	8 years
Maximum [Member] | Capitalized Software Costs [Member]
Business And Significant Accounting Policies [Line Items]
Average estimated useful life	15 years

Significant Accounting Polici55

Significant Accounting Policies - Summary of Expenses in Special Items (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Biomet-related
Merger compensation expense	$ 90.4	$ 0	$ 0
Retention plans	73
Employee termination benefits	101
Consulting and professional fees	167.4	61.5
Dedicated project personnel	62.3	0.4
Relocated facilities	5.6
Contract terminations	95
Information technology integration	5.2
Other	19.2
Other
Employee termination benefits	1.9	0.9	14.2
Consulting and professional fees	114.8	115.2	99.1
Dedicated project personnel	31.8	50.4	34
Impairment/loss on disposal of assets	2.3	24	10.9
Certain R&D agreements		4.5	0.8
Relocated facilities		0.7	3.6
Distributor acquisitions		0.6	0.4
Certain litigation matters	31.2	70	26.9
Contract terminations		1.8	3.9
Information technology integration	1.8
Contingent consideration adjustments	2.4	0.6	9
Accelerated software amortization	1.5	6	6
Other	25	4.5	1.5
Special items	$ 831.8	$ 341.1	$ 210.3

Significant Accounting Polici56

Significant Accounting Policies - Summary of Liabilities Related to Integration Plans (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
Schedule Of Business Acquisitions Liabilities Related To Integration Plans [Line Items]
Additions	$ 196
Cash payments	(93.1)
Foreign currency exchange rate changes	(0.1)
Closing Balance	102.8
Employee Termination Benefits [Member]
Schedule Of Business Acquisitions Liabilities Related To Integration Plans [Line Items]
Additions	101
Cash payments	(54.1)
Foreign currency exchange rate changes	(0.1)
Closing Balance	46.8
Contract Terminations [Member]
Schedule Of Business Acquisitions Liabilities Related To Integration Plans [Line Items]
Additions	95
Cash payments	(39)
Closing Balance	$ 56

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions

Jun. 24, 2015

Mar. 31, 2015

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Business Acquisition [Line Items]

Business acquisition liability incurred

$ 2,740

$ 2,740

Gain on divestiture of assets

19

Consideration paid, cash

$ 54.3

$ 74.2

Consideration paid, common stock value

3,722.7

Biomet merger consideration compensation expense

90.4

0

0

Net assets acquired

11,939.9

11,939.9

Operating income (loss)

467.3

1,037.3

1,068.6

Net Sales

1,933.6

$ 1,762.2

$ 1,167.6

$ 1,134.4

$ 1,222.9

$ 1,106

$ 1,182.9

$ 1,161.5

5,997.8

4,673.3

$ 4,623.4

Merger retention plans, expenses recognized

$ 73

Maximum expected period to complete research and development projects

2 years

Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Weighted-average amortization period

15 years

Technology [Member]

Business Acquisition [Line Items]

Weighted-average amortization period

15 years

Customer Relationships [Member]

Business Acquisition [Line Items]

Weighted-average amortization period

18 years

LVB Acquisition Inc [Member]

Business Acquisition [Line Items]

Total consideration

$ 12,030.3

Consideration paid, cash

$ 8,307.6

Consideration paid, shares

32.7

Consideration paid, common stock value

$ 3,722.7

Consideration paid, common stock price

$ 113.83

Biomet merger consideration compensation expense

$ 90.4

Net assets acquired

$ 11,939.9

Merger retention plans, expenses recognized

73

Musculoskeletal Industry [Member] | LVB Acquisition Inc [Member]

Business Acquisition [Line Items]

Net worth

50,000

50,000

Biomet [Member]

Business Acquisition [Line Items]

Operating income (loss)

(295.8)

Net Sales

1,602

Operating Income (Loss) [Member] | LVB Acquisition Inc [Member]

Business Acquisition [Line Items]

Biomet merger consideration compensation expense

90.4

Merger retention plans, expenses recognized

73

Operating Expenses [Member] | LVB Acquisition Inc [Member]

Business Acquisition [Line Items]

Biomet merger consideration compensation expense

90.4

Merger retention plans, expenses recognized

73

Merger transaction costs

$ 17.7

$ 17.7

Senior Notes [Member] | LVB Acquisition Inc [Member]

Business Acquisition [Line Items]

Business acquisition liability incurred

$ 2,740

$ 2,740

Senior Unsecured Term Loan [Member]

Business Acquisition [Line Items]

Proceeds from senior unsecured notes

$ 3,000

Senior Unsecured Notes [Member]

Business Acquisition [Line Items]

Proceeds from senior unsecured notes

$ 7,650

Business Combinations - Summary

Business Combinations - Summary of Preliminary Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 24, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Cash	$ 494.8
Accounts receivable, net	529
Inventory	1,245.7
Other current assets	26.4
Property, plant and equipment	791.4
Other assets	241.1
Goodwill	9,934.2		$ 2,514.2	$ 2,611.2
Total assets acquired	19,464.4
Current liabilities	628.1
Long-term debt	2,740
Deferred taxes	4,097.5
Other long-term liabilities	58.9
Total liabilities assumed	7,524.5
Net assets acquired	11,939.9
In Process Research and Development (IPR&D) [Member]
Business Acquisition [Line Items]
Intangible assets not subject to amortization	246
Technology [Member]
Business Acquisition [Line Items]
Intangible assets subject to amortization	2,492.1
Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets subject to amortization	4,956
Trademarks and Trade Names [Member]
Business Acquisition [Line Items]
Intangible assets not subject to amortization	479
Intangible assets subject to amortization	389
As Reported [Member]
Business Acquisition [Line Items]
Cash		$ 494.8
Accounts receivable, net		544.7
Inventory		1,161.7
Other current assets		123.4
Property, plant and equipment		699.4
Other assets		29.5
Goodwill		5,270.2
Total assets acquired		17,743
Current liabilities		588.9
Long-term debt		2,740
Deferred taxes		2,489.7
Other long-term liabilities		58.2
Total liabilities assumed		5,876.8
Net assets acquired		11,866.2
As Reported [Member] | Technology [Member]
Business Acquisition [Line Items]
Intangible assets subject to amortization		3,075.3
As Reported [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets subject to amortization		5,829
As Reported [Member] | Trademarks and Trade Names [Member]
Business Acquisition [Line Items]
Intangible assets not subject to amortization		$ 515
Adjustments [Member]
Business Acquisition [Line Items]
Accounts receivable, net	(15.7)
Inventory	84
Other current assets	(97)
Property, plant and equipment	92
Other assets	211.6
Goodwill	2,303.7
Total assets acquired	1,721.4
Current liabilities	39.2
Deferred taxes	1,607.8
Other long-term liabilities	0.7
Total liabilities assumed	1,647.7
Net assets acquired	73.7
Adjustments [Member] | In Process Research and Development (IPR&D) [Member]
Business Acquisition [Line Items]
Intangible assets not subject to amortization	246
Adjustments [Member] | Technology [Member]
Business Acquisition [Line Items]
Intangible assets subject to amortization	(583.2)
Adjustments [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets subject to amortization	(873)
Adjustments [Member] | Trademarks and Trade Names [Member]
Business Acquisition [Line Items]
Intangible assets not subject to amortization	(36)
Intangible assets subject to amortization	$ 389

Business Combinations - Pro for

Business Combinations - Pro forma Financial Information Adjusted to Give Effect to the Merger (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Business Combination Increase Decrease To Reflect Liabilities Acquired At Fair Value [Abstract]
Net Sales	$ 7,517.7	$ 7,965.2
Net Earnings	$ 327.4	$ 314.5

Share-Based Compensation - Shar

Share-Based Compensation - Share-Based Compensation Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation Related Costs [Abstract]
Total expense, pre-tax	$ 46.4	$ 49.4	$ 48.5
Tax benefit related to awards	(14.5)	(15.5)	(15.6)
Total expense, net of tax	$ 31.9	$ 33.9	$ 32.9

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock registered for award	57,900,000
Shares available for future grants	5,600,000
Vesting period	4 years
Maximum contractual life	10 years
Unrecognized share-based payment expense	$ 40.3
Weighted average period expected to be recognized	3 years
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period for stock award	1 year
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period for stock award	4 years
RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period expected to be recognized	2 years 4 months 24 days
Estimated outstanding RSU	795,000
Unrecognized share-based payment expense related to nonvested stock options	$ 39.6
Fair value of RSUs vesting during the year	$ 40.6	$ 29.3	$ 32.5
RSUs [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years
Requisite service period for stock award	1 year
RSUs [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Requisite service period for stock award	4 years

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Outstanding stock options, Beginning balance | shares	7,846
Options granted | shares	1,717
Options exercised | shares	(1,404)
Options forfeited | shares	(185)
Options expired | shares	(43)
Outstanding stock options, Ending Balance | shares	7,931
Number of outstanding options, Vested or expected to vest | shares	7,497
Exercisable, Stock options | shares	4,969
Outstanding Weighted average exercise price, Beginning Balance | $ / shares	$ 71.94
Options granted, Weighted average exercise price | $ / shares	107.10
Options exercised, Weighted average exercise price | $ / shares	73.09
Options forfeited, Weighted average exercise price | $ / shares	97.02
Options expired, Weighted average exercise price | $ / shares	80.59
Outstanding Weighted average exercise price, ending Balance | $ / shares	78.73
Outstanding Weighted average exercise price, Vested or expected to vest | $ / shares	77.59
Exercisable, Weighted average exercise price | $ / shares	$ 68.67
Weighted Average Remaining Contractual Life, Outstanding at December 31, 2015	5 years 8 months 12 days
Weighted Average Remaining Contractual Life, Vested or expected to vest as of December 31, 2015	5 years 6 months
Weighted Average Remaining Contractual Life, Exercisable at December 31, 2015	3 years 10 months 24 days
Intrinsic Value, Outstanding at December 31, 2015 | $	$ 201.1
Intrinsic Value, Vested or expected to vest as of December 31, 2015 | $	197.4
Intrinsic Value, Exercisable at December 31, 2015 | $	$ 168.6

Share-Based Compensation - Weig

Share-Based Compensation - Weighted Average Fair Value for Stock Options Granted (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Dividend yield	0.80%	0.90%	1.10%
Volatility	22.20%	25.20%	24.50%
Risk-free interest rate	1.70%	1.80%	1.10%
Expected life (years)	5 years 3 months 18 days	5 years 6 months	6 years 1 month 6 days
Weighted average fair value of options granted	$ 22.30	$ 22.59	$ 16.33
Intrinsic value of options exercised (in millions)	$ 49.4	$ 99.6	$ 97.9

Share-Based Compensation - Su64

Share-Based Compensation - Summary of Nonvested RSU Activity (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
RSUs, Outstanding Beginning Balance | shares	1,475
RSUs, Granted | shares	556
RSUs, Vested | shares	(347)
RSUs, Forfeited | shares	(384)
RSUs, Outstanding Ending Balance | shares	1,300
Weighted Average Grant Date Fair Value, Outstanding Beginning Balance | $ / shares	$ 76.60
Weighted Average Grant Date Fair Value, Granted | $ / shares	104.77
Weighted Average Grant Date Fair Value, Vested | $ / shares	67.50
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	74.82
Weighted Average Grant Date Fair Value, Outstanding Ending Balance | $ / shares	$ 91.64

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Finished goods	$ 1,827.9	$ 924.2
Work in progress	146.1	87.8
Raw materials	280.1	181.3
Inventories	$ 2,254.1	$ 1,193.3

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Amounts charged for excess obsolete inventory	$ 118.4	$ 51.8	$ 112
Biomet [Member]
Inventory [Line Items]
Finished goods inventory step-up	$ 284.4

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 4,427.9	$ 3,407.1
Accumulated depreciation	(2,365.3)	(2,121.8)
Property, plant and equipment, net	2,062.6	1,285.3	$ 1,229.5
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	39.6	20.4
Building And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	1,789.3	1,283.4
Capitalized Software Costs [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	330.1	294.7
Instruments [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	2,160.5	1,692.8
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 108.4	$ 115.8

Property, Plant and Equipment68

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property Plant and Equipment Useful Life and Values [Abstract]
Depreciation expense	$ 375	$ 268.6	$ 262.6

Investments - Investments in Sh

Investments - Investments in Short and Long-Term Classified as Available-for-Sale Securities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost	$ 273.5	$ 869.3
Available-for-sale Securities, Gross Unrealized Gains	0.1	0.1
Available-for-sale Securities, Gross Unrealized Losses	(0.5)	(0.5)
Available-for-sale Securities, Fair Value	273.1	868.9
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost	245.7	516.9
Available-for-sale Securities, Gross Unrealized Gains	0.1	0.1
Available-for-sale Securities, Gross Unrealized Losses	(0.4)	(0.5)
Available-for-sale Securities, Fair Value	245.4	516.5
U.S. Government and Agency Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost	21.6	194.3
Available-for-sale Securities, Gross Unrealized Gains		0
Available-for-sale Securities, Gross Unrealized Losses	(0.1)	0
Available-for-sale Securities, Fair Value	21.5	194.3
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost	4.2	57.8
Available-for-sale Securities, Gross Unrealized Gains		0
Available-for-sale Securities, Gross Unrealized Losses		0
Available-for-sale Securities, Fair Value	4.2	57.8
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost	2	100.3
Available-for-sale Securities, Gross Unrealized Gains		0
Available-for-sale Securities, Gross Unrealized Losses		0
Available-for-sale Securities, Fair Value	$ 2	$ 100.3

Investments - Cost and Fair Val

Investments - Cost and Fair Value of Available-for-Sale Fixed-Maturity Securities by Contractual Maturity (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Amortized Cost and Fair Value Debt Securities [Abstract]
Available-for-sale Securities, Debt Maturities, Due in One Year or less, Amortized Cost	$ 164.7
Available-for-sale Securities, Debt Maturities, Due after One year through two Years, Amortized Cost	108.8
Available-for-sale Securities, Amortized Cost	273.5	$ 869.3
Available-for-sale Securities, Debt Maturities, Due in One Year or less, Fair Value	164.6
Available-for-sale Securities, Debt Maturities, Due after One year through two Years, Fair Value	108.5
Available-for-sale Securities, Fair Value	$ 273.1	$ 868.9

Fair Value Measurements of As71

Fair Value Measurements of Assets and Liabilities - Fair Value Measurements of Assets and Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value	$ 273.1	$ 868.9
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value	273.1	868.9
Total fair value measurement of assets	396.8	1,018.4
Total fair value measurement of liabilities	1.6	61
Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value	245.4	516.5
Fair Value, Measurements, Recurring [Member] | U.S. Government and Agency Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value	21.5	194.3
Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value	4.2	57.8
Fair Value, Measurements, Recurring [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value	2	100.3
Fair Value, Measurements, Recurring [Member] | Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives, current and long-term	96.9	125.5
Derivatives, current and long-term	1.6	1.7
Fair Value, Measurements, Recurring [Member] | Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives, current and long-term	26.8	24
Fair Value, Measurements, Recurring [Member] | Forward Starting Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives, current and long-term		59.3
Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value	273.1	868.9
Total fair value measurement of assets	396.8	1,018.4
Total fair value measurement of liabilities	1.6	61
Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value	245.4	516.5
Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | U.S. Government and Agency Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value	21.5	194.3
Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value	4.2	57.8
Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value	2	100.3
Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives, current and long-term	96.9	125.5
Derivatives, current and long-term	1.6	1.7
Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives, current and long-term	$ 26.8	24
Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member] | Forward Starting Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives, current and long-term		$ 59.3

Goodwill and Other Intangible72

Goodwill and Other Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Line Items]
Goodwill, Beginning Balance	$ 2,887.2	$ 2,984.2
Accumulated impairment losses, Beginning Balance	(373)	(373)
Goodwill, net of accumulated impairment losses, Beginning Balance	2,514.2	2,611.2
Acquisitions	7,573.9	40.6
Currency translation	(153.9)	(137.6)
Goodwill, Ending Balance	10,307.2	2,887.2
Accumulated impairment losses, Ending Balance	(373)	(373)
Goodwill, net of accumulated impairment losses, Ending Balance	9,934.2	2,514.2
Americas [Member]
Goodwill [Line Items]
Goodwill, Beginning Balance	931.1	894.8
Goodwill, net of accumulated impairment losses, Beginning Balance	931.1	894.8
Acquisitions	6,445.2	40.6
Currency translation	(48.3)	(4.3)
Goodwill, Ending Balance	7,328	931.1
Goodwill, net of accumulated impairment losses, Ending Balance	7,328	931.1
EMEA [Member]
Goodwill [Line Items]
Goodwill, Beginning Balance	1,157.3	1,271.9
Goodwill, net of accumulated impairment losses, Beginning Balance	1,157.3	1,271.9
Acquisitions	225.6
Currency translation	(91.9)	(114.6)
Goodwill, Ending Balance	1,291	1,157.3
Goodwill, net of accumulated impairment losses, Ending Balance	1,291	1,157.3
Asia Pacific [Member]
Goodwill [Line Items]
Goodwill, Beginning Balance	148.2	161.8
Goodwill, net of accumulated impairment losses, Beginning Balance	148.2	161.8
Acquisitions	408.1
Currency translation	(7.4)	(13.6)
Goodwill, Ending Balance	548.9	148.2
Goodwill, net of accumulated impairment losses, Ending Balance	548.9	148.2
Product Category Operating Segments [Member]
Goodwill [Line Items]
Goodwill, Beginning Balance	650.6	655.7
Accumulated impairment losses, Beginning Balance	(373)	(373)
Goodwill, net of accumulated impairment losses, Beginning Balance	277.6	282.7
Acquisitions	495
Currency translation	(6.3)	(5.1)
Goodwill, Ending Balance	1,139.3	650.6
Accumulated impairment losses, Ending Balance	(373)	(373)
Goodwill, net of accumulated impairment losses, Ending Balance	$ 766.3	$ 277.6

Goodwill and Other Intangible73

Goodwill and Other Intangible Assets - Components of Identifiable Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Identifiable Intangible Assets Acquired [Line Items]
Gross carrying amount	$ 9,160.7	$ 1,282.5
Accumulated amortization	(1,142)	(808)
Gross carrying amount	727.6	129
Total identifiable intangible assets	8,746.3	603.5
Technology [Member]
Identifiable Intangible Assets Acquired [Line Items]
Gross carrying amount	3,161.6	727.2
Accumulated amortization	(591.9)	(458.3)
Gross carrying amount		0
Total identifiable intangible assets	2,569.7	268.9
Intellectual Property Rights [Member]
Identifiable Intangible Assets Acquired [Line Items]
Gross carrying amount	181	173.4
Accumulated amortization	(164.8)	(157.7)
Total identifiable intangible assets	16.2	15.7
Trademarks and Trade Names [Member]
Identifiable Intangible Assets Acquired [Line Items]
Gross carrying amount	583.3	74.2
Accumulated amortization	(50.9)	(34.1)
Gross carrying amount	479	129
Total identifiable intangible assets	1,011.4	169.1
Customer Relationships [Member]
Identifiable Intangible Assets Acquired [Line Items]
Gross carrying amount	5,133	213.8
Accumulated amortization	(269.6)	(99.6)
Total identifiable intangible assets	4,863.4	114.2
In Process Research and Development (IPR&D) [Member]
Identifiable Intangible Assets Acquired [Line Items]
Gross carrying amount	248.6
Total identifiable intangible assets	248.6
Other [Member]
Identifiable Intangible Assets Acquired [Line Items]
Gross carrying amount	101.8	93.9
Accumulated amortization	(64.8)	(58.3)
Total identifiable intangible assets	$ 37	$ 35.6

Goodwill and Other Intangible74

Goodwill and Other Intangible Assets - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
Trademarks and Trade Names [Member]
Identifiable Intangible Assets Acquired [Line Items]
Increase in finite lived intangible assets	$ 129
Trademarks and Trade Names [Member]
Identifiable Intangible Assets Acquired [Line Items]
Decrease in indefinite lived intangible assets	$ (129)

Goodwill and Other Intangible75

Goodwill and Other Intangible Assets - Estimated Annual Amortization Expense Based on Intangible Assets Recognized (Detail) $ in Millions	Dec. 31, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,016	$ 559.9
2,017	546.2
2,018	529.3
2,019	516.1
2,020	$ 514.4

Other Current and Long-term L76

Other Current and Long-term Liabilities - Summary of Other Current and Long-Term Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Other current liabilities:
License and service agreements	$ 144.1	$ 100.2
Certain claims accrual (Note 20)	50	50
Litigation settlement accrual (Note 20)		70
Forward starting interest rate swaps		59.3
Salaries, wages and benefits	265.9	167.7
Accrued liabilities	725.9	351.3
Total other current liabilities	1,185.9	798.5
Other long-term liabilities:
Long-term income tax payable	478.1	189.9
Certain claims accrual (Note 20)	264.6	307.2
Other long-term liabilities	263	113.8
Total other long-term liabilities	$ 1,005.7	$ 610.9

Debt - Summary of Debt Instrume

Debt - Summary of Debt Instruments (Detail) $ in Millions, ¥ in Billions	Dec. 31, 2015USD ($)	Dec. 31, 2015JPY (¥)	Dec. 31, 2014USD ($)
Long-term debt
Senior Notes due	$ 8,950
Other long-term debt	4.6		$ 4.9
Debt discount	(21.9)		(1.4)
Adjustment related to interest rate swaps	26.8		24
Total long-term debt	11,556.3		1,425.5
Senior Notes [Member] | 1.450% [Member] | Due in 2017 [Member]
Long-term debt
Senior Notes due	500
Senior Notes [Member] | 2.0% [Member] | Due in 2018 [Member]
Long-term debt
Senior Notes due	1,150
Senior Notes [Member] | 4.625% [Member] | Due in 2019 [Member]
Long-term debt
Senior Notes due	500		500
Senior Notes [Member] | 2.70% [Member] | Due in 2020 [Member]
Long-term debt
Senior Notes due	1,500
Senior Notes [Member] | 3.375% [Member] | Due in 2021 [Member]
Long-term debt
Senior Notes due	300		300
Senior Notes [Member] | 3.150% [Member] | Due in 2022 [Member]
Long-term debt
Senior Notes due	750
Senior Notes [Member] | 3.550% [Member] | Due in 2025 [Member]
Long-term debt
Senior Notes due	2,000
Senior Notes [Member] | 4.250% [Member] | Due in 2035 [Member]
Long-term debt
Senior Notes due	500
Senior Notes [Member] | 5.750% [Member] | Due in 2039 [Member]
Long-term debt
Senior Notes due	500		500
Senior Notes [Member] | 4.450% [Member] | Due in 2045 [Member]
Long-term debt
Senior Notes due	1,250
U.S. Term Loan [Member]
Long-term debt
Term loan	2,500
Japan Term Loan [Member]
Long-term debt
Term loan	$ 96.8	¥ 11.7	$ 98

Debt - Summary of Debt Instru78

Debt - Summary of Debt Instruments (Parenthetical) (Detail) - Senior Notes [Member]	Dec. 31, 2015	Dec. 31, 2014
1.450% [Member] | Due in 2017 [Member]
Debt Instrument [Line Items]
Interest rate of Senior Notes	1.45%
2.0% [Member] | Due in 2018 [Member]
Debt Instrument [Line Items]
Interest rate of Senior Notes	2.00%
4.625% [Member] | Due in 2019 [Member]
Debt Instrument [Line Items]
Interest rate of Senior Notes	4.625%	4.625%
2.70% [Member] | Due in 2020 [Member]
Debt Instrument [Line Items]
Interest rate of Senior Notes	2.70%
3.375% [Member] | Due in 2021 [Member]
Debt Instrument [Line Items]
Interest rate of Senior Notes	3.375%	3.375%
3.150% [Member] | Due in 2022 [Member]
Debt Instrument [Line Items]
Interest rate of Senior Notes	3.15%
3.550% [Member] | Due in 2025 [Member]
Debt Instrument [Line Items]
Interest rate of Senior Notes	3.55%
4.250% [Member] | Due in 2035 [Member]
Debt Instrument [Line Items]
Interest rate of Senior Notes	4.25%
5.750% [Member] | Due in 2039 [Member]
Debt Instrument [Line Items]
Interest rate of Senior Notes	5.75%	5.75%
4.450% [Member] | Due in 2045 [Member]
Debt Instrument [Line Items]
Interest rate of Senior Notes	4.45%

Debt - Additional Information (

Debt - Additional Information (Detail) ¥ in Billions	1 Months Ended	6 Months Ended	12 Months Ended
	Mar. 31, 2015USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)Ratio	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015JPY (¥)	Jun. 24, 2015USD ($)
Debt Instrument [Line Items]
Aggregate principal amount of Senior Notes			$ 8,950,000,000
Other debt, debt discount and fair value adjustments			9,500,000
Payments on term loan			500,000,000
Proceeds from senior notes	$ 7,650,000,000
Fair value of principal amount plus interest		$ 2,798,600,000
Debt recognized amount		$ 22,000,000
Estimated fair value of Senior Notes and term loan			8,837,500,000
Available uncommitted credit facilities, Net			$ 35,800,000
Weighted average interest rate for all borrowings, long-term debt			2.90%	3.50%		2.90%
Interest paid on Debt			$ 207,100,000	$ 67,500,000	$ 68,100,000
Senior Credit Facility [Member]
Debt Instrument [Line Items]
Principal amount, unsecured credit facility			$ 4,350,000,000
Principal amount, term loan description			Credit Agreement that contains (i) a 5-year unsecured term loan facility in the principal amount of $3.0 billion (the "U.S. Term Loan Facility"), and (ii) a 5-year unsecured multicurrency revolving facility in the principal amount of $1.35 billion (the "Multicurrency Revolving Facility").
Leverage ratio description under line of credit facility on financial covenants			Financial covenants include a consolidated indebtedness to consolidated EBITDA ratio of no greater than 5.0 to 1.0 through June 24, 2016 and no greater than 4.5 to 1.0 thereafter.
U.S. Term Loan [Member]
Debt Instrument [Line Items]
Term loan current			$ 2,500,000,000
Term loan			2,500,000,000
Principal amount, unsecured credit facility							$ 3,000,000,000
Principal payments due on a quarterly basis starting September 30, 2015, during first three years			75,000,000
Principal payments due on a quarterly basis starting September 30, 2015, during fourth year			112,500,000
Principal payments due on a quarterly basis starting September 30, 2015, during fifth year			412,500,000
Payments on term loan			500,000,000
Japan Term Loan [Member]
Debt Instrument [Line Items]
Term loan			$ 96,800,000	$ 98,000,000		¥ 11.7
Maturity date of term loan			May 31, 2018
Estimated fair value of Senior Notes and term loan			$ 96,400,000
Term Loan [Member] | Senior Credit Facility [Member]
Debt Instrument [Line Items]
Principal amount, unsecured credit facility			$ 3,000,000,000
Debt instrument term			5 years
Multicurrency Revolving Facility [Member]
Debt Instrument [Line Items]
Outstanding Senior Credit Facility			$ 0
Multicurrency Revolving Facility [Member] | Senior Credit Facility [Member]
Debt Instrument [Line Items]
Principal amount, unsecured credit facility			$ 1,350,000,000
Debt instrument term			5 years
Term Loan Through June 24, 2016 [Member]
Debt Instrument [Line Items]
Maximum Leverage Ratio | Ratio			5
Thereafter Term Loan [Member]
Debt Instrument [Line Items]
Maximum Leverage Ratio | Ratio			4.5
Senior Notes [Member] | 1.450% [Member] | Due in 2017 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of Senior Notes			$ 500,000,000
Interest rate of Senior Notes			1.45%			1.45%
Senior Notes [Member] | 2.0% [Member] | Due in 2018 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of Senior Notes			$ 1,150,000,000
Interest rate of Senior Notes			2.00%			2.00%
Senior Notes [Member] | 2.70% [Member] | Due in 2020 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of Senior Notes			$ 1,500,000,000
Interest rate of Senior Notes			2.70%			2.70%
Senior Notes [Member] | 3.150% [Member] | Due in 2022 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of Senior Notes			$ 750,000,000
Interest rate of Senior Notes			3.15%			3.15%
Senior Notes [Member] | 3.550% [Member] | Due in 2025 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of Senior Notes			$ 2,000,000,000
Interest rate of Senior Notes			3.55%			3.55%
Senior Notes [Member] | 4.250% [Member] | Due in 2035 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of Senior Notes			$ 500,000,000
Interest rate of Senior Notes			4.25%			4.25%
Senior Notes [Member] | 4.450% [Member] | Due in 2045 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of Senior Notes			$ 1,250,000,000
Interest rate of Senior Notes			4.45%			4.45%
3.375% Senior Notes due 2021 [Member]
Debt Instrument [Line Items]
Interest rate of Senior Notes			3.375%			3.375%
3.375% Senior Notes due 2021 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument redemption period			1 month
3.375% Senior Notes due 2021 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument redemption period			6 months

Accumulated Other Comprehensi80

Accumulated Other Comprehensive (Loss) Income - Changes in Components of Other Comprehensive Income, Net of Tax (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
Other Comprehensive Income Loss [Line Items]
Accumulated Other Comprehensive Income, Beginning Balance	$ 38.1
Accumulated Other Comprehensive Income, Ending Balance	(329)
Foreign Currency Translation [Member]
Other Comprehensive Income Loss [Line Items]
Accumulated Other Comprehensive Income, Beginning Balance	111.8
OCI before reclassifications	(305.2)
Accumulated Other Comprehensive Income, Ending Balance	(193.4)
Unrealized Gains on Securities [Member]
Other Comprehensive Income Loss [Line Items]
Accumulated Other Comprehensive Income, Beginning Balance	(0.4)
OCI before reclassifications	(0.2)
Accumulated Other Comprehensive Income, Ending Balance	(0.6)
Defined Benefit Plan Items [Member]
Other Comprehensive Income Loss [Line Items]
Accumulated Other Comprehensive Income, Beginning Balance	(143.4)
OCI before reclassifications	(30.6)
Reclassifications	9.2
Accumulated Other Comprehensive Income, Ending Balance	(164.8)
Cash Flow Hedges [Member]
Other Comprehensive Income Loss [Line Items]
Accumulated Other Comprehensive Income, Beginning Balance	70.1
OCI before reclassifications	52.7
Reclassifications	(93)
Accumulated Other Comprehensive Income, Ending Balance	$ 29.8

Accumulated Other Comprehensi81

Accumulated Other Comprehensive (Loss) Income - Reclassification Adjustments from Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Other Comprehensive Income Loss [Line Items]
Interest income	$ 9.4	$ 11.9	$ 15.6
Cost of products sold	1,800.6	1,242.8	1,266.7
Provision for income taxes	7	220.2	229.5
Reclassification out of Accumulated Other Comprehensive Income [Member]
Other Comprehensive Income Loss [Line Items]
Net of tax	83.8	15.1	(3.5)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash Flow Hedges [Member]
Other Comprehensive Income Loss [Line Items]
Total before tax	121	33.3	7.8
Provision for income taxes	28	14.4	3.4
Net of tax	93	18.9	4.4
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash Flow Hedges [Member] | Foreign Exchange Forward Contracts [Member]
Other Comprehensive Income Loss [Line Items]
Cost of products sold	122.3	33.3	8
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash Flow Hedges [Member] | Foreign Exchange Options [Member]
Other Comprehensive Income Loss [Line Items]
Cost of products sold			(0.2)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash Flow Hedges [Member] | Forward Starting Interest Rate Swaps [Member]
Other Comprehensive Income Loss [Line Items]
Interest expenses	(1.3)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Defined Benefit Plan Items [Member]
Other Comprehensive Income Loss [Line Items]
Prior service cost	5.6	3.9	3.9
Unrecognized actuarial (loss)	(20.1)	(11.1)	(16.6)
Total before tax	(14.5)	(7.2)	(12.7)
Provision for income taxes	(5.3)	(3)	(4.8)
Net of tax	$ (9.2)	(4.2)	$ (7.9)
Investments [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Other Comprehensive Income Loss [Line Items]
Interest income		0.4
Total before tax		0.4
Net of tax		$ 0.4

Accumulated Other Comprehensi82

Accumulated Other Comprehensive (Loss) Income - Tax Effects on Each Component of Other Comprehensive Income Recognized in Statements of Comprehensive Income (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Foreign currency cumulative translation adjustments, Before Tax	$ (305.2)	$ (223.1)	$ (35)
Unrealized cash flow hedge gains, Before Tax	59.1	60.5	63.6
Reclassification adjustments on foreign currency hedges, Before Tax	(121)	(33.3)	(7.8)
Reclassification adjustments on securities, Before Tax		(0.4)
Unrealized gains/(losses) on securities, Before Tax	(0.2)	(0.5)	0.1
Adjustments to prior service cost and unrecognized actuarial assumptions, Before Tax	(25)	(104.8)	50.3
Total Other Comprehensive (Loss) Income, Before Tax	(392.3)	(301.6)	71.2
Foreign currency cumulative translation adjustments, Tax	0	0	0
Unrealized cash flow hedge gains, Tax	6.4	4.6	30.2
Reclassification adjustments on foreign currency hedges, Tax	(28)	(14.4)	(3.4)
Reclassification adjustments on securities, Tax	0	0	0
Unrealized gains/(losses) on securities, Tax	0	0	0
Adjustments to prior service cost and unrecognized actuarial assumptions, Tax	(3.6)	(29)	11.8
Total Other Comprehensive (Loss) Income, Tax	(25.2)	(38.8)	38.6
Foreign currency cumulative translation adjustments, net of tax	(305.2)	(223.1)	(35)
Unrealized cash flow hedge gains, net of tax	52.7	55.9	33.4
Reclassification adjustments on foreign currency hedges, net of tax	(93)	(18.9)	(4.4)
Reclassification adjustments on securities, net of tax		(0.4)	0
Unrealized gains/(losses) on securities, net of tax	(0.2)	(0.5)	0.1
Adjustments to prior service cost and unrecognized actuarial assumptions, net of tax	(21.4)	(75.8)	38.5
Total Other Comprehensive (Loss) Income, net of tax	$ (367.1)	$ (262.8)	$ 32.6

Derivative Instruments and He83

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Derivative Instruments, Gain (Loss) [Line Items]
Derivative notional amount, Total	$ 1,000,000,000
Loss on settlement of forward starting interest rate swaps	$ 97,600,000
Expected months of hedging of inter company sales of inventory to minimize the effects of foreign exchange rate movements		30 months
Amounts excluded from the assessment of hedge effectiveness		$ 0	$ 0	$ 0
Fair value of outstanding derivative instruments, net unrealized gain deferred in other comprehensive income		26,100,000
Cost of Products Sold [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Fair value of outstanding derivative instruments, net unrealized gain (loss) expected to be reclassified to earnings		101,400,000
Fair value of outstanding derivative instruments, unrealized gain (loss) net of taxes expected to be reclassified to earnings		76,700,000
Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Fair value of outstanding derivative instruments, net unrealized gain (loss) expected to be reclassified to earnings		(1,700,000)
Fair value of outstanding derivative instruments, unrealized gain (loss) net of taxes expected to be reclassified to earnings		(1,100,000)
Cash Flow Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Fair value of outstanding derivative instruments, unrealized gain net of taxes deferred in other comprehensive income		29,800,000
4.625% Senior Notes due 2019 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative notional amount, Total		$ 250,000,000
Interest rate of Senior Notes		4.625%
Description of terms of Interest rate Derivatives terms		Receive a fixed interest rate of 4.625 percent and pay variable interest equal to the three-month LIBOR plus an average of 133 basis points.
Description of variable interest rate basis		Three-month LIBOR
4.625% Senior Notes due 2019 [Member] | LIBOR [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest rate swap basis spread on variable rate		1.33%
3.375% Senior Notes due 2021 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative notional amount, Total		$ 300,000,000
Interest rate of Senior Notes		3.375%
Description of terms of Interest rate Derivatives terms		We receive a fixed interest rate of 3.375 percent and pay variable interest equal to the three-month LIBOR plus an average of 99 basis points.
Description of variable interest rate basis		Three-month LIBOR
3.375% Senior Notes due 2021 [Member] | LIBOR [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest rate swap basis spread on variable rate		0.99%
4.450% Senior Notes due 2045 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest rate of Senior Notes		4.45%
Hedged senior notes maturity period		30 years
Foreign Exchange Contract [Member] | U.S. Dollars [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative notional amount, Total		$ 1,427,500,000
Foreign Exchange Contract [Member] | Swiss Francs [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative notional amount, Total		307,200,000
Foreign Exchange Forward Contracts [Member] | Nondesignated [Member] | Minimum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative notional amount, Total		1,500,000,000
Foreign Exchange Forward Contracts [Member] | Nondesignated [Member] | Maximum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative notional amount, Total		$ 2,000,000,000

Derivative Instruments and He84

Derivative Instruments and Hedging Activities - Derivative Instruments Designated as Fair Value Hedges (Detail) - Interest Rate Swaps [Member] - Interest Expense [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (Loss) on Instrument	$ 2.8	$ 14.7	$ (24.6)
Gain (Loss) on Hedged Item	$ (2.8)	$ (14.7)	$ 24.6

Derivative Instruments and He85

Derivative Instruments and Hedging Activities - Gross Unrealized Losses from Derivative Instruments (Detail) - Cash Flow Hedges [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain / (Loss) Recognized in OCI	$ 59.1	$ 60.5	$ 63.6
Amount of Gain / (Loss) Reclassified from OCI	121	33.3	7.8
Foreign Exchange Forward Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain / (Loss) Recognized in OCI	97.4	119.8	63.9
Foreign Exchange Forward Contracts [Member] | Cost of Products Sold [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain / (Loss) Reclassified from OCI	122.3	33.3	8
Foreign Exchange Options [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain / (Loss) Recognized in OCI			(0.3)
Foreign Exchange Options [Member] | Cost of Products Sold [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain / (Loss) Reclassified from OCI			$ (0.2)
Forward Starting Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain / (Loss) Recognized in OCI	(38.3)	$ (59.3)
Forward Starting Interest Rate Swaps [Member] | Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain / (Loss) Reclassified from OCI	$ (1.3)

Derivative Instruments and He86

Derivative Instruments and Hedging Activities - Derivative Instruments Not Designated as Hedging Instruments (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Nondesignated [Member] | Foreign Exchange Forward Contracts [Member] | Other Expense, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gains from derivative instruments not designated as hedging instruments	$ 28.8	$ 15.3

Derivative Instruments and He87

Derivative Instruments and Hedging Activities - Fair Value of Derivative Instruments on Gross Basis (Detail) - Designated as Hedging Instrument [Member] - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Derivative Assets	$ 147.1	$ 175.8
Derivative Liabilities	25	87.3
Foreign Exchange Forward Contracts [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	100.5	98.7
Foreign Exchange Forward Contracts [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	19.8	53.1
Foreign Exchange Forward Contracts [Member] | Other Current Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	16.7	16.4
Foreign Exchange Forward Contracts [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	8.3	11.6
Interest Rate Swaps [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	$ 26.8	24
Forward Starting Interest Rate Swaps [Member] | Other Current Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities		$ 59.3

Derivative Instruments and He88

Derivative Instruments and Hedging Activities - Schedule of Effects of Master Netting Agreements on Consolidated Balance Sheets (Detail) - Cash Flow Hedges [Member] - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Other Current Assets [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross Amount	$ 100.5	$ 98.7
Offset	16.3	15.9
Net Amount in Balance Sheet	84.2	82.8
Other Assets [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross Amount	19.8	53.1
Offset	7.1	10.4
Net Amount in Balance Sheet	12.7	42.7
Other Current Liabilities [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross Amount	16.7	16.4
Offset	16.3	15.9
Net Amount in Balance Sheet	0.4	0.5
Other Long-term Liabilities [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross Amount	8.3	11.6
Offset	7.1	10.4
Net Amount in Balance Sheet	$ 1.2	$ 1.2

Retirement Benefit Plans - Comp

Retirement Benefit Plans - Components of Net Pension Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
U.S. and Puerto Rico [Member]
Schedule of Expected Future Pension Benefit Payment [Line Items]
Service cost	$ 11.8	$ 10.9	$ 11.9
Interest cost	15.8	15.5	13.2
Expected return on plan assets	(31.8)	(30.8)	(28.7)
Amortization of prior service cost	(3.7)	(2.6)	(2.6)
Amortization of unrecognized actuarial loss	17.4	10.6	14.8
Net periodic benefit cost	9.5	3.6	8.6
Foreign-based Defined Benefit Plans [Member]
Schedule of Expected Future Pension Benefit Payment [Line Items]
Service cost	18.9	14.7	16.1
Interest cost	8.8	9.2	5.6
Expected return on plan assets	(13.9)	(11)	(6.7)
Amortization of prior service cost	(1.9)	(1.3)	(1.3)
Amortization of unrecognized actuarial loss	2.7	0.5	1.8
Net periodic benefit cost	$ 14.6	$ 12.1	$ 15.5

Retirement Benefit Plans - Weig

Retirement Benefit Plans - Weighted Average Actuarial Assumptions Used to Determine Net Pension Expense for Our Defined Benefit Retirement Plans (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
U.S. and Puerto Rico [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Discount rate	4.56%	4.98%	4.32%
Rate of compensation increase	3.29%	3.29%	3.29%
Expected long-term rate of return on plan assets	7.75%	7.75%	7.75%
Foreign-based Defined Benefit Plans [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Discount rate	1.94%	2.46%	2.13%
Rate of compensation increase	2.00%	1.48%	2.29%
Expected long-term rate of return on plan assets	3.05%	2.88%	2.74%

Retirement Benefit Plans - Chan

Retirement Benefit Plans - Changes in Projected Benefit Obligations and Plan Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
U.S. and Puerto Rico [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Projected benefit obligation - beginning of year	$ 386.6	$ 316.7
Service cost	11.8	10.9	$ 11.9
Interest cost	15.8	15.5	13.2
Plan amendments	(21.9)
Benefits paid	(12.3)	(10)
Actuarial (gain) loss	(4.9)	53.5
Projected benefit obligation - end of year	375.1	386.6	316.7
Foreign-based Defined Benefit Plans [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Projected benefit obligation - beginning of year	423.7	371.5
Obligation assumed from Biomet	159.4
Service cost	18.9	14.7	16.1
Interest cost	8.8	9.2	5.6
Plan amendments		(7)
Employee contributions	16.9	18.5
Benefits paid	(24.1)	(22.6)
Actuarial (gain) loss	(18.9)	77.9
Expenses paid	(0.3)	(0.2)
Settlement	(0.2)
Translation (gain) loss	(15.6)	(38.3)
Projected benefit obligation - end of year	$ 568.6	$ 423.7	$ 371.5

Retirement Benefit Plan - Chang

Retirement Benefit Plan - Changes in Fair Value of Plan Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
U.S. and Puerto Rico [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value - beginning of year	$ 402.2	$ 398.6
Actual return on plan assets	(16.6)	10.9
Employer contributions	0.8	2.7
Benefits paid	(12.3)	(10)
Plan assets at fair market value - end of year	374.1	402.2
Funded status	(1)	15.6
Foreign-based Defined Benefit Plans [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value - beginning of year	385.4	372.3
Assets contributed by Biomet	129.4
Actual return on plan assets	(4)	38
Employer contributions	14.8	14.7
Employee contributions	16.9	18.5
Plan amendments	(0.2)
Benefits paid	(24.1)	(22.6)
Expenses paid	(0.3)	(0.2)
Translation gain (loss)	(12.3)	(35.3)
Plan assets at fair market value - end of year	505.6	385.4
Funded status	$ (63)	$ (38.3)

Retirement Benefit Plan - Summa

Retirement Benefit Plan - Summary of Amounts Recognized in Balance Sheet (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
U.S. and Puerto Rico [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Prepaid pension	$ 14.6	$ 29.4
Short-term accrued benefit liability	(1)	(0.7)
Long-term accrued benefit liability	(14.6)	(13.1)
Net amount recognized	(1)	15.6
Foreign-based Defined Benefit Plans [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Prepaid pension	16.5	12.4
Short-term accrued benefit liability	(0.6)	(0.5)
Long-term accrued benefit liability	(78.9)	(50.2)
Net amount recognized	$ (63)	$ (38.3)

Retirement Benefit Plan - Sum94

Retirement Benefit Plan - Summary of Amounts Recognized in Other Comprehensive Income Income (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
U.S. and Puerto Rico [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Unrecognized prior service cost	$ (5.9)
Unrecognized actuarial loss	17.1
Total amount recognized	11.2
Foreign-based Defined Benefit Plans [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Unrecognized prior service cost	(1.9)
Unrecognized actuarial loss	2.9
Total amount recognized	$ 1

Retirement Benefit Plans - We95

Retirement Benefit Plans - Weighted Average Actuarial Assumptions Used to Determine Projected Benefit Obligation for Defined Benefit Retirement Plans (Detail)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
U.S. and Puerto Rico [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Discount rate	4.36%	4.10%	4.98%
Rate of compensation increase	3.29%	3.29%	3.29%
Foreign-based Defined Benefit Plans [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Discount rate	1.86%	1.38%	2.45%
Rate of compensation increase	2.02%	1.43%	1.52%

Retirement Benefit Plans - Plan

Retirement Benefit Plans - Plans with Benefit Obligations in Excess of Plan Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
U.S. and Puerto Rico [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Projected benefit obligation	$ 53.8	$ 54.6
Plan assets at fair market value	38.2	40.8
Foreign-based Defined Benefit Plans [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Projected benefit obligation	393.4	365.2
Plan assets at fair market value	$ 319.6	$ 315

Retirement Benefit Plans - Tota

Retirement Benefit Plans - Total Accumulated Benefit Obligations and Plans with Accumulated Benefit Obligations in Excess of Plan Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
U.S. and Puerto Rico [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Total accumulated benefit obligations	$ 354.6	$ 337.5
Plans with accumulated benefit obligations in excess of plan assets:
Accumulated benefit obligation	34.8	32.8
Plan assets at fair market value	20.6	22
Foreign-based Defined Benefit Plans [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Total accumulated benefit obligations	556.8	413.1
Plans with accumulated benefit obligations in excess of plan assets:
Accumulated benefit obligation	380.1	358.6
Plan assets at fair market value	$ 314.9	$ 315

Retirement Benefit Plans - Summ

Retirement Benefit Plans - Summary of Benefits Expected to be Paid Out (Detail) $ in Millions	Dec. 31, 2015USD ($)
U.S. and Puerto Rico [Member]
Schedule of Expected Future Pension Benefit Payment [Line Items]
2,016	$ 14.3
2,017	15.8
2,018	17.3
2,019	19.1
2,020	20.6
2021-2025	118.4
Foreign-based Defined Benefit Plans [Member]
Schedule of Expected Future Pension Benefit Payment [Line Items]
2,016	22.4
2,017	22.5
2,018	23
2,019	24
2,020	23.9
2021-2025	$ 125.2

Retirement Benefit Plans - Addi

Retirement Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Expense related to defined contribution plan	$ 40.2	$ 32.8	$ 29.6
U.S. and Puerto Rico [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Contribution towards defined benefit plans	$ 0
U.S. and Puerto Rico [Member] | Equity Securities [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Minimum range of assets held by defined benefit plan for cash funds	40.00%
Maximum range of assets held by defined benefit plan for cash funds	45.00%
U.S. and Puerto Rico [Member] | Debt Securities [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Minimum range of assets held by defined benefit plan for cash funds	30.00%
Maximum range of assets held by defined benefit plan for cash funds	35.00%
U.S. and Puerto Rico [Member] | Non-Traditional Investments [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Minimum range of assets held by defined benefit plan for cash funds	20.00%
Maximum range of assets held by defined benefit plan for cash funds	25.00%
Foreign-based Defined Benefit Plans [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Contribution towards defined benefit plans	$ 15.1
Foreign-based Defined Benefit Plans [Member] | Equity Securities [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Minimum range of assets held by defined benefit plan for cash funds	20.00%
Maximum range of assets held by defined benefit plan for cash funds	37.00%
Foreign-based Defined Benefit Plans [Member] | Debt Securities [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Minimum range of assets held by defined benefit plan for cash funds	30.00%
Maximum range of assets held by defined benefit plan for cash funds	50.00%
Foreign-based Defined Benefit Plans [Member] | Real Estate [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Minimum range of assets held by defined benefit plan for cash funds	15.00%
Maximum range of assets held by defined benefit plan for cash funds	24.00%
Foreign-based Defined Benefit Plans [Member] | Cash Fund [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Minimum range of assets held by defined benefit plan for cash funds	3.00%
Maximum range of assets held by defined benefit plan for cash funds	15.00%
Foreign-based Defined Benefit Plans [Member] | Other Funds [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Minimum range of assets held by defined benefit plan for cash funds	0.00%
Maximum range of assets held by defined benefit plan for cash funds	12.00%

Retirement Benefit Plans - Fair

Retirement Benefit Plans - Fair Value of U.S. and Puerto Rico Pension Plan Assets (Detail) - U.S. and Puerto Rico [Member] - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	$ 374.1	$ 402.2	$ 398.6
Cash and Cash Equivalents [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	2.5	1.4
Real Estate [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	27	49.1
Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	2.5	1.4
Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Cash and Cash Equivalents [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	2.5	1.4
Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	371.6	400.8
Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member] | Real Estate [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	27	49.1
U.S. Large-cap [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	79.2	83.7
U.S. Large-cap [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	79.2	83.7
U.S. Small-cap [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	25.6	23
U.S. Small-cap [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	25.6	23
International [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	93.2	83
International [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	93.2	83
Commodity- linked Mutual Funds [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	16.4	36
Commodity- linked Mutual Funds [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	16.4	36
Intermediate Fixed Income Debt Securities [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	130.2	126
Intermediate Fixed Income Debt Securities [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	$ 130.2	$ 126

Retirement Benefit Plans - F101

Retirement Benefit Plans - Fair Value of Foreign Pension Plan Assets (Detail) - Foreign-based Defined Benefit Plans [Member] - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	$ 505.6	$ 385.4	$ 372.3
Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	146	132.2
Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	285.7	184.6
Fair Value Measurements at Reporting Date Using: Significant Unobservable Inputs (Level 3) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	73.9	68.6
Cash and Cash Equivalents [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	34	31
Cash and Cash Equivalents [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	34	31
Energy [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	4.7	4.7
Energy [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	4.7	4.7
Materials [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	6.7	7.1
Materials [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	6.7	7.1
Industrials [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	8.2	7.5
Industrials [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	8.2	7.5
Consumer Discretionary [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	6.3	6.5
Consumer Discretionary [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	6.3	6.5
Consumer Staples [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	8.5	7.5
Consumer Staples [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	8.5	7.5
Health Care [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	8.6	6.8
Health Care [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	8.6	6.8
Financials [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	17.4	16.3
Financials [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	17.4	16.3
Information Technology [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	5.7	4.9
Information Technology [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	5.7	4.9
Telecommunication Services [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	2	2
Telecommunication Services [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	2	2
Utilities [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	3.3	3.4
Utilities [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	3.3	3.4
Other [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	80.7	36.7
Other [Member] | Fair Value Measurements at Reporting Date Using: Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	40.6	34.5
Other [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	40.1	2.2
Government Bonds [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	104	72.5
Government Bonds [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	104	72.5
Corporate Bonds [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	74.5	58.9
Corporate Bonds [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	74.5	58.9
Asset-backed Securities [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	14.8	22
Asset-backed Securities [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	14.8	22
Other Debt [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	11.3	1.7
Other Debt [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	11.3	1.7
Mortgage Loans [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	9.8	9.2
Mortgage Loans [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	9.8	9.2
Insurance Contracts [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	5.8	6.1
Insurance Contracts [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	5.8	6.1
Other Investments [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	14.7	12
Other Investments [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	14.7	12
Real Estate [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	84.6	68.6
Real Estate [Member] | Fair Value Measurements at Reporting Date Using: Significant Other Observable Inputs (Level 2) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	10.7
Real Estate [Member] | Fair Value Measurements at Reporting Date Using: Significant Unobservable Inputs (Level 3) [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Plan assets at fair market value	$ 73.9	$ 68.6

Retirement Benefit Plans - Reco

Retirement Benefit Plans - Reconciliation of Beginning and Ending Balances of Foreign Pension Plan Assets Measured at Fair Value (Detail) - Foreign-based Defined Benefit Plans [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Schedule of Fair Values of Plan Assets [Line Items]
Plan assets at fair market value - beginning of year	$ 385.4	$ 372.3
Translation loss	(12.3)	(35.3)
Plan assets at fair market value - end of year	505.6	385.4
Fair Value Measurements at Reporting Date Using: Significant Unobservable Inputs (Level 3) [Member]
Schedule of Fair Values of Plan Assets [Line Items]
Plan assets at fair market value - beginning of year	68.6
Gains on assets sold	0.2
Change in fair value of assets	2.2
Net purchases and sales	3.5
Translation loss	(0.6)
Plan assets at fair market value - end of year	$ 73.9	$ 68.6

Income Taxes - Components of Ea

Income Taxes - Components of Earnings Before Taxes and Income Taxes Paid (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
United States operations	$ (246.2)	$ 403.3	$ 412.4
Foreign operations	399.4	536.1	595.7
Total	153.2	939.4	1,008.1
Current:
Federal	55.8	178.2	207.2
State	18.9	16.5	20.8
Foreign	96.3	116	127.7
Current, Total	171	310.7	355.7
Deferred:
Federal	(120.6)	(54.8)	(91.8)
State	(20)	(6.6)	(8.4)
Foreign	(23.4)	(29.1)	(26)
Deferred, Total	(164)	(90.5)	(126.2)
Provision for income taxes	7	220.2	229.5
Income taxes paid	$ 193.6	$ 340.1	$ 272.3

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Our Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
U.S. statutory income tax rate	35.00%	35.00%	35.00%
State taxes, net of federal deduction	(2.40%)	0.70%	0.80%
Tax impact of foreign operations, including foreign tax credits	(40.20%)	(11.70%)	(12.10%)
Change in valuation allowance	(3.70%)
Non-deductible expenses	2.40%
Tax impact of certain significant transactions	21.60%	1.40%	1.60%
Tax benefit relating to U.S. manufacturer's deduction and export sales	(6.20%)	(1.90%)	(1.80%)
R&D credit	(2.50%)	(0.20%)	(0.60%)
Other	0.60%	0.10%	(0.10%)
Effective income tax rate	4.60%	23.40%	22.80%

Income Taxes - Components of De

Income Taxes - Components of Deferred Taxes (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Inventory	$ 159.7	$ 275.1
Net operating loss carryover	117.4	116.9
Tax credit carryover	207.8	185.5
Capital loss carryover	4.2	7.4
Accrued liabilities	190.2	106.7
Share-based compensation	59	59.9
Accounts receivable	23.7
Unremitted earnings of foreign subsidiaries		32.3
Other	133.6	50.3
Total deferred tax assets	895.6	834.1
Less: Valuation allowances	(72.7)	(122.8)
Total deferred tax assets after valuation allowances	822.9	711.3
Deferred tax liabilities:
Fixed assets	(144.6)	(104.3)
Intangible assets	(2,337.2)	(95.9)
Unremitted earnings of foreign subsidiaries	(1,374.8)
Other	(4.3)
Total deferred tax liabilities	(3,860.9)	(200.2)
Total net deferred income taxes	$ (3,038)
Total net deferred income taxes		$ 511.1

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax [Line Items]
Net operating loss carryovers expire with in the period	$ 103.9
Net operating loss carryovers with indefinite life	13.5
Valuation allowances for net operating loss carryovers	47	$ 99
Total tax credit carryovers	207.8	185.5
Valuation allowances for certain tax credit carryovers	14.4	11.5
Capital loss carryovers	4.2
Valuation allowances for net Capital loss carryovers	4.2	7.4
Valuation allowances for potential capital losses	7.1	4.9
Unremitted earnings of foreign subsidiaries	3,853
Unrecognized tax benefits income tax penalties and interest expense recognized	4.8	5.9	$ 8.1
Recognized liability for interest and penalties	$ 82.9	$ 48.3	$ 42.4
State examination period after notification	Up to one year
Biomet [Member]
Income Tax [Line Items]
Unrecognized tax benefits income tax penalties and interest expense increase related to Biomet merger	$ 29.8
Minimum [Member]
Income Tax [Line Items]
Maturity period for net operating loss carryovers	1 year
Maturity period for tax credit carryovers	1 year
Maturity period for net Capital loss carryovers	2 years
Foreign jurisdictions statutes of limitation period	3 years
Maximum [Member]
Income Tax [Line Items]
Maturity period for net operating loss carryovers	20 years
Maturity period for tax credit carryovers	10 years
Maturity period for net Capital loss carryovers	4 years
Foreign jurisdictions statutes of limitation period	5 years

Income Taxes - Tabular Reconcil

Income Taxes - Tabular Reconciliation of Total Amounts of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Balance at January 1	$ 321.7	$ 311	$ 293.9
Increase related to the merger	247.6
Increases related to prior periods	1.3	0.9	16.5
Decreases related to prior periods		(3.8)	(17.3)
Increases related to current period	25.7	18.3	20.8
Decreases related to settlements with taxing authorities	(1.4)	(3)	(2.9)
Decreases related to lapse of statute of limitations	(3)	(1.7)
Balance at December 31	591.9	321.7	311
Amounts impacting effective tax rate, if recognized balance at December 31	$ 526.6	$ 186.3	$ 191.2

Capital Stock and Earnings p108

Capital Stock and Earnings per Share - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Preferred stock, shares authorized	250,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Options to purchase shares of common stock not included in the computation of diluted earnings per share	500,000		3,100,000
Repurchased shares of common stock	1,400,000
Average price per share	$ 106.01
Total cash outlay	$ 150	$ 400.5	$ 719

Capital Stock and Earnings p109

Capital Stock and Earnings per Share - Reconciliation of Weighted Average Share for Basic and Diluted Share Computations (Detail) - shares shares in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Weighted average shares outstanding for basic net earnings per share	187.4	169	169.6
Effect of dilutive stock options and other equity awards	2.4	2.7	2.2
Weighted average shares outstanding for diluted net earnings per share	189.8	171.7	171.8

Segment Data - Additional Infor

Segment Data - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)Segment	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | Segment	7
Share of revenue from an individual country in net sales	Less than 10 percent
Reportable Segment Assets [Member] | Property, Plant and Equipment [Member]
Segment Reporting Information [Line Items]
Property, plant and equipment percentage	10.00%
US [Member]
Segment Reporting Information [Line Items]
Sales from United States region | $	$ 3,447.2	$ 2,397.9	$ 2,418.2

Segment Data - Summary of Net S

Segment Data - Summary of Net Sales and Other Information by Segment (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Sales Information [Line Items]
Net Sales	$ 1,933.6	$ 1,762.2	$ 1,167.6	$ 1,134.4	$ 1,222.9	$ 1,106	$ 1,182.9	$ 1,161.5	$ 5,997.8	$ 4,673.3	$ 4,623.4
Depreciation and amortization									712.4	375.8	358.5
Operating profit									467.3	1,037.3	1,068.6
Total Assets	27,219.5				9,658				27,219.5	9,658	9,595
Additions to instruments									266.4	197.4	192.9
Additions to other property, plant and equipment									167.7	144.9	100
Intangible asset amortization									(337.4)	(92.5)	(78.5)
Certain claims									(7.7)	(21.5)	(47)
Special items									831.8	341.1	210.3
Biomet [Member]
Sales Information [Line Items]
Net Sales									1,602
Operating profit									(295.8)
Operating Segments [Member]
Sales Information [Line Items]
Operating profit									1,993	1,528.7	1,493.1
Operating Segments [Member] | Americas [Member]
Sales Information [Line Items]
Net Sales									3,109.4	2,320.2	2,347.6
Depreciation and amortization									110	70.5	62.6
Operating profit									1,647	1,215.4	1,293.5
Total Assets	1,525				1,012				1,525	1,012	947.9
Additions to instruments									1.6	0.2	0.2
Additions to other property, plant and equipment									21.7	8.6	8.7
Operating Segments [Member] | EMEA [Member]
Sales Information [Line Items]
Net Sales									1,302.9	1,189.1	1,134
Depreciation and amortization									61.1	46	48.2
Operating profit									445.3	435.6	401.2
Total Assets	1,382.2				924				1,382.2	924	974.5
Additions to instruments									0.2	0.1	0.3
Additions to other property, plant and equipment									3.4	2.1	1.2
Operating Segments [Member] | Asia Pacific [Member]
Sales Information [Line Items]
Net Sales									881.6	789.2	771.9
Depreciation and amortization									37.9	30.2	30
Operating profit									421.9	371	335.6
Total Assets	642.4				380.3				642.4	380.3	375.9
Additions to instruments									4.7	6	6.5
Additions to other property, plant and equipment									9	9.1	7.6
Operating Segments [Member] | Immaterial Product Category Operating Segments [Member]
Sales Information [Line Items]
Net Sales									703.9	374.8	369.9
Depreciation and amortization									21	7.5	7.7
Operating profit									167.9	76.5	79.9
Total Assets	788.3				295.1				788.3	295.1	322.9
Additions to instruments									22.8	16.3	14.9
Additions to other property, plant and equipment									4.6	2.6	4.6
Global Operations and Corporate Functions [Member]
Sales Information [Line Items]
Depreciation and amortization									482.4	221.6	210
Operating profit									(689.1)	(569.8)	(617.1)
Total Assets	$ 22,881.6				$ 7,046.6				22,881.6	7,046.6	6,973.8
Additions to instruments									237.1	174.8	171
Additions to other property, plant and equipment									129	122.5	77.9
Segment Reconciling Items [Member]
Sales Information [Line Items]
Inventory step-up and certain other inventory and manufacturing related charges									(348.8)	(36.3)	(88.7)
Intangible asset amortization									(337.4)	(92.5)	(78.5)
Certain claims									(7.7)	(21.5)	(47)
Special items									0	0	0
Other special items									(212.7)	(279.2)	$ (210.3)
Segment Reconciling Items [Member] | Biomet [Member]
Sales Information [Line Items]
Biomet merger related									$ (619.1)	$ (61.9)

Segment Data - Disclosure on Ge

Segment Data - Disclosure on Geographic Areas, Long-Lived Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Sales Information [Line Items]
Property, plant and equipment, net	$ 2,062.6	$ 1,285.3	$ 1,229.5
US [Member]
Sales Information [Line Items]
Property, plant and equipment, net	1,188.6	794.4	737.6
Switzerland [Member]
Sales Information [Line Items]
Property, plant and equipment, net	200.9	198.7	211.5
Other Countries [Member]
Sales Information [Line Items]
Property, plant and equipment, net	$ 673.1	$ 292.2	$ 280.4

Segment Data - Summary of Ne113

Segment Data - Summary of Net Sales by Product Category (Detail) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue from External Customer [Line Items]
Net Sales	$ 1,933.6	$ 1,762.2	$ 1,167.6	$ 1,134.4	$ 1,222.9	$ 1,106	$ 1,182.9	$ 1,161.5	$ 5,997.8	$ 4,673.3	$ 4,623.4
Knees [Member]
Revenue from External Customer [Line Items]
Net Sales									2,276.8	1,895.2	1,862.2
Hips [Member]
Revenue from External Customer [Line Items]
Net Sales									1,537.2	1,326.4	1,330.5
S.E.T [Member]
Revenue from External Customer [Line Items]
Net Sales									1,214.9	863.2	847.2
Dental [Member]
Revenue from External Customer [Line Items]
Net Sales									335.7	242.8	239.3
Spine and CMF [Member]
Revenue from External Customer [Line Items]
Net Sales									404.4	207.2	202.3
Other [Member]
Revenue from External Customer [Line Items]
Net Sales									$ 228.8	$ 138.5	$ 141.9

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Leases [Abstract]
Lease rent expenses	$ 60.1	$ 48.4	$ 49.2

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Rental Commitments Under Non-Cancelable Operating Leases (Detail) $ in Millions	Dec. 31, 2015USD ($)
Leases [Abstract]
2,016	$ 59.1
2,017	44.7
2,018	33.9
2,019	26.4
2,020	21.8
Thereafter	$ 45.9

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended		3 Months Ended	12 Months Ended			96 Months Ended
	Jul. 31, 2015USD ($)	Dec. 31, 2008EUR (€)	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)Patents	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015USD ($)Patents	Oct. 19, 2015USD ($)	Mar. 01, 2013USD ($)	Jun. 10, 2011USD ($)
Loss Contingencies [Line Items]
Certain claims				$ 7,700,000	$ 21,500,000	$ 47,000,000
Compensatory damages awarded				$ 27,600,000
Percentage of fault apportioned to plaintiffs				30.00%
Percentage of fault apportioned to company				34.00%
Percentage of fault apportioned to unrelated third party				36.00%
Verdict in full and entered judgment										$ 20,300,000
Compensatory damages vacated									$ 27,600,000
Durom Cup Related Claims [Member]
Loss Contingencies [Line Items]
Certain claims				$ 7,700,000	$ 21,500,000	$ 47,000,000	$ 479,400,000
Self-insured retention amount				20.00%
Estimated liability outstanding				$ 314,600,000			314,600,000
Estimated liability classified as short-term				50,000,000			50,000,000
Estimated liability classified as long-term				264,600,000			264,600,000
Durom Cup Related Claims [Member] | Other Assets [Member]
Loss Contingencies [Line Items]
Estimated insurance recoveries				95,300,000			95,300,000
Biomet Metal On Metal Hip Implant Claims [Member]
Loss Contingencies [Line Items]
Estimated liability classified as short-term				$ 33,400,000			$ 33,400,000
Heraeus Trade Secret Misappropriation Lawsuits [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Loss Contingency, Damages incurred | €		€ 30,000,000
Stryker Corporation [Member]
Loss Contingencies [Line Items]
Number of patents infringed | Patents				3			3
Monetary damages for lost profits				$ 70,000,000
Estimated charges	$ 90,300,000		$ 70,000,000
Stryker Corporation [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Estimated charges								$ 140,000,000

Quarterly Financial Informat117

Quarterly Financial Information (Unaudited) - Quarterly Financial Information (Unaudited) (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Net Sales	$ 1,933.6	$ 1,762.2	$ 1,167.6	$ 1,134.4	$ 1,222.9	$ 1,106	$ 1,182.9	$ 1,161.5	$ 5,997.8	$ 4,673.3	$ 4,623.4
Gross profit	1,102.9	1,087.5	840.3	829.1	888.6	789.5	833.1	826.8
Net earnings of Zimmer Biomet Holdings, Inc.	$ 127	$ 22.2	$ (173.6)	$ 171.4	$ 153.8	$ 173.1	$ 172.4	$ 221	$ 147	$ 720.3	$ 780.4
Earnings per common share
Basic	$ 0.62	$ 0.11	$ (1)	$ 1.01	$ 0.91	$ 1.02	$ 1.02	$ 1.31	$ 0.78	$ 4.26	$ 4.60
Diluted	$ 0.62	$ 0.11	$ (1)	$ 0.99	$ 0.89	$ 1.01	$ 1.01	$ 1.29	$ 0.77	$ 4.20	$ 4.54

Schedule - Valuation and Qualif

Schedule - Valuation and Qualifying Accounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 22.3	$ 22.7	$ 22.8
Additions Charged (Credited) to Expense	13.5	2	1.9
Deductions to Reserve	(0.4)	(1.4)	(1.5)
Effects of Foreign Currency	(1.3)	(1)	(0.5)
Balance at End of Period	34.1	22.3	22.7
Deferred Tax Asset Valuation Allowances [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	122.8	42.7	41.3
Additions Charged (Credited) to Expense	(53.7)	74.7	1.5
Deductions to Reserve	(5.6)	(9.2)	(0.1)
Effects of Foreign Currency	(1.6)
Acquired Allowances	10.8	14.6
Balance at End of Period	$ 72.7	$ 122.8	$ 42.7